Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,9360515,area under the GH curve,"The area under the GH curve was lower in older subjects (young, 3978 +/- 1532 micrograms/L.24 h; older, 1144 +/- 79; P = 0.001), whereas the elimination half-life did not differ with age (young, 18.1 +/- 0.9 min; older, 16.4 +/- 0.8; P = NS).","Metabolic effects and pharmacokinetics of a growth hormone pulse in healthy adults: relation to age, sex, and body composition. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9360515/),[μg] / [24·h·l],3978,200,DB00052,Somatropin recombinant
,9360515,area under the GH curve,"The area under the GH curve was lower in older subjects (young, 3978 +/- 1532 micrograms/L.24 h; older, 1144 +/- 79; P = 0.001), whereas the elimination half-life did not differ with age (young, 18.1 +/- 0.9 min; older, 16.4 +/- 0.8; P = NS).","Metabolic effects and pharmacokinetics of a growth hormone pulse in healthy adults: relation to age, sex, and body composition. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9360515/),,1144,201,DB00052,Somatropin recombinant
,9360515,elimination half-life,"The area under the GH curve was lower in older subjects (young, 3978 +/- 1532 micrograms/L.24 h; older, 1144 +/- 79; P = 0.001), whereas the elimination half-life did not differ with age (young, 18.1 +/- 0.9 min; older, 16.4 +/- 0.8; P = NS).","Metabolic effects and pharmacokinetics of a growth hormone pulse in healthy adults: relation to age, sex, and body composition. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9360515/),min,18.1,202,DB00052,Somatropin recombinant
,9360515,elimination half-life,"The area under the GH curve was lower in older subjects (young, 3978 +/- 1532 micrograms/L.24 h; older, 1144 +/- 79; P = 0.001), whereas the elimination half-life did not differ with age (young, 18.1 +/- 0.9 min; older, 16.4 +/- 0.8; P = NS).","Metabolic effects and pharmacokinetics of a growth hormone pulse in healthy adults: relation to age, sex, and body composition. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9360515/),,16.4,203,DB00052,Somatropin recombinant
,9360515,MCR,"The MCR and apparent distribution volume of GH were higher in older subjects [MCR: young, 0.11 +/- 0.02 min/L; older, 0.19 +/- 0.01; P = 0.001; apparent distribution volume: young, 2.5 +/- 0.4 L; older, 4.5 +/- 0.3; P < 0.001).","Metabolic effects and pharmacokinetics of a growth hormone pulse in healthy adults: relation to age, sex, and body composition. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9360515/),[min] / [l],0.11,204,DB00052,Somatropin recombinant
,9360515,MCR,"The MCR and apparent distribution volume of GH were higher in older subjects [MCR: young, 0.11 +/- 0.02 min/L; older, 0.19 +/- 0.01; P = 0.001; apparent distribution volume: young, 2.5 +/- 0.4 L; older, 4.5 +/- 0.3; P < 0.001).","Metabolic effects and pharmacokinetics of a growth hormone pulse in healthy adults: relation to age, sex, and body composition. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9360515/),,0.19,205,DB00052,Somatropin recombinant
,9360515,apparent distribution volume,"The MCR and apparent distribution volume of GH were higher in older subjects [MCR: young, 0.11 +/- 0.02 min/L; older, 0.19 +/- 0.01; P = 0.001; apparent distribution volume: young, 2.5 +/- 0.4 L; older, 4.5 +/- 0.3; P < 0.001).","Metabolic effects and pharmacokinetics of a growth hormone pulse in healthy adults: relation to age, sex, and body composition. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9360515/),l,2.5,206,DB00052,Somatropin recombinant
,9360515,apparent distribution volume,"The MCR and apparent distribution volume of GH were higher in older subjects [MCR: young, 0.11 +/- 0.02 min/L; older, 0.19 +/- 0.01; P = 0.001; apparent distribution volume: young, 2.5 +/- 0.4 L; older, 4.5 +/- 0.3; P < 0.001).","Metabolic effects and pharmacokinetics of a growth hormone pulse in healthy adults: relation to age, sex, and body composition. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9360515/),,4.5,207,DB00052,Somatropin recombinant
,9132167,half-life time,"The mutant hGH showed an altered half-life time (7 min) as compared to that (11 min) for native form hGH, while the biological activity was not affected by the mutation.",Site-directed mutagenesis at 134/135 in human growth hormone alters its in vivo half-life in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9132167/),min,7,4750,DB00052,Somatropin recombinant
,9132167,half-life time,"The mutant hGH showed an altered half-life time (7 min) as compared to that (11 min) for native form hGH, while the biological activity was not affected by the mutation.",Site-directed mutagenesis at 134/135 in human growth hormone alters its in vivo half-life in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9132167/),min,11,4751,DB00052,Somatropin recombinant
,21903773,disease control rate,"Of 69 evaluable patients, three had confirmed partial responses and six had stable disease for 16 weeks or more (disease control rate = 13.0%); all nine of these tumors were HR+ (two were also HER2+).",A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21903773/),%,13.0,6894,DB00052,Somatropin recombinant
,25332052,ζ-potential,"Particularly one formulation, which was designed to be mucus penetrative by addition of a high quantity of TPGS 400 and a ζ-potential close to 0 mV, showed a very strong mucus association in the duodenum and jejunum.",Improved oral bioavailability of human growth hormone by a combination of liposomes containing bio-enhancers and tetraether lipids and omeprazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25332052/),m,0,7677,DB00052,Somatropin recombinant
,25332052,bioavailability,"Vesicles with CpCl 33% (mol/mol) led to a relative hGH bioavailability of 3.4% compared with s.c. control, whereas free hGH administered orally showed a bioavailability of only 0.01%.",Improved oral bioavailability of human growth hormone by a combination of liposomes containing bio-enhancers and tetraether lipids and omeprazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25332052/),%,3.4,7678,DB00052,Somatropin recombinant
,25332052,bioavailability,"Vesicles with CpCl 33% (mol/mol) led to a relative hGH bioavailability of 3.4% compared with s.c. control, whereas free hGH administered orally showed a bioavailability of only 0.01%.",Improved oral bioavailability of human growth hormone by a combination of liposomes containing bio-enhancers and tetraether lipids and omeprazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25332052/),%,0.01,7679,DB00052,Somatropin recombinant
,32325373,t1/2,Mean t1/2 was 3.51 h for macimorelin 0.5 and 1.0 mg/kg and 8.29 h for macimorelin 2.0 mg/kg; median tmax occurred at 0.5 to 0.75 h.,"Safety, tolerability, pharmacokinetics, and pharmacodynamics of macimorelin in healthy adults: Results of a single-dose, randomized controlled study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32325373/),h,3.51,8073,DB00052,Somatropin recombinant
,32325373,t1/2,Mean t1/2 was 3.51 h for macimorelin 0.5 and 1.0 mg/kg and 8.29 h for macimorelin 2.0 mg/kg; median tmax occurred at 0.5 to 0.75 h.,"Safety, tolerability, pharmacokinetics, and pharmacodynamics of macimorelin in healthy adults: Results of a single-dose, randomized controlled study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32325373/),h,8.29,8074,DB00052,Somatropin recombinant
,32325373,tmax,Mean t1/2 was 3.51 h for macimorelin 0.5 and 1.0 mg/kg and 8.29 h for macimorelin 2.0 mg/kg; median tmax occurred at 0.5 to 0.75 h.,"Safety, tolerability, pharmacokinetics, and pharmacodynamics of macimorelin in healthy adults: Results of a single-dose, randomized controlled study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32325373/),h,0.5 to 0.75,8075,DB00052,Somatropin recombinant
,32325373,tmax,"GH levels increased after dosing, with a tmax of 0.75 h to 1.0 h.","Safety, tolerability, pharmacokinetics, and pharmacodynamics of macimorelin in healthy adults: Results of a single-dose, randomized controlled study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32325373/),h,0.75,8076,DB00052,Somatropin recombinant
,32325373,tmax,"GH levels increased after dosing, with a tmax of 0.75 h to 1.0 h.","Safety, tolerability, pharmacokinetics, and pharmacodynamics of macimorelin in healthy adults: Results of a single-dose, randomized controlled study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32325373/),h,1.0,8077,DB00052,Somatropin recombinant
,32325373,Cmax,"Mean GH Cmax was similar with the macimorelin 0.5- and 1.0-mg/kg doses (31.9 and 37.8 ng/mL, respectively) and was ~50% lower with macimorelin 2.0 mg/kg (18.4 ng/mL).","Safety, tolerability, pharmacokinetics, and pharmacodynamics of macimorelin in healthy adults: Results of a single-dose, randomized controlled study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32325373/),[ng] / [ml],31.9,8078,DB00052,Somatropin recombinant
,32325373,Cmax,"Mean GH Cmax was similar with the macimorelin 0.5- and 1.0-mg/kg doses (31.9 and 37.8 ng/mL, respectively) and was ~50% lower with macimorelin 2.0 mg/kg (18.4 ng/mL).","Safety, tolerability, pharmacokinetics, and pharmacodynamics of macimorelin in healthy adults: Results of a single-dose, randomized controlled study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32325373/),[ng] / [ml],37.8,8079,DB00052,Somatropin recombinant
,32325373,Cmax,"Mean GH Cmax was similar with the macimorelin 0.5- and 1.0-mg/kg doses (31.9 and 37.8 ng/mL, respectively) and was ~50% lower with macimorelin 2.0 mg/kg (18.4 ng/mL).","Safety, tolerability, pharmacokinetics, and pharmacodynamics of macimorelin in healthy adults: Results of a single-dose, randomized controlled study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32325373/),[ng] / [ml],18.4,8080,DB00052,Somatropin recombinant
,6995479,steady-state plasma epinephrine concentrations,"These 30 infusions resulted in steady-state plasma epinephrine concentrations ranging from 24 to 1,020 pg/ml.",Epinephrine plasma metabolic clearance rates and physiologic thresholds for metabolic and hemodynamic actions in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6995479/),[pg] / [ml],"24 to 1,020",9497,DB00052,Somatropin recombinant
,6995479,plasma metabolic clearance rate,"At steady-state plasma epinephrine concentrations of 24-74 pg/ml, values overlapping the basal normal range, the mean (+/-SE) plasma metabolic clearance rate of epinephrine was 52 +/- 4 ml x min-1 x kg-1; this value rose to 89 +/- 6 ml x min-1 x kg-1 (P less than 0.01) at steady-state epinephrine concentrations of 90-1,020 pg/ml.",Epinephrine plasma metabolic clearance rates and physiologic thresholds for metabolic and hemodynamic actions in man. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6995479/),[ml] / [kg·min],52,9498,DB00052,Somatropin recombinant
,6995479,plasma metabolic clearance rate,"At steady-state plasma epinephrine concentrations of 24-74 pg/ml, values overlapping the basal normal range, the mean (+/-SE) plasma metabolic clearance rate of epinephrine was 52 +/- 4 ml x min-1 x kg-1; this value rose to 89 +/- 6 ml x min-1 x kg-1 (P less than 0.01) at steady-state epinephrine concentrations of 90-1,020 pg/ml.",Epinephrine plasma metabolic clearance rates and physiologic thresholds for metabolic and hemodynamic actions in man. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6995479/),[ml] / [kg·min],89,9499,DB00052,Somatropin recombinant
,29959799,maximum tolerable dose,"Single-dose Jintrolong® injection was well tolerated in healthy adult subjects, and the maximum tolerable dose was no lower than 0.8 mg/kg.","A long-acting pegylated recombinant human growth hormone (Jintrolong® ) in healthy adult subjects: Two single-dose trials evaluating safety, tolerability and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29959799/),[mg] / [kg],0.8,11418,DB00052,Somatropin recombinant
,33964572,progression-free survival rate,"The sixteen-week progression-free survival rate was 52.4% (90% confidence interval [CI]: 32.8, 71.4) in the RCC cohort, 35.3% (90% CI: 16.6, 58.0) in the prior pNET cohort and 30.0% (90% CI: 8.7, 60.7) in the prior mTORi cohort.","Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33964572/),%,52,11753,DB00052,Somatropin recombinant
,33964572,progression-free survival rate,"The sixteen-week progression-free survival rate was 52.4% (90% confidence interval [CI]: 32.8, 71.4) in the RCC cohort, 35.3% (90% CI: 16.6, 58.0) in the prior pNET cohort and 30.0% (90% CI: 8.7, 60.7) in the prior mTORi cohort.","Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33964572/),%,35,11754,DB00052,Somatropin recombinant
,33964572,progression-free survival rate,"The sixteen-week progression-free survival rate was 52.4% (90% confidence interval [CI]: 32.8, 71.4) in the RCC cohort, 35.3% (90% CI: 16.6, 58.0) in the prior pNET cohort and 30.0% (90% CI: 8.7, 60.7) in the prior mTORi cohort.","Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33964572/),%,30,11755,DB00052,Somatropin recombinant
,17347858,peak responses,"In the patients plasma insulin (baseline, 15.9 +/- 3.9 microIU/ml) and C-peptide (baseline, 2.5 +/- 0.3 ng/ml) showed opposite changes with peak responses at 30 min (insulin, 109.5 +/- 15.6 microIU/ml) or 60 min (C-peptide, 10.3 +/- 1.1 ng/ml).",Plasma ghrelin response to an oral glucose load in growth hormone-deficient adults treated with growth hormone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17347858/),[μiu] / [ml],109.5,12847,DB00052,Somatropin recombinant
,17347858,peak responses,"In the patients plasma insulin (baseline, 15.9 +/- 3.9 microIU/ml) and C-peptide (baseline, 2.5 +/- 0.3 ng/ml) showed opposite changes with peak responses at 30 min (insulin, 109.5 +/- 15.6 microIU/ml) or 60 min (C-peptide, 10.3 +/- 1.1 ng/ml).",Plasma ghrelin response to an oral glucose load in growth hormone-deficient adults treated with growth hormone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17347858/),[ng] / [ml],10.3,12848,DB00052,Somatropin recombinant
,21177789,peak plasma concentration,"A clear dose-dependent pharmacodynamic response in circulating IGF-I levels was observed [from a predose mean (SD) IGF-I SD score of -3.2 (1.7) to peak plasma concentration of -0.5 (1.3), 1.6 (1.3), 2.1 (0.5), and 4.4 (0.9) in the four dose groups, respectively].","Pegylated long-acting human growth hormone possesses a promising once-weekly treatment profile, and multiple dosing is well tolerated in adult patients with growth hormone deficiency. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21177789/),,-0.5,14044,DB00052,Somatropin recombinant
,21177789,peak plasma concentration,"A clear dose-dependent pharmacodynamic response in circulating IGF-I levels was observed [from a predose mean (SD) IGF-I SD score of -3.2 (1.7) to peak plasma concentration of -0.5 (1.3), 1.6 (1.3), 2.1 (0.5), and 4.4 (0.9) in the four dose groups, respectively].","Pegylated long-acting human growth hormone possesses a promising once-weekly treatment profile, and multiple dosing is well tolerated in adult patients with growth hormone deficiency. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21177789/),,1.6,14045,DB00052,Somatropin recombinant
,21177789,peak plasma concentration,"A clear dose-dependent pharmacodynamic response in circulating IGF-I levels was observed [from a predose mean (SD) IGF-I SD score of -3.2 (1.7) to peak plasma concentration of -0.5 (1.3), 1.6 (1.3), 2.1 (0.5), and 4.4 (0.9) in the four dose groups, respectively].","Pegylated long-acting human growth hormone possesses a promising once-weekly treatment profile, and multiple dosing is well tolerated in adult patients with growth hormone deficiency. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21177789/),,2.1,14046,DB00052,Somatropin recombinant
,21177789,peak plasma concentration,"A clear dose-dependent pharmacodynamic response in circulating IGF-I levels was observed [from a predose mean (SD) IGF-I SD score of -3.2 (1.7) to peak plasma concentration of -0.5 (1.3), 1.6 (1.3), 2.1 (0.5), and 4.4 (0.9) in the four dose groups, respectively].","Pegylated long-acting human growth hormone possesses a promising once-weekly treatment profile, and multiple dosing is well tolerated in adult patients with growth hormone deficiency. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21177789/),,4.4,14047,DB00052,Somatropin recombinant
,18684735,number,"On Day 8, the mean (standard deviation) number of follicles >or=11 mm was 6.8 (4.4), 10.1 (6.1) and 12.8 (7.5), respectively.",A randomized dose-response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18684735/),,6.8,14531,DB00052,Somatropin recombinant
,18684735,number,"On Day 8, the mean (standard deviation) number of follicles >or=11 mm was 6.8 (4.4), 10.1 (6.1) and 12.8 (7.5), respectively.",A randomized dose-response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18684735/),,10.1,14532,DB00052,Somatropin recombinant
,18684735,number,"On Day 8, the mean (standard deviation) number of follicles >or=11 mm was 6.8 (4.4), 10.1 (6.1) and 12.8 (7.5), respectively.",A randomized dose-response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18684735/),,12.8,14533,DB00052,Somatropin recombinant
,31493626,growth velocity,"At end of study or the 12th month treatment, the means growth velocity was 9.7 cm/year and 9.5 cm/year, for r-hGH Cristalia and Genotropin™, respectively.","Efficacy and safety of a biosimilar recombinant human growth hormone (r-hGH Cristalia) compared with reference r-hGH in children with growth hormone deficiency (CERES study): A randomized, multicentric, investigator-blind, phase 3 trial. ",Vmax velocity-Q2,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31493626/),[cm] / [year],9.7,16233,DB00052,Somatropin recombinant
,31493626,growth velocity,"At end of study or the 12th month treatment, the means growth velocity was 9.7 cm/year and 9.5 cm/year, for r-hGH Cristalia and Genotropin™, respectively.","Efficacy and safety of a biosimilar recombinant human growth hormone (r-hGH Cristalia) compared with reference r-hGH in children with growth hormone deficiency (CERES study): A randomized, multicentric, investigator-blind, phase 3 trial. ",Vmax velocity-Q2,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31493626/),[cm] / [year],9.5,16234,DB00052,Somatropin recombinant
,33492568,elimination half-life,"Abemaciclib exhibited slow absorption and clearance at single dose, with maximum concentrations achieved after around 6 h and an elimination half-life of approximately 24 h.",A Randomized Phase I Study of Abemaciclib in Chinese Patients with Advanced and/or Metastatic Cancers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33492568/),h,24,22859,DB00052,Somatropin recombinant
,26370910,Cmax,A single sc injection of rhGH-Fc at a dose of 0.2 mg/kg slowly reached a Cmax of 16.80 ng/mL and remained for 7 days with a half-life of 51.1 h.,"Pharmacokinetics, Pharmacodynamics, and Efficacy of a Novel Long-Acting Human Growth Hormone: Fc Fusion Protein. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26370910/),[ng] / [ml],16.80,25904,DB00052,Somatropin recombinant
,26370910,half-life,A single sc injection of rhGH-Fc at a dose of 0.2 mg/kg slowly reached a Cmax of 16.80 ng/mL and remained for 7 days with a half-life of 51.1 h.,"Pharmacokinetics, Pharmacodynamics, and Efficacy of a Novel Long-Acting Human Growth Hormone: Fc Fusion Protein. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26370910/),h,51.1,25905,DB00052,Somatropin recombinant
,26370910,Cmax,"Conversely, a single sc injection of rhGH 0.2 mg/kg rapidly reached a Cmax of 46.88 ng/mL and declined with a half-life of 0.55 h to baseline values in 4 h.","Pharmacokinetics, Pharmacodynamics, and Efficacy of a Novel Long-Acting Human Growth Hormone: Fc Fusion Protein. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26370910/),[ng] / [ml],46.88,25906,DB00052,Somatropin recombinant
,26370910,half-life,"Conversely, a single sc injection of rhGH 0.2 mg/kg rapidly reached a Cmax of 46.88 ng/mL and declined with a half-life of 0.55 h to baseline values in 4 h.","Pharmacokinetics, Pharmacodynamics, and Efficacy of a Novel Long-Acting Human Growth Hormone: Fc Fusion Protein. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26370910/),h,0.55,25907,DB00052,Somatropin recombinant
,11743895,area under drug concentration-time curve,The area under drug concentration-time curve (32686.9 microg . min .,Pharmacokinetics of lactosaminated recombinant human growth hormone in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11743895/),min·μg,32686.9,25945,DB00052,Somatropin recombinant
,11743895,serum mean residence time,L-1) in blood and serum mean residence time (21.4 min) of hGH-L are less than that of hGH (36913.1 microg . min . L-1 and 24.9 min) (P < 0.05).,Pharmacokinetics of lactosaminated recombinant human growth hormone in mice. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11743895/),min,21.4,25946,DB00052,Somatropin recombinant
,11743895,serum mean residence time,L-1) in blood and serum mean residence time (21.4 min) of hGH-L are less than that of hGH (36913.1 microg . min . L-1 and 24.9 min) (P < 0.05).,Pharmacokinetics of lactosaminated recombinant human growth hormone in mice. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11743895/),[min·μg] / [l],36913.1,25947,DB00052,Somatropin recombinant
,11743895,serum mean residence time,L-1) in blood and serum mean residence time (21.4 min) of hGH-L are less than that of hGH (36913.1 microg . min . L-1 and 24.9 min) (P < 0.05).,Pharmacokinetics of lactosaminated recombinant human growth hormone in mice. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11743895/),min,24.9,25948,DB00052,Somatropin recombinant
,11743895,distribution half life,"In target organ liver, hGH-L distribution half life (1.8 min) and elimination half life (11.1 min) are shorter than that of hGH (2.1 min and 27.7 min) (P < 0.05).",Pharmacokinetics of lactosaminated recombinant human growth hormone in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11743895/),min,1.8,25949,DB00052,Somatropin recombinant
,11743895,distribution half life,"In target organ liver, hGH-L distribution half life (1.8 min) and elimination half life (11.1 min) are shorter than that of hGH (2.1 min and 27.7 min) (P < 0.05).",Pharmacokinetics of lactosaminated recombinant human growth hormone in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11743895/),min,2.1,25950,DB00052,Somatropin recombinant
,11743895,elimination half life,"In target organ liver, hGH-L distribution half life (1.8 min) and elimination half life (11.1 min) are shorter than that of hGH (2.1 min and 27.7 min) (P < 0.05).",Pharmacokinetics of lactosaminated recombinant human growth hormone in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11743895/),min,11.1,25951,DB00052,Somatropin recombinant
,11743895,elimination half life,"In target organ liver, hGH-L distribution half life (1.8 min) and elimination half life (11.1 min) are shorter than that of hGH (2.1 min and 27.7 min) (P < 0.05).",Pharmacokinetics of lactosaminated recombinant human growth hormone in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11743895/),min,2.1,25952,DB00052,Somatropin recombinant
,11743895,elimination half life,"In target organ liver, hGH-L distribution half life (1.8 min) and elimination half life (11.1 min) are shorter than that of hGH (2.1 min and 27.7 min) (P < 0.05).",Pharmacokinetics of lactosaminated recombinant human growth hormone in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11743895/),min,27.7,25953,DB00052,Somatropin recombinant
,11743895,area under drug concentration-time curve,The area under drug concentration-time curve (17621.9 microg . min .,Pharmacokinetics of lactosaminated recombinant human growth hormone in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11743895/),min·μg,17621.9,25954,DB00052,Somatropin recombinant
,11743895,L,L-1) of hGH-L is bigger than that of hGH(12148.2 microg . min . L-1) (P < 0.05) in liver.,Pharmacokinetics of lactosaminated recombinant human growth hormone in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11743895/),[min·μg] / [l],12148.2,25955,DB00052,Somatropin recombinant
,2598470,urinary sodium excretion,Bio-hGH administration resulted in a significant increase in body weight (80.0 +/- 4.5 to 81.1 +/- 4.3 kg; P less than 0.01) which was associated with a marked reduction in urinary sodium excretion (196 +/- 38 to 45 +/- 20 mmol/day; P less than 0.025).,"The pharmacokinetics, safety and endocrine effects of authentic biosynthetic human growth hormone in normal subjects. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598470/),[mM] / [d],196,29974,DB00052,Somatropin recombinant
,2598470,urinary sodium excretion,Bio-hGH administration resulted in a significant increase in body weight (80.0 +/- 4.5 to 81.1 +/- 4.3 kg; P less than 0.01) which was associated with a marked reduction in urinary sodium excretion (196 +/- 38 to 45 +/- 20 mmol/day; P less than 0.025).,"The pharmacokinetics, safety and endocrine effects of authentic biosynthetic human growth hormone in normal subjects. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598470/),[mM] / [d],45,29975,DB00052,Somatropin recombinant
,10443692,peak serum GH concentrations,"The resultant peak serum GH concentrations were 18 +/- 4, 36+/-8, and 70+/-9 microg/L in six women and 17+/-2, 30+/-4, and 84+/-25 microg/L in six men (P = NS, gender contrast).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[μg] / [l],18,30139,DB00052,Somatropin recombinant
,10443692,peak serum GH concentrations,"The resultant peak serum GH concentrations were 18 +/- 4, 36+/-8, and 70+/-9 microg/L in six women and 17+/-2, 30+/-4, and 84+/-25 microg/L in six men (P = NS, gender contrast).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[μg] / [l],36,30140,DB00052,Somatropin recombinant
,10443692,peak serum GH concentrations,"The resultant peak serum GH concentrations were 18 +/- 4, 36+/-8, and 70+/-9 microg/L in six women and 17+/-2, 30+/-4, and 84+/-25 microg/L in six men (P = NS, gender contrast).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[μg] / [l],70,30141,DB00052,Somatropin recombinant
,10443692,peak serum GH concentrations,"The resultant peak serum GH concentrations were 18 +/- 4, 36+/-8, and 70+/-9 microg/L in six women and 17+/-2, 30+/-4, and 84+/-25 microg/L in six men (P = NS, gender contrast).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[μg] / [l],17,30142,DB00052,Somatropin recombinant
,10443692,peak serum GH concentrations,"The resultant peak serum GH concentrations were 18 +/- 4, 36+/-8, and 70+/-9 microg/L in six women and 17+/-2, 30+/-4, and 84+/-25 microg/L in six men (P = NS, gender contrast).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[μg] / [l],30,30143,DB00052,Somatropin recombinant
,10443692,peak serum GH concentrations,"The resultant peak serum GH concentrations were 18 +/- 4, 36+/-8, and 70+/-9 microg/L in six women and 17+/-2, 30+/-4, and 84+/-25 microg/L in six men (P = NS, gender contrast).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[μg] / [l],84,30144,DB00052,Somatropin recombinant
,10443692,Vo,"Corresponding Vo values were 66+/-1, 71+/-1, and 60+/-1 mL/kg in women and 69+/-1, 78+/-1, and 73+/-1 mL/kg in men (P = NS).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[ml] / [kg],66,30145,DB00052,Somatropin recombinant
,10443692,Vo,"Corresponding Vo values were 66+/-1, 71+/-1, and 60+/-1 mL/kg in women and 69+/-1, 78+/-1, and 73+/-1 mL/kg in men (P = NS).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[ml] / [kg],71,30146,DB00052,Somatropin recombinant
,10443692,Vo,"Corresponding Vo values were 66+/-1, 71+/-1, and 60+/-1 mL/kg in women and 69+/-1, 78+/-1, and 73+/-1 mL/kg in men (P = NS).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[ml] / [kg],60,30147,DB00052,Somatropin recombinant
,10443692,Vo,"Corresponding Vo values were 66+/-1, 71+/-1, and 60+/-1 mL/kg in women and 69+/-1, 78+/-1, and 73+/-1 mL/kg in men (P = NS).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[ml] / [kg],69,30148,DB00052,Somatropin recombinant
,10443692,Vo,"Corresponding Vo values were 66+/-1, 71+/-1, and 60+/-1 mL/kg in women and 69+/-1, 78+/-1, and 73+/-1 mL/kg in men (P = NS).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[ml] / [kg],78,30149,DB00052,Somatropin recombinant
,10443692,Vo,"Corresponding Vo values were 66+/-1, 71+/-1, and 60+/-1 mL/kg in women and 69+/-1, 78+/-1, and 73+/-1 mL/kg in men (P = NS).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[ml] / [kg],73,30150,DB00052,Somatropin recombinant
,10443692,t1/2,"Matching monoexponential GH t1/2 values were 7.6+/-0.3, 8.2+/-0.4, and 8.8+/-0.7 min in women and 9.8+/-0.8, 10+/-1, and 9.5+/-1 min in men (average 1.7 min longer in men).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,7.6,30151,DB00052,Somatropin recombinant
,10443692,t1/2,"Matching monoexponential GH t1/2 values were 7.6+/-0.3, 8.2+/-0.4, and 8.8+/-0.7 min in women and 9.8+/-0.8, 10+/-1, and 9.5+/-1 min in men (average 1.7 min longer in men).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,8.2,30152,DB00052,Somatropin recombinant
,10443692,t1/2,"Matching monoexponential GH t1/2 values were 7.6+/-0.3, 8.2+/-0.4, and 8.8+/-0.7 min in women and 9.8+/-0.8, 10+/-1, and 9.5+/-1 min in men (average 1.7 min longer in men).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,8.8,30153,DB00052,Somatropin recombinant
,10443692,t1/2,"Matching monoexponential GH t1/2 values were 7.6+/-0.3, 8.2+/-0.4, and 8.8+/-0.7 min in women and 9.8+/-0.8, 10+/-1, and 9.5+/-1 min in men (average 1.7 min longer in men).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,9.8,30154,DB00052,Somatropin recombinant
,10443692,t1/2,"Matching monoexponential GH t1/2 values were 7.6+/-0.3, 8.2+/-0.4, and 8.8+/-0.7 min in women and 9.8+/-0.8, 10+/-1, and 9.5+/-1 min in men (average 1.7 min longer in men).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,10,30155,DB00052,Somatropin recombinant
,10443692,t1/2,"Matching monoexponential GH t1/2 values were 7.6+/-0.3, 8.2+/-0.4, and 8.8+/-0.7 min in women and 9.8+/-0.8, 10+/-1, and 9.5+/-1 min in men (average 1.7 min longer in men).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,9.5,30156,DB00052,Somatropin recombinant
,10443692,t 1/2,"Regression analysis disclosed no relationship between serum estradiol concentrations and peak serum GH levels, GH t 1/2, or Vo. GH t 1/2 values were also invariant of menstrual cycle stage, e.g. t 1/2 values of 8.1+/-0.5, 9.1+/-1.0, and 8.1+/-0.4 min for the early follicular, late follicular, and midluteal phases, respectively.","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,8.1,30157,DB00052,Somatropin recombinant
,10443692,t 1/2,"Regression analysis disclosed no relationship between serum estradiol concentrations and peak serum GH levels, GH t 1/2, or Vo. GH t 1/2 values were also invariant of menstrual cycle stage, e.g. t 1/2 values of 8.1+/-0.5, 9.1+/-1.0, and 8.1+/-0.4 min for the early follicular, late follicular, and midluteal phases, respectively.","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,9.1,30158,DB00052,Somatropin recombinant
,10443692,t 1/2,"Regression analysis disclosed no relationship between serum estradiol concentrations and peak serum GH levels, GH t 1/2, or Vo. GH t 1/2 values were also invariant of menstrual cycle stage, e.g. t 1/2 values of 8.1+/-0.5, 9.1+/-1.0, and 8.1+/-0.4 min for the early follicular, late follicular, and midluteal phases, respectively.","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,8.1,30159,DB00052,Somatropin recombinant
,10443692,normalized MCRs,"Corresponding normalized MCRs were 319+/-39 (early follicular), 340+/-48 (late follicular), and 340+/-71 (midluteal) L/m2 x day in women and 336+/-50 L/m2 x day in men (P = NS).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[l] / [d·m2],319,30160,DB00052,Somatropin recombinant
,10443692,normalized MCRs,"Corresponding normalized MCRs were 319+/-39 (early follicular), 340+/-48 (late follicular), and 340+/-71 (midluteal) L/m2 x day in women and 336+/-50 L/m2 x day in men (P = NS).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[l] / [d·m2],340,30161,DB00052,Somatropin recombinant
,10443692,normalized MCRs,"Corresponding normalized MCRs were 319+/-39 (early follicular), 340+/-48 (late follicular), and 340+/-71 (midluteal) L/m2 x day in women and 336+/-50 L/m2 x day in men (P = NS).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[l] / [d·m2],340,30162,DB00052,Somatropin recombinant
,10443692,normalized MCRs,"Corresponding normalized MCRs were 319+/-39 (early follicular), 340+/-48 (late follicular), and 340+/-71 (midluteal) L/m2 x day in women and 336+/-50 L/m2 x day in men (P = NS).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[l] / [d·m2],336,30163,DB00052,Somatropin recombinant
,10443692,t 1/2,"At doses of 0.5, 1.5, and 4.5 microg/kg x min, steady state GH t 1/2 values were 9+/-1, 12+/-1, and 15+/-1 min (at respective steady state serum GH concentrations of 0.5+/-0.05, 2.1+/-0.2, and 7.5+/-0.5 microg/L).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,9,30164,DB00052,Somatropin recombinant
,10443692,t 1/2,"At doses of 0.5, 1.5, and 4.5 microg/kg x min, steady state GH t 1/2 values were 9+/-1, 12+/-1, and 15+/-1 min (at respective steady state serum GH concentrations of 0.5+/-0.05, 2.1+/-0.2, and 7.5+/-0.5 microg/L).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,12,30165,DB00052,Somatropin recombinant
,10443692,t 1/2,"At doses of 0.5, 1.5, and 4.5 microg/kg x min, steady state GH t 1/2 values were 9+/-1, 12+/-1, and 15+/-1 min (at respective steady state serum GH concentrations of 0.5+/-0.05, 2.1+/-0.2, and 7.5+/-0.5 microg/L).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,15,30166,DB00052,Somatropin recombinant
,10443692,steady state serum GH concentrations,"At doses of 0.5, 1.5, and 4.5 microg/kg x min, steady state GH t 1/2 values were 9+/-1, 12+/-1, and 15+/-1 min (at respective steady state serum GH concentrations of 0.5+/-0.05, 2.1+/-0.2, and 7.5+/-0.5 microg/L).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[μg] / [l],0.5,30167,DB00052,Somatropin recombinant
,10443692,steady state serum GH concentrations,"At doses of 0.5, 1.5, and 4.5 microg/kg x min, steady state GH t 1/2 values were 9+/-1, 12+/-1, and 15+/-1 min (at respective steady state serum GH concentrations of 0.5+/-0.05, 2.1+/-0.2, and 7.5+/-0.5 microg/L).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[μg] / [l],2.1,30168,DB00052,Somatropin recombinant
,10443692,steady state serum GH concentrations,"At doses of 0.5, 1.5, and 4.5 microg/kg x min, steady state GH t 1/2 values were 9+/-1, 12+/-1, and 15+/-1 min (at respective steady state serum GH concentrations of 0.5+/-0.05, 2.1+/-0.2, and 7.5+/-0.5 microg/L).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),[μg] / [l],7.5,30169,DB00052,Somatropin recombinant
,10443692,t 1/2,"In a third analysis in the same volunteers, stopping the constant iv infusions revealed t 1/2 values of GH decay from equilibrium of 26+/-5 and 23+/-2.3 min for the two higher GH infusion rates.","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,26,30170,DB00052,Somatropin recombinant
,10443692,t 1/2,"In a third analysis in the same volunteers, stopping the constant iv infusions revealed t 1/2 values of GH decay from equilibrium of 26+/-5 and 23+/-2.3 min for the two higher GH infusion rates.","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,23,30171,DB00052,Somatropin recombinant
,10443692,t 1/2,"In a fourth paradigm, endogenous GH t 1/2 values, as assessed in the same individuals by deconvolution analysis of overnight (10-min sampled) serum GH concentration profiles, averaged 18+/-1.3 min.","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,18,30172,DB00052,Somatropin recombinant
,10443692,t 1/2,"In summary, the foregoing clinical experiments in healthy men and women indicate that 1) the nonequilibrium GH t 1/2, (body surface area-normalized) Vo, and MCR are independent of GH dose, sex, menstrual cycle stage, and serum estradiol concentrations; 2) the GH t 1/2 calculated after iv bolus injection is significantly (50%) shorter than that assessed during or after steady-state GH infusions or endogenously (overnight) by deconvolution analysis; and 3) the descending rank order of GH t 1/2 values in healthy volunteers is approximately: decay from steady state (23+/-2.3 min) > endogenously secreted GH (18+/-1.3 min) > during equilibrium infusion (15+/-1 min) > after bolus infusion (9.8+/-0.8 min).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,23,30173,DB00052,Somatropin recombinant
,10443692,t 1/2,"In summary, the foregoing clinical experiments in healthy men and women indicate that 1) the nonequilibrium GH t 1/2, (body surface area-normalized) Vo, and MCR are independent of GH dose, sex, menstrual cycle stage, and serum estradiol concentrations; 2) the GH t 1/2 calculated after iv bolus injection is significantly (50%) shorter than that assessed during or after steady-state GH infusions or endogenously (overnight) by deconvolution analysis; and 3) the descending rank order of GH t 1/2 values in healthy volunteers is approximately: decay from steady state (23+/-2.3 min) > endogenously secreted GH (18+/-1.3 min) > during equilibrium infusion (15+/-1 min) > after bolus infusion (9.8+/-0.8 min).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,18,30174,DB00052,Somatropin recombinant
,10443692,t 1/2,"In summary, the foregoing clinical experiments in healthy men and women indicate that 1) the nonequilibrium GH t 1/2, (body surface area-normalized) Vo, and MCR are independent of GH dose, sex, menstrual cycle stage, and serum estradiol concentrations; 2) the GH t 1/2 calculated after iv bolus injection is significantly (50%) shorter than that assessed during or after steady-state GH infusions or endogenously (overnight) by deconvolution analysis; and 3) the descending rank order of GH t 1/2 values in healthy volunteers is approximately: decay from steady state (23+/-2.3 min) > endogenously secreted GH (18+/-1.3 min) > during equilibrium infusion (15+/-1 min) > after bolus infusion (9.8+/-0.8 min).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,15,30175,DB00052,Somatropin recombinant
,10443692,t 1/2,"In summary, the foregoing clinical experiments in healthy men and women indicate that 1) the nonequilibrium GH t 1/2, (body surface area-normalized) Vo, and MCR are independent of GH dose, sex, menstrual cycle stage, and serum estradiol concentrations; 2) the GH t 1/2 calculated after iv bolus injection is significantly (50%) shorter than that assessed during or after steady-state GH infusions or endogenously (overnight) by deconvolution analysis; and 3) the descending rank order of GH t 1/2 values in healthy volunteers is approximately: decay from steady state (23+/-2.3 min) > endogenously secreted GH (18+/-1.3 min) > during equilibrium infusion (15+/-1 min) > after bolus infusion (9.8+/-0.8 min).","Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10443692/),min,9.8,30176,DB00052,Somatropin recombinant
,26921845,total s.c,"The final model described rhGH PK as a two compartmental model with parallel linear and non-linear elimination terms, parallel first-order absorption with a total s.c. bioavailability of 87% in rats.",Translational mixed-effects PKPD modelling of recombinant human growth hormone - from hypophysectomized rat to patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26921845/),%,87,31102,DB00052,Somatropin recombinant
,18697865,half-lives,"In pilot iv bolus ghrelin infusions, the median half-lives of acylated and total ghrelin were 21 and 36 min (P<0.01), MCRs 58 and 8.1 liters/kg.d (P<0.01), and volumes of distribution of 1.0 and 0.32 liters/kg (P<0.01), respectively.",Estrogen elevates the peak overnight production rate of acylated ghrelin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18697865/),min,21,34430,DB00052,Somatropin recombinant
,18697865,half-lives,"In pilot iv bolus ghrelin infusions, the median half-lives of acylated and total ghrelin were 21 and 36 min (P<0.01), MCRs 58 and 8.1 liters/kg.d (P<0.01), and volumes of distribution of 1.0 and 0.32 liters/kg (P<0.01), respectively.",Estrogen elevates the peak overnight production rate of acylated ghrelin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18697865/),min,36,34431,DB00052,Somatropin recombinant
,18697865,MCRs,"In pilot iv bolus ghrelin infusions, the median half-lives of acylated and total ghrelin were 21 and 36 min (P<0.01), MCRs 58 and 8.1 liters/kg.d (P<0.01), and volumes of distribution of 1.0 and 0.32 liters/kg (P<0.01), respectively.",Estrogen elevates the peak overnight production rate of acylated ghrelin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18697865/),[l] / [d·kg],58,34432,DB00052,Somatropin recombinant
,18697865,MCRs,"In pilot iv bolus ghrelin infusions, the median half-lives of acylated and total ghrelin were 21 and 36 min (P<0.01), MCRs 58 and 8.1 liters/kg.d (P<0.01), and volumes of distribution of 1.0 and 0.32 liters/kg (P<0.01), respectively.",Estrogen elevates the peak overnight production rate of acylated ghrelin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18697865/),[l] / [d·kg],8.1,34433,DB00052,Somatropin recombinant
,18697865,volumes of distribution,"In pilot iv bolus ghrelin infusions, the median half-lives of acylated and total ghrelin were 21 and 36 min (P<0.01), MCRs 58 and 8.1 liters/kg.d (P<0.01), and volumes of distribution of 1.0 and 0.32 liters/kg (P<0.01), respectively.",Estrogen elevates the peak overnight production rate of acylated ghrelin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18697865/),[l] / [kg],1.0,34434,DB00052,Somatropin recombinant
,18697865,volumes of distribution,"In pilot iv bolus ghrelin infusions, the median half-lives of acylated and total ghrelin were 21 and 36 min (P<0.01), MCRs 58 and 8.1 liters/kg.d (P<0.01), and volumes of distribution of 1.0 and 0.32 liters/kg (P<0.01), respectively.",Estrogen elevates the peak overnight production rate of acylated ghrelin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18697865/),[l] / [kg],0.32,34435,DB00052,Somatropin recombinant
,18697865,peak nighttime acylated ghrelin concentrations,Transdermal E2 supplementation for 3 wk increased peak nighttime acylated ghrelin concentrations from 99+/-12 to 141+/-34 pg/ml (P=0.039).,Estrogen elevates the peak overnight production rate of acylated ghrelin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18697865/),[pg] / [ml],99,34436,DB00052,Somatropin recombinant
,18697865,peak nighttime acylated ghrelin concentrations,Transdermal E2 supplementation for 3 wk increased peak nighttime acylated ghrelin concentrations from 99+/-12 to 141+/-34 pg/ml (P=0.039).,Estrogen elevates the peak overnight production rate of acylated ghrelin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18697865/),[pg] / [ml],141,34437,DB00052,Somatropin recombinant
,18697865,peak nighttime production rates,These data predict peak nighttime production rates of acylated ghrelin of 3.8+/-0.9 (E2) and 1.9+/-0.2 (no E2) ng/kg.min (P=0.039).,Estrogen elevates the peak overnight production rate of acylated ghrelin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18697865/),[ng] / [kg·min],3.8,34438,DB00052,Somatropin recombinant
,18697865,peak nighttime production rates,These data predict peak nighttime production rates of acylated ghrelin of 3.8+/-0.9 (E2) and 1.9+/-0.2 (no E2) ng/kg.min (P=0.039).,Estrogen elevates the peak overnight production rate of acylated ghrelin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18697865/),[ng] / [kg·min],1.9,34439,DB00052,Somatropin recombinant
,24235081,terminal elimination of half-life,Velcalcetide plasma exposure increased in a dose-related manner and the terminal elimination of half-life was comparable across the dose range evaluated and ranged from 18.4 to 20.0 h.,"Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24235081/),h,18.4 to 20.0,39957,DB00052,Somatropin recombinant
,32423203,circulating half-life,Pharmacokinetic analysis demonstrated that the circulating half-life of PEGylated B20 was 15.2 h in mice.,Long-Acting Human Growth Hormone Receptor Antagonists Produced in E. coli and Conjugated with Polyethylene Glycol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32423203/),h,15.2,41171,DB00052,Somatropin recombinant
,12466380,concentrations,"Pegvisomant concentrations averaged 4860 +/- 480 micro g/liter (+/-SEM) across the infusion interval, thus exceeding low steady state GH concentrations by 3000-fold.",Impact of experimental blockade of peripheral growth hormone (GH) receptors on the kinetics of endogenous and exogenous GH removal in healthy women and men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12466380/),[μg] / [l],4860,46314,DB00052,Somatropin recombinant
,12466380,half-life,"ANOVA disclosed that prior administration of pegvisomant (compared with placebo) did not alter: 1) the calculated half-life (minutes) of secreted GH, which averaged 15 +/- 1.3 (placebo) and 14 +/- 0.69 (drug); 2) the half-time of disappearance (minutes) of an iv pulse of rhGH, 15 +/- 1.0 (placebo) and 13 +/- 0.5 (drug) (for the 10 micro g/kg dose); 3) the distribution volume (milliliters per kilogram) of rhGH, 59 +/- 6.2 (placebo) and 58 +/- 3.5 (drug); 4) the steady state GH concentration (micrograms per liter) attained during constant iv infusion of rhGH (at a rate of 5 micro g/kg every 2 h), 18.2 +/- 2.4 (placebo) and 18.3 +/- 2.3 (drug); 5) the half-life (minutes) of elimination of GH from equilibrium, 16 +/- 0.98 (placebo) and 16 +/- 1.8 (drug); and 6) the steady state MCR (liters per kilogram per day) of rhGH, 3.8 +/- 0.32 (placebo) and 3.5 +/- 0.31 (drug).",Impact of experimental blockade of peripheral growth hormone (GH) receptors on the kinetics of endogenous and exogenous GH removal in healthy women and men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12466380/),min,15,46315,DB00052,Somatropin recombinant
,12466380,half-life,"ANOVA disclosed that prior administration of pegvisomant (compared with placebo) did not alter: 1) the calculated half-life (minutes) of secreted GH, which averaged 15 +/- 1.3 (placebo) and 14 +/- 0.69 (drug); 2) the half-time of disappearance (minutes) of an iv pulse of rhGH, 15 +/- 1.0 (placebo) and 13 +/- 0.5 (drug) (for the 10 micro g/kg dose); 3) the distribution volume (milliliters per kilogram) of rhGH, 59 +/- 6.2 (placebo) and 58 +/- 3.5 (drug); 4) the steady state GH concentration (micrograms per liter) attained during constant iv infusion of rhGH (at a rate of 5 micro g/kg every 2 h), 18.2 +/- 2.4 (placebo) and 18.3 +/- 2.3 (drug); 5) the half-life (minutes) of elimination of GH from equilibrium, 16 +/- 0.98 (placebo) and 16 +/- 1.8 (drug); and 6) the steady state MCR (liters per kilogram per day) of rhGH, 3.8 +/- 0.32 (placebo) and 3.5 +/- 0.31 (drug).",Impact of experimental blockade of peripheral growth hormone (GH) receptors on the kinetics of endogenous and exogenous GH removal in healthy women and men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12466380/),min,14,46316,DB00052,Somatropin recombinant
,12466380,half-time of disappearance,"ANOVA disclosed that prior administration of pegvisomant (compared with placebo) did not alter: 1) the calculated half-life (minutes) of secreted GH, which averaged 15 +/- 1.3 (placebo) and 14 +/- 0.69 (drug); 2) the half-time of disappearance (minutes) of an iv pulse of rhGH, 15 +/- 1.0 (placebo) and 13 +/- 0.5 (drug) (for the 10 micro g/kg dose); 3) the distribution volume (milliliters per kilogram) of rhGH, 59 +/- 6.2 (placebo) and 58 +/- 3.5 (drug); 4) the steady state GH concentration (micrograms per liter) attained during constant iv infusion of rhGH (at a rate of 5 micro g/kg every 2 h), 18.2 +/- 2.4 (placebo) and 18.3 +/- 2.3 (drug); 5) the half-life (minutes) of elimination of GH from equilibrium, 16 +/- 0.98 (placebo) and 16 +/- 1.8 (drug); and 6) the steady state MCR (liters per kilogram per day) of rhGH, 3.8 +/- 0.32 (placebo) and 3.5 +/- 0.31 (drug).",Impact of experimental blockade of peripheral growth hormone (GH) receptors on the kinetics of endogenous and exogenous GH removal in healthy women and men. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12466380/),min,15,46317,DB00052,Somatropin recombinant
,12466380,half-time of disappearance,"ANOVA disclosed that prior administration of pegvisomant (compared with placebo) did not alter: 1) the calculated half-life (minutes) of secreted GH, which averaged 15 +/- 1.3 (placebo) and 14 +/- 0.69 (drug); 2) the half-time of disappearance (minutes) of an iv pulse of rhGH, 15 +/- 1.0 (placebo) and 13 +/- 0.5 (drug) (for the 10 micro g/kg dose); 3) the distribution volume (milliliters per kilogram) of rhGH, 59 +/- 6.2 (placebo) and 58 +/- 3.5 (drug); 4) the steady state GH concentration (micrograms per liter) attained during constant iv infusion of rhGH (at a rate of 5 micro g/kg every 2 h), 18.2 +/- 2.4 (placebo) and 18.3 +/- 2.3 (drug); 5) the half-life (minutes) of elimination of GH from equilibrium, 16 +/- 0.98 (placebo) and 16 +/- 1.8 (drug); and 6) the steady state MCR (liters per kilogram per day) of rhGH, 3.8 +/- 0.32 (placebo) and 3.5 +/- 0.31 (drug).",Impact of experimental blockade of peripheral growth hormone (GH) receptors on the kinetics of endogenous and exogenous GH removal in healthy women and men. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12466380/),min,13,46318,DB00052,Somatropin recombinant
,12466380,distribution volume,"ANOVA disclosed that prior administration of pegvisomant (compared with placebo) did not alter: 1) the calculated half-life (minutes) of secreted GH, which averaged 15 +/- 1.3 (placebo) and 14 +/- 0.69 (drug); 2) the half-time of disappearance (minutes) of an iv pulse of rhGH, 15 +/- 1.0 (placebo) and 13 +/- 0.5 (drug) (for the 10 micro g/kg dose); 3) the distribution volume (milliliters per kilogram) of rhGH, 59 +/- 6.2 (placebo) and 58 +/- 3.5 (drug); 4) the steady state GH concentration (micrograms per liter) attained during constant iv infusion of rhGH (at a rate of 5 micro g/kg every 2 h), 18.2 +/- 2.4 (placebo) and 18.3 +/- 2.3 (drug); 5) the half-life (minutes) of elimination of GH from equilibrium, 16 +/- 0.98 (placebo) and 16 +/- 1.8 (drug); and 6) the steady state MCR (liters per kilogram per day) of rhGH, 3.8 +/- 0.32 (placebo) and 3.5 +/- 0.31 (drug).",Impact of experimental blockade of peripheral growth hormone (GH) receptors on the kinetics of endogenous and exogenous GH removal in healthy women and men. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12466380/),[milliliters] / [kg],59,46319,DB00052,Somatropin recombinant
,12466380,distribution volume,"ANOVA disclosed that prior administration of pegvisomant (compared with placebo) did not alter: 1) the calculated half-life (minutes) of secreted GH, which averaged 15 +/- 1.3 (placebo) and 14 +/- 0.69 (drug); 2) the half-time of disappearance (minutes) of an iv pulse of rhGH, 15 +/- 1.0 (placebo) and 13 +/- 0.5 (drug) (for the 10 micro g/kg dose); 3) the distribution volume (milliliters per kilogram) of rhGH, 59 +/- 6.2 (placebo) and 58 +/- 3.5 (drug); 4) the steady state GH concentration (micrograms per liter) attained during constant iv infusion of rhGH (at a rate of 5 micro g/kg every 2 h), 18.2 +/- 2.4 (placebo) and 18.3 +/- 2.3 (drug); 5) the half-life (minutes) of elimination of GH from equilibrium, 16 +/- 0.98 (placebo) and 16 +/- 1.8 (drug); and 6) the steady state MCR (liters per kilogram per day) of rhGH, 3.8 +/- 0.32 (placebo) and 3.5 +/- 0.31 (drug).",Impact of experimental blockade of peripheral growth hormone (GH) receptors on the kinetics of endogenous and exogenous GH removal in healthy women and men. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12466380/),[milliliters] / [kg],58,46320,DB00052,Somatropin recombinant
,12466380,steady state GH concentration,"ANOVA disclosed that prior administration of pegvisomant (compared with placebo) did not alter: 1) the calculated half-life (minutes) of secreted GH, which averaged 15 +/- 1.3 (placebo) and 14 +/- 0.69 (drug); 2) the half-time of disappearance (minutes) of an iv pulse of rhGH, 15 +/- 1.0 (placebo) and 13 +/- 0.5 (drug) (for the 10 micro g/kg dose); 3) the distribution volume (milliliters per kilogram) of rhGH, 59 +/- 6.2 (placebo) and 58 +/- 3.5 (drug); 4) the steady state GH concentration (micrograms per liter) attained during constant iv infusion of rhGH (at a rate of 5 micro g/kg every 2 h), 18.2 +/- 2.4 (placebo) and 18.3 +/- 2.3 (drug); 5) the half-life (minutes) of elimination of GH from equilibrium, 16 +/- 0.98 (placebo) and 16 +/- 1.8 (drug); and 6) the steady state MCR (liters per kilogram per day) of rhGH, 3.8 +/- 0.32 (placebo) and 3.5 +/- 0.31 (drug).",Impact of experimental blockade of peripheral growth hormone (GH) receptors on the kinetics of endogenous and exogenous GH removal in healthy women and men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12466380/),[μg] / [l],18.2,46321,DB00052,Somatropin recombinant
,12466380,steady state GH concentration,"ANOVA disclosed that prior administration of pegvisomant (compared with placebo) did not alter: 1) the calculated half-life (minutes) of secreted GH, which averaged 15 +/- 1.3 (placebo) and 14 +/- 0.69 (drug); 2) the half-time of disappearance (minutes) of an iv pulse of rhGH, 15 +/- 1.0 (placebo) and 13 +/- 0.5 (drug) (for the 10 micro g/kg dose); 3) the distribution volume (milliliters per kilogram) of rhGH, 59 +/- 6.2 (placebo) and 58 +/- 3.5 (drug); 4) the steady state GH concentration (micrograms per liter) attained during constant iv infusion of rhGH (at a rate of 5 micro g/kg every 2 h), 18.2 +/- 2.4 (placebo) and 18.3 +/- 2.3 (drug); 5) the half-life (minutes) of elimination of GH from equilibrium, 16 +/- 0.98 (placebo) and 16 +/- 1.8 (drug); and 6) the steady state MCR (liters per kilogram per day) of rhGH, 3.8 +/- 0.32 (placebo) and 3.5 +/- 0.31 (drug).",Impact of experimental blockade of peripheral growth hormone (GH) receptors on the kinetics of endogenous and exogenous GH removal in healthy women and men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12466380/),[μg] / [l],18.3,46322,DB00052,Somatropin recombinant
,12466380,half-life,"ANOVA disclosed that prior administration of pegvisomant (compared with placebo) did not alter: 1) the calculated half-life (minutes) of secreted GH, which averaged 15 +/- 1.3 (placebo) and 14 +/- 0.69 (drug); 2) the half-time of disappearance (minutes) of an iv pulse of rhGH, 15 +/- 1.0 (placebo) and 13 +/- 0.5 (drug) (for the 10 micro g/kg dose); 3) the distribution volume (milliliters per kilogram) of rhGH, 59 +/- 6.2 (placebo) and 58 +/- 3.5 (drug); 4) the steady state GH concentration (micrograms per liter) attained during constant iv infusion of rhGH (at a rate of 5 micro g/kg every 2 h), 18.2 +/- 2.4 (placebo) and 18.3 +/- 2.3 (drug); 5) the half-life (minutes) of elimination of GH from equilibrium, 16 +/- 0.98 (placebo) and 16 +/- 1.8 (drug); and 6) the steady state MCR (liters per kilogram per day) of rhGH, 3.8 +/- 0.32 (placebo) and 3.5 +/- 0.31 (drug).",Impact of experimental blockade of peripheral growth hormone (GH) receptors on the kinetics of endogenous and exogenous GH removal in healthy women and men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12466380/),min,16,46323,DB00052,Somatropin recombinant
,8364604,t1/2 gamma,The half-life for the rapid compartment was shorter in transgenic than in normal mice (t1/2 gamma: 1.2 +/- 0.3 vs. 2.2 +/- 0.5 min).,Pharmacokinetics of radioiodinated human and ovine growth hormones in transgenic mice expressing bovine growth hormone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8364604/),min,1.2,47116,DB00052,Somatropin recombinant
,8364604,t1/2 gamma,The half-life for the rapid compartment was shorter in transgenic than in normal mice (t1/2 gamma: 1.2 +/- 0.3 vs. 2.2 +/- 0.5 min).,Pharmacokinetics of radioiodinated human and ovine growth hormones in transgenic mice expressing bovine growth hormone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8364604/),min,2.2,47117,DB00052,Somatropin recombinant
,8364604,t1/2 alpha,The slow compartment had a t1/2 alpha of 160 +/- 23 min for transgenic and 70 +/- 8 min for normal mice while the middle compartment had a t1/2 beta of approximately 10 min for both groups of mice.,Pharmacokinetics of radioiodinated human and ovine growth hormones in transgenic mice expressing bovine growth hormone. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8364604/),min,160,47118,DB00052,Somatropin recombinant
,8364604,t1/2 alpha,The slow compartment had a t1/2 alpha of 160 +/- 23 min for transgenic and 70 +/- 8 min for normal mice while the middle compartment had a t1/2 beta of approximately 10 min for both groups of mice.,Pharmacokinetics of radioiodinated human and ovine growth hormones in transgenic mice expressing bovine growth hormone. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8364604/),min,70,47119,DB00052,Somatropin recombinant
,8364604,t1/2 beta,The slow compartment had a t1/2 alpha of 160 +/- 23 min for transgenic and 70 +/- 8 min for normal mice while the middle compartment had a t1/2 beta of approximately 10 min for both groups of mice.,Pharmacokinetics of radioiodinated human and ovine growth hormones in transgenic mice expressing bovine growth hormone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8364604/),min,10,47120,DB00052,Somatropin recombinant
,8364604,mean residence times,"The mean residence times were 167 +/- 24 and 55 +/- 5 min for transgenic and normal mice, respectively.",Pharmacokinetics of radioiodinated human and ovine growth hormones in transgenic mice expressing bovine growth hormone. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8364604/),min,167,47121,DB00052,Somatropin recombinant
,8364604,mean residence times,"The mean residence times were 167 +/- 24 and 55 +/- 5 min for transgenic and normal mice, respectively.",Pharmacokinetics of radioiodinated human and ovine growth hormones in transgenic mice expressing bovine growth hormone. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8364604/),min,55,47122,DB00052,Somatropin recombinant
,8364604,ED50%,"Uptake of labelled hGH by the liver was dose-dependent and the doses that prevented 50% of liver uptake (ED50%) were 8 and 165 micrograms per 50 g body weight for normal and transgenic mice, respectively.",Pharmacokinetics of radioiodinated human and ovine growth hormones in transgenic mice expressing bovine growth hormone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8364604/),μg,8,47123,DB00052,Somatropin recombinant
,8364604,ED50%,"Uptake of labelled hGH by the liver was dose-dependent and the doses that prevented 50% of liver uptake (ED50%) were 8 and 165 micrograms per 50 g body weight for normal and transgenic mice, respectively.",Pharmacokinetics of radioiodinated human and ovine growth hormones in transgenic mice expressing bovine growth hormone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8364604/),μg,165,47124,DB00052,Somatropin recombinant
,16352683,half-life,The estimated half-life of CJC-1295 was 5.8-8.1 d.,"Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16352683/),d,5.8-8.1,49990,DB00052,Somatropin recombinant
,1814654,peak,"The peak GH and growth hormone area under the curve were significantly higher after injection in the abdomen compared with the thigh (GH peak (mean +/- SEM) 103 +/- 20 vs 41 +/- 8 mU/l, P = 0.002 and GH area 528 +/- 86 vs 239 +/- 34 mU/l h, P = 0.003 respectively).",The effect of subcutaneous injection site on absorption of human growth hormone: abdomen versus thigh. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1814654/),[mu] / [l],103,51592,DB00052,Somatropin recombinant
,1814654,peak,"The peak GH and growth hormone area under the curve were significantly higher after injection in the abdomen compared with the thigh (GH peak (mean +/- SEM) 103 +/- 20 vs 41 +/- 8 mU/l, P = 0.002 and GH area 528 +/- 86 vs 239 +/- 34 mU/l h, P = 0.003 respectively).",The effect of subcutaneous injection site on absorption of human growth hormone: abdomen versus thigh. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1814654/),[mu] / [l],41,51593,DB00052,Somatropin recombinant
,1814654,area,"The peak GH and growth hormone area under the curve were significantly higher after injection in the abdomen compared with the thigh (GH peak (mean +/- SEM) 103 +/- 20 vs 41 +/- 8 mU/l, P = 0.002 and GH area 528 +/- 86 vs 239 +/- 34 mU/l h, P = 0.003 respectively).",The effect of subcutaneous injection site on absorption of human growth hormone: abdomen versus thigh. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1814654/),[mu] / [h·l],528,51594,DB00052,Somatropin recombinant
,1814654,area,"The peak GH and growth hormone area under the curve were significantly higher after injection in the abdomen compared with the thigh (GH peak (mean +/- SEM) 103 +/- 20 vs 41 +/- 8 mU/l, P = 0.002 and GH area 528 +/- 86 vs 239 +/- 34 mU/l h, P = 0.003 respectively).",The effect of subcutaneous injection site on absorption of human growth hormone: abdomen versus thigh. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1814654/),[mu] / [h·l],239,51595,DB00052,Somatropin recombinant
,22539587,peak plasma concentration,"Both 20 mg oral octreotide and injection of 0.1 mg sc octreotide resulted in equivalent pharmacokinetic parameters [mean peak plasma concentration, 3.77 ± 0.25 vs. 3.97 ± 0.19 ng/ml; mean area under the curve, 16.2 ± 1.25 vs. 12.1 ± 0.45 h × ng/ml); and median time ≥ 0.5 ng/ml, 7.67 vs. 5.88 h, respectively).",Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22539587/),[ng] / [ml],3.77,52140,DB00052,Somatropin recombinant
,22539587,peak plasma concentration,"Both 20 mg oral octreotide and injection of 0.1 mg sc octreotide resulted in equivalent pharmacokinetic parameters [mean peak plasma concentration, 3.77 ± 0.25 vs. 3.97 ± 0.19 ng/ml; mean area under the curve, 16.2 ± 1.25 vs. 12.1 ± 0.45 h × ng/ml); and median time ≥ 0.5 ng/ml, 7.67 vs. 5.88 h, respectively).",Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22539587/),[ng] / [ml],3.97,52141,DB00052,Somatropin recombinant
,22539587,area under the curve,"Both 20 mg oral octreotide and injection of 0.1 mg sc octreotide resulted in equivalent pharmacokinetic parameters [mean peak plasma concentration, 3.77 ± 0.25 vs. 3.97 ± 0.19 ng/ml; mean area under the curve, 16.2 ± 1.25 vs. 12.1 ± 0.45 h × ng/ml); and median time ≥ 0.5 ng/ml, 7.67 vs. 5.88 h, respectively).",Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22539587/),[h·ng] / [ml],16.2,52142,DB00052,Somatropin recombinant
,22539587,area under the curve,"Both 20 mg oral octreotide and injection of 0.1 mg sc octreotide resulted in equivalent pharmacokinetic parameters [mean peak plasma concentration, 3.77 ± 0.25 vs. 3.97 ± 0.19 ng/ml; mean area under the curve, 16.2 ± 1.25 vs. 12.1 ± 0.45 h × ng/ml); and median time ≥ 0.5 ng/ml, 7.67 vs. 5.88 h, respectively).",Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22539587/),[h·ng] / [ml],12.1,52143,DB00052,Somatropin recombinant
≥,22539587,time,"Both 20 mg oral octreotide and injection of 0.1 mg sc octreotide resulted in equivalent pharmacokinetic parameters [mean peak plasma concentration, 3.77 ± 0.25 vs. 3.97 ± 0.19 ng/ml; mean area under the curve, 16.2 ± 1.25 vs. 12.1 ± 0.45 h × ng/ml); and median time ≥ 0.5 ng/ml, 7.67 vs. 5.88 h, respectively).",Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22539587/),[ng] / [ml],0.5,52144,DB00052,Somatropin recombinant
,22539587,time,"Both 20 mg oral octreotide and injection of 0.1 mg sc octreotide resulted in equivalent pharmacokinetic parameters [mean peak plasma concentration, 3.77 ± 0.25 vs. 3.97 ± 0.19 ng/ml; mean area under the curve, 16.2 ± 1.25 vs. 12.1 ± 0.45 h × ng/ml); and median time ≥ 0.5 ng/ml, 7.67 vs. 5.88 h, respectively).",Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22539587/),h,7.67,52145,DB00052,Somatropin recombinant
,22539587,time,"Both 20 mg oral octreotide and injection of 0.1 mg sc octreotide resulted in equivalent pharmacokinetic parameters [mean peak plasma concentration, 3.77 ± 0.25 vs. 3.97 ± 0.19 ng/ml; mean area under the curve, 16.2 ± 1.25 vs. 12.1 ± 0.45 h × ng/ml); and median time ≥ 0.5 ng/ml, 7.67 vs. 5.88 h, respectively).",Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22539587/),h,5.88,52146,DB00052,Somatropin recombinant
,12888486,infusion,"During sleep, both the median infusion and clearance half-life estimates were 13.8 min, and the median number of secretory events was 2.",A statistical model of diurnal variation in human growth hormone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12888486/),min,13.8,53706,DB00052,Somatropin recombinant
,12888486,infusion half-life,"During the constant routine, the median infusion half-life estimate was 12.6 min, the median clearance half-life estimate was 11.7 min, and the median number of secretory events was 5.",A statistical model of diurnal variation in human growth hormone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12888486/),min,12.6,53707,DB00052,Somatropin recombinant
,12888486,clearance half-life,"During the constant routine, the median infusion half-life estimate was 12.6 min, the median clearance half-life estimate was 11.7 min, and the median number of secretory events was 5.",A statistical model of diurnal variation in human growth hormone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12888486/),min,11.7,53708,DB00052,Somatropin recombinant
,24838219,Tmax,"Pharmacokinetic studies showed that the rhGH-coated microneedle patches, delivered with high efficiency and the doses delivered indicated linearity with average Tmax of 30 min.","Human Growth Hormone Delivery with a Microneedle Transdermal System: Preclinical Formulation, Stability, Delivery and PK of Therapeutically Relevant Doses. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24838219/),min,30,54115,DB00052,Somatropin recombinant
>,30002437,trough plasma concentration (Ctrough),Primary endpoint was percentage of patients with trough plasma concentration (Ctrough) >20 μg/ml at Cycle 5 (Cycle 6 predose).,Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30002437/),[μg] / [ml],20,55339,DB00052,Somatropin recombinant
>,30002437,Ctrough,"For PF-05280014 vs trastuzumab-EU patients, respectively, 92.1% vs 93.3% had Cycle 5 Ctrough >20 μg/ml; the lower limit of the 95% confidence interval (- 8.02%, 6.49%) for the stratified difference between groups was above the non-inferiority margin (- 12.5%).",Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30002437/),,20,55340,DB00052,Somatropin recombinant
,30002437,Pathological complete response,Pathological complete response (47.0% vs 50.0%) and central radiology review-assessed objective response (88.1% vs 82.0%) rates were comparable.,Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30002437/),%,47.0,55341,DB00052,Somatropin recombinant
,30002437,Pathological complete response,Pathological complete response (47.0% vs 50.0%) and central radiology review-assessed objective response (88.1% vs 82.0%) rates were comparable.,Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30002437/),%,50.0,55342,DB00052,Somatropin recombinant
,15359571,Mon,"Monomeric content of hGH recovered from SR-hGH was 97.4% by SEC analysis, and its purity was 96% by RP-HPLC analysis.",Characterization and in vivo study of sustained-release formulation of human growth hormone using sodium hyaluronate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15359571/),%,97.4,55510,DB00052,Somatropin recombinant
,15359571,Cmax,Delayed absorption of hGH was observed with Cmax of 69.5+/-8.0 ng/ml and Tmax between 10 and 12 h.,Characterization and in vivo study of sustained-release formulation of human growth hormone using sodium hyaluronate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15359571/),[ng] / [ml],69.5,55511,DB00052,Somatropin recombinant
,15359571,Tmax,Delayed absorption of hGH was observed with Cmax of 69.5+/-8.0 ng/ml and Tmax between 10 and 12 h.,Characterization and in vivo study of sustained-release formulation of human growth hormone using sodium hyaluronate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15359571/),h,10 and 12,55512,DB00052,Somatropin recombinant
,11578108,biological bioavailability,"Hexarelin, a hexapeptide with growth hormone-releasing activity, has been found in man to have a biological bioavailability (estimated from growth hormone levels) of 0.3+/-0.1% after oral administration.",Hexarelin--evaluation of factors influencing oral bioavailability and ways to improve absorption. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11578108/),%,0.3,56071,DB00052,Somatropin recombinant
,7937569,half-lives,Similar half-lives of 4-5 min.,Pharmacological characterization of a biosynthetic trisulfide-containing hydrophobic derivative of human growth hormone: comparison with standard 22 K growth hormone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7937569/),min,4-5,60445,DB00052,Somatropin recombinant
,10487702,clearance,"The mean values and coefficients of variance (SD/mean) of GH pharmacokinetic parameters in our 15 subjects were: clearance, 0.236 L/min (24%); volume of distribution, 3.46 L (30%); and terminal half-life, 12.3 min (37%).",Appraisal of growth hormone (GH) secretion: evaluation of a composite pharmacokinetic model that discriminates multiple components of GH input. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10487702/),[l] / [min],0.236,60461,DB00052,Somatropin recombinant
,10487702,volume of distribution,"The mean values and coefficients of variance (SD/mean) of GH pharmacokinetic parameters in our 15 subjects were: clearance, 0.236 L/min (24%); volume of distribution, 3.46 L (30%); and terminal half-life, 12.3 min (37%).",Appraisal of growth hormone (GH) secretion: evaluation of a composite pharmacokinetic model that discriminates multiple components of GH input. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10487702/),l,3.46,60462,DB00052,Somatropin recombinant
,10487702,terminal half-life,"The mean values and coefficients of variance (SD/mean) of GH pharmacokinetic parameters in our 15 subjects were: clearance, 0.236 L/min (24%); volume of distribution, 3.46 L (30%); and terminal half-life, 12.3 min (37%).",Appraisal of growth hormone (GH) secretion: evaluation of a composite pharmacokinetic model that discriminates multiple components of GH input. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10487702/),min,12.3,60463,DB00052,Somatropin recombinant
,10487702,basal concentration,"The values for the cosinor parameters were: basal concentration, 0.22 ng/mL (85%); amplitude, 0.758 (50%); cycle, 121 min (27%); and time shift (acrophase), 60.3 min (53.6%).",Appraisal of growth hormone (GH) secretion: evaluation of a composite pharmacokinetic model that discriminates multiple components of GH input. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10487702/),[ng] / [ml],0.22,60464,DB00052,Somatropin recombinant
,10487702,amplitude,"The values for the cosinor parameters were: basal concentration, 0.22 ng/mL (85%); amplitude, 0.758 (50%); cycle, 121 min (27%); and time shift (acrophase), 60.3 min (53.6%).",Appraisal of growth hormone (GH) secretion: evaluation of a composite pharmacokinetic model that discriminates multiple components of GH input. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10487702/),,0.758,60465,DB00052,Somatropin recombinant
,10487702,cycle,"The values for the cosinor parameters were: basal concentration, 0.22 ng/mL (85%); amplitude, 0.758 (50%); cycle, 121 min (27%); and time shift (acrophase), 60.3 min (53.6%).",Appraisal of growth hormone (GH) secretion: evaluation of a composite pharmacokinetic model that discriminates multiple components of GH input. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10487702/),min,121,60466,DB00052,Somatropin recombinant
,10487702,time shift (acrophase),"The values for the cosinor parameters were: basal concentration, 0.22 ng/mL (85%); amplitude, 0.758 (50%); cycle, 121 min (27%); and time shift (acrophase), 60.3 min (53.6%).",Appraisal of growth hormone (GH) secretion: evaluation of a composite pharmacokinetic model that discriminates multiple components of GH input. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10487702/),min,60.3,60467,DB00052,Somatropin recombinant
,10487702,clearance,"During the 9-h study, clearance decreased from 0.259 +/- 0.09 to 0.214 +/- 0.06 L/min (P < 0.03), and basal concentration increased from 0.20 +/- 0.22 to 0.33 +/- 0.33 ng/mL (P < 0.5).",Appraisal of growth hormone (GH) secretion: evaluation of a composite pharmacokinetic model that discriminates multiple components of GH input. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10487702/),[l] / [min],0.259,60468,DB00052,Somatropin recombinant
,10487702,clearance,"During the 9-h study, clearance decreased from 0.259 +/- 0.09 to 0.214 +/- 0.06 L/min (P < 0.03), and basal concentration increased from 0.20 +/- 0.22 to 0.33 +/- 0.33 ng/mL (P < 0.5).",Appraisal of growth hormone (GH) secretion: evaluation of a composite pharmacokinetic model that discriminates multiple components of GH input. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10487702/),[l] / [min],0.214,60469,DB00052,Somatropin recombinant
,10487702,basal concentration,"During the 9-h study, clearance decreased from 0.259 +/- 0.09 to 0.214 +/- 0.06 L/min (P < 0.03), and basal concentration increased from 0.20 +/- 0.22 to 0.33 +/- 0.33 ng/mL (P < 0.5).",Appraisal of growth hormone (GH) secretion: evaluation of a composite pharmacokinetic model that discriminates multiple components of GH input. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10487702/),[ng] / [ml],0.20,60470,DB00052,Somatropin recombinant
,10487702,basal concentration,"During the 9-h study, clearance decreased from 0.259 +/- 0.09 to 0.214 +/- 0.06 L/min (P < 0.03), and basal concentration increased from 0.20 +/- 0.22 to 0.33 +/- 0.33 ng/mL (P < 0.5).",Appraisal of growth hormone (GH) secretion: evaluation of a composite pharmacokinetic model that discriminates multiple components of GH input. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10487702/),[ng] / [ml],0.33,60471,DB00052,Somatropin recombinant
greater,27242314,residence time,"The in vivo fluorescence images of mice injected with rhodamine B isothiocyanate-labelled nanogel suspension showed fluorescence intensity up to 96h after intravenous injection, indicating that the in vivo residence time of the nanogel was greater than 96h.","In vivo residence duration of human growth hormone loaded in nanogels comprising cinnamoyl alginate, cinnamoyl Pluronic F127 and cinnamoyl poly(ethylene glycol). ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27242314/),h,96,61121,DB00052,Somatropin recombinant
,1283730,Tmax,Pharmacokinetic parameters derived from baseline adjusted IGF-I measurements revealed a slow absorption of the administered dose with a Tmax of 5.0 +/- 0.43 hours and an elimination half-life of 10.8 +/- 1.2 hours.,Administration of human recombinant insulin-like growth factor-I to patients following major gastrointestinal surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1283730/),h,5.0,61452,DB00052,Somatropin recombinant
,1283730,elimination half-life,Pharmacokinetic parameters derived from baseline adjusted IGF-I measurements revealed a slow absorption of the administered dose with a Tmax of 5.0 +/- 0.43 hours and an elimination half-life of 10.8 +/- 1.2 hours.,Administration of human recombinant insulin-like growth factor-I to patients following major gastrointestinal surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1283730/),h,10.8,61453,DB00052,Somatropin recombinant
,1283730,volume of distribution,The computed volume of distribution was 0.33 +/- 0.05 I/kg and the clearance on average 25 ml/min.,Administration of human recombinant insulin-like growth factor-I to patients following major gastrointestinal surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1283730/),[i] / [kg],0.33,61454,DB00052,Somatropin recombinant
,1283730,clearance,The computed volume of distribution was 0.33 +/- 0.05 I/kg and the clearance on average 25 ml/min.,Administration of human recombinant insulin-like growth factor-I to patients following major gastrointestinal surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1283730/),[ml] / [min],25,61455,DB00052,Somatropin recombinant
,10690862,half-lives,Maximum serum 20K-hGH levels were reached at 3-4 h and decreased with half-lives of 2-3 h.,Exogenous 20K growth hormone (GH) suppresses endogenous 22K GH secretion in normal men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10690862/),h,2-3,62679,DB00052,Somatropin recombinant
,9818710,half-life,"The calculated half-life was 7.7 +/- 0.7 min, with a clearance of 4.5 +/- 0.3 mL min(-1), values consistent with literature reports for growth hormone in rats.",Pharmacokinetic and metabolism studies using uniformly stable isotope labeled proteins with HPLC/CRIMS detection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9818710/),min,7.7,66758,DB00052,Somatropin recombinant
,9818710,clearance,"The calculated half-life was 7.7 +/- 0.7 min, with a clearance of 4.5 +/- 0.3 mL min(-1), values consistent with literature reports for growth hormone in rats.",Pharmacokinetic and metabolism studies using uniformly stable isotope labeled proteins with HPLC/CRIMS detection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9818710/),[ml] / [min],4.5,66759,DB00052,Somatropin recombinant
,28656605,maximum concentration,Mean serum concentrations of somapacitan increased in a dose-dependent but nonlinear manner: maximum concentration ranged from 21.8 ng/mL (0.02 mg/kg dose) to 458.4 ng/mL (0.16 mg/kg dose).,"Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: A randomized dose-escalation trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28656605/),[ng] / [ml],21.8,67055,DB00052,Somatropin recombinant
,28656605,maximum concentration,Mean serum concentrations of somapacitan increased in a dose-dependent but nonlinear manner: maximum concentration ranged from 21.8 ng/mL (0.02 mg/kg dose) to 458.4 ng/mL (0.16 mg/kg dose).,"Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: A randomized dose-escalation trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28656605/),[ng] / [ml],458.4,67056,DB00052,Somatropin recombinant
,29697217,Kin,"The three compounds showed comparable initial brain influx, with Kin=0.38±0.14 µL/(g×min), 0.36±0.16 µL/(g×min) and 0.28±0.18 µL/(g×min), respectively.",Blood-brain barrier transport kinetics of NOTA-modified proteins: the somatropin case. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29697217/),[μl] / [g·min],0.38,68308,DB00052,Somatropin recombinant
,29697217,Kin,"The three compounds showed comparable initial brain influx, with Kin=0.38±0.14 µL/(g×min), 0.36±0.16 µL/(g×min) and 0.28±0.18 µL/(g×min), respectively.",Blood-brain barrier transport kinetics of NOTA-modified proteins: the somatropin case. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29697217/),[μl] / [g·min],0.36,68309,DB00052,Somatropin recombinant
,29697217,Kin,"The three compounds showed comparable initial brain influx, with Kin=0.38±0.14 µL/(g×min), 0.36±0.16 µL/(g×min) and 0.28±0.18 µL/(g×min), respectively.",Blood-brain barrier transport kinetics of NOTA-modified proteins: the somatropin case. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29697217/),[μl] / [g·min],0.28,68310,DB00052,Somatropin recombinant
,33754315,AUC0-168 h,"AUC0-168 h of IGF-I was increased in the moderate impairment group (1.35 [1.09-1.66]), severe impairment group (1.40 [1.10-1.78]), and requiring hemodialysis group (1.24 [1.01-1.52]), compared with the normal function group.","Effect of Kidney or Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Somapacitan: Two Open-Label, Parallel-Group Trials. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33754315/),,1.35,69510,DB00052,Somatropin recombinant
,33754315,AUC0-168 h,"AUC0-168 h of IGF-I was increased in the moderate impairment group (1.35 [1.09-1.66]), severe impairment group (1.40 [1.10-1.78]), and requiring hemodialysis group (1.24 [1.01-1.52]), compared with the normal function group.","Effect of Kidney or Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Somapacitan: Two Open-Label, Parallel-Group Trials. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33754315/),,1.40,69511,DB00052,Somatropin recombinant
,33754315,AUC0-168 h,"AUC0-168 h of IGF-I was increased in the moderate impairment group (1.35 [1.09-1.66]), severe impairment group (1.40 [1.10-1.78]), and requiring hemodialysis group (1.24 [1.01-1.52]), compared with the normal function group.","Effect of Kidney or Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Somapacitan: Two Open-Label, Parallel-Group Trials. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33754315/),,1.24,69512,DB00052,Somatropin recombinant
,33754315,AUC0-168 h,"In the hepatic impairment trial, somapacitan AUC0-168 h was significantly higher in the moderate impairment group compared with the normal hepatic function group (4.69 [2.92-7.52]).","Effect of Kidney or Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Somapacitan: Two Open-Label, Parallel-Group Trials. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33754315/),,4.69,69513,DB00052,Somatropin recombinant
,33754315,AUC0-168 h,IGF-I AUC0-168 h was lower in both hepatic impairment groups (0.85 [0.67-1.08] for the mild impairment group and 0.75 [0.60-0.95] for the moderate impairment group) compared with the normal function group.,"Effect of Kidney or Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Somapacitan: Two Open-Label, Parallel-Group Trials. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33754315/),,0.85,69514,DB00052,Somatropin recombinant
,33754315,AUC0-168 h,IGF-I AUC0-168 h was lower in both hepatic impairment groups (0.85 [0.67-1.08] for the mild impairment group and 0.75 [0.60-0.95] for the moderate impairment group) compared with the normal function group.,"Effect of Kidney or Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Somapacitan: Two Open-Label, Parallel-Group Trials. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33754315/),,0.75,69515,DB00052,Somatropin recombinant
,26425883,relative bioavailability,The relative bioavailability was about 3%.,Intranasal Human Growth Hormone (hGH) Induces IGF-1 Levels Comparable With Subcutaneous Injection With Lower Systemic Exposure to hGH in Healthy Volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26425883/),%,3,71623,DB00052,Somatropin recombinant
,10856481,number,"The mean (+/-SD) number of follicles >/=8 mm on the day of maximum stimulation in the 150 IU and 225 IU s. c. and 150 IU i.m. groups were 14.0 +/- 7.1, 14.3 +/- 8.2, and 6.5 +/- 4.7.",A dose proportionality study of subcutaneously and intramuscularly administered recombinant human follicle-stimulating hormone (Follistim*/Puregon) in healthy female volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10856481/),,14.0,73277,DB00052,Somatropin recombinant
,10856481,number,"The mean (+/-SD) number of follicles >/=8 mm on the day of maximum stimulation in the 150 IU and 225 IU s. c. and 150 IU i.m. groups were 14.0 +/- 7.1, 14.3 +/- 8.2, and 6.5 +/- 4.7.",A dose proportionality study of subcutaneously and intramuscularly administered recombinant human follicle-stimulating hormone (Follistim*/Puregon) in healthy female volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10856481/),,14.3,73278,DB00052,Somatropin recombinant
,10856481,number,"The mean (+/-SD) number of follicles >/=8 mm on the day of maximum stimulation in the 150 IU and 225 IU s. c. and 150 IU i.m. groups were 14.0 +/- 7.1, 14.3 +/- 8.2, and 6.5 +/- 4.7.",A dose proportionality study of subcutaneously and intramuscularly administered recombinant human follicle-stimulating hormone (Follistim*/Puregon) in healthy female volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10856481/),,6.5,73279,DB00052,Somatropin recombinant
,17922895,tmax,"click 2 the tmax was less (3.0 hours) than for needle and syringe delivery (4.5 hours), p = 0.002 (Friedman test), although this is unlikely to have any clinical implications.","Pharmacokinetics of recombinant human growth hormone administered by cool. click 2, a new needle-free device, compared with subcutaneous administration using a conventional syringe and needle. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17922895/),h,3.0,74779,DB00052,Somatropin recombinant
,17922895,tmax,"click 2 the tmax was less (3.0 hours) than for needle and syringe delivery (4.5 hours), p = 0.002 (Friedman test), although this is unlikely to have any clinical implications.","Pharmacokinetics of recombinant human growth hormone administered by cool. click 2, a new needle-free device, compared with subcutaneous administration using a conventional syringe and needle. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17922895/),h,4.5,74780,DB00052,Somatropin recombinant
,21724838,AUC(0)(-),"Mean values for IGF1 AUC(0)(-)(168 h)/168 h and C(max) were higher for GH than for NNC126-0083, although the difference was not statistically significant for cohort's 0.06 mg protein/kg.","Long-acting pegylated human GH in children with GH deficiency: a single-dose, dose-escalation trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21724838/),h,168,76851,DB00052,Somatropin recombinant
,8924193,S(+)/R(-) ratio,Determination of the citalopram enantiomers yielded a balanced S(+)/R(-) ratio of 0.9 to 1.2.,Neuroendocrine effects of a 20-mg citalopram infusion in healthy males. A placebo-controlled evaluation of citalopram as 5-HT function probe. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8924193/),,0,76966,DB00052,Somatropin recombinant
,12501599,area under curve (AUC),"The results showed that the area under curve (AUC) of blood drug concentration-time curve of hGH-L was 32,686.90, the mean remain time (MRT) of hGH-L in blood was 21.37 minutes, but the AUC of blood drug concentration-time curve of hGH was 36,913.08 and the MRT of hGH in blood was 24.98 minutes.",[Pharmacokinetic analysis of lactosaminated human growth hormone and human growth hormone]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12501599/),,"32,686.90",79823,DB00052,Somatropin recombinant
,12501599,remain time (MRT),"The results showed that the area under curve (AUC) of blood drug concentration-time curve of hGH-L was 32,686.90, the mean remain time (MRT) of hGH-L in blood was 21.37 minutes, but the AUC of blood drug concentration-time curve of hGH was 36,913.08 and the MRT of hGH in blood was 24.98 minutes.",[Pharmacokinetic analysis of lactosaminated human growth hormone and human growth hormone]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12501599/),min,21.37,79824,DB00052,Somatropin recombinant
,12501599,AUC of blood drug concentration-time curve,"The results showed that the area under curve (AUC) of blood drug concentration-time curve of hGH-L was 32,686.90, the mean remain time (MRT) of hGH-L in blood was 21.37 minutes, but the AUC of blood drug concentration-time curve of hGH was 36,913.08 and the MRT of hGH in blood was 24.98 minutes.",[Pharmacokinetic analysis of lactosaminated human growth hormone and human growth hormone]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12501599/),,"36,913.08",79825,DB00052,Somatropin recombinant
,12501599,MRT,"The results showed that the area under curve (AUC) of blood drug concentration-time curve of hGH-L was 32,686.90, the mean remain time (MRT) of hGH-L in blood was 21.37 minutes, but the AUC of blood drug concentration-time curve of hGH was 36,913.08 and the MRT of hGH in blood was 24.98 minutes.",[Pharmacokinetic analysis of lactosaminated human growth hormone and human growth hormone]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12501599/),min,24.98,79826,DB00052,Somatropin recombinant
,12501599,half-time of distribution (t1/2 alpha),"In liver, for hGH-L, the half-time of distribution (t1/2 alpha) was 1.84 minutes, the half-time of removal(t1/2 beta) was 11.09 minutes, the AUC of liver drug concentration-time curve was 17,621.9; for hGH, the t1/2 alpha was 2.11 minutes, the t1/2 beta was 75.65 minutes, the AUC of liver drug concentration-time curve was 12,148.2.",[Pharmacokinetic analysis of lactosaminated human growth hormone and human growth hormone]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12501599/),min,1.84,79827,DB00052,Somatropin recombinant
,12501599,half-time of removal(t1/2 beta),"In liver, for hGH-L, the half-time of distribution (t1/2 alpha) was 1.84 minutes, the half-time of removal(t1/2 beta) was 11.09 minutes, the AUC of liver drug concentration-time curve was 17,621.9; for hGH, the t1/2 alpha was 2.11 minutes, the t1/2 beta was 75.65 minutes, the AUC of liver drug concentration-time curve was 12,148.2.",[Pharmacokinetic analysis of lactosaminated human growth hormone and human growth hormone]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12501599/),min,11.09,79828,DB00052,Somatropin recombinant
,12501599,AUC,"In liver, for hGH-L, the half-time of distribution (t1/2 alpha) was 1.84 minutes, the half-time of removal(t1/2 beta) was 11.09 minutes, the AUC of liver drug concentration-time curve was 17,621.9; for hGH, the t1/2 alpha was 2.11 minutes, the t1/2 beta was 75.65 minutes, the AUC of liver drug concentration-time curve was 12,148.2.",[Pharmacokinetic analysis of lactosaminated human growth hormone and human growth hormone]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12501599/),,"17,621.9",79829,DB00052,Somatropin recombinant
,12501599,t1/2 alpha,"In liver, for hGH-L, the half-time of distribution (t1/2 alpha) was 1.84 minutes, the half-time of removal(t1/2 beta) was 11.09 minutes, the AUC of liver drug concentration-time curve was 17,621.9; for hGH, the t1/2 alpha was 2.11 minutes, the t1/2 beta was 75.65 minutes, the AUC of liver drug concentration-time curve was 12,148.2.",[Pharmacokinetic analysis of lactosaminated human growth hormone and human growth hormone]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12501599/),min,2.11,79830,DB00052,Somatropin recombinant
,12501599,t1/2 beta,"In liver, for hGH-L, the half-time of distribution (t1/2 alpha) was 1.84 minutes, the half-time of removal(t1/2 beta) was 11.09 minutes, the AUC of liver drug concentration-time curve was 17,621.9; for hGH, the t1/2 alpha was 2.11 minutes, the t1/2 beta was 75.65 minutes, the AUC of liver drug concentration-time curve was 12,148.2.",[Pharmacokinetic analysis of lactosaminated human growth hormone and human growth hormone]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12501599/),min,75.65,79831,DB00052,Somatropin recombinant
,12501599,AUC,"In liver, for hGH-L, the half-time of distribution (t1/2 alpha) was 1.84 minutes, the half-time of removal(t1/2 beta) was 11.09 minutes, the AUC of liver drug concentration-time curve was 17,621.9; for hGH, the t1/2 alpha was 2.11 minutes, the t1/2 beta was 75.65 minutes, the AUC of liver drug concentration-time curve was 12,148.2.",[Pharmacokinetic analysis of lactosaminated human growth hormone and human growth hormone]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12501599/),,"12,148.2",79832,DB00052,Somatropin recombinant
,17169119,LD50,"In intravenous single-dose studies in mice, the LD50 was 731.26 microg/kg and 676.03 microg/kg in male and female mice respectively.",A recombinant protein LHRH-PE40 for tumour therapy: preclinical safety studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17169119/),[μg] / [kg],731.26,80845,DB00052,Somatropin recombinant
,17169119,LD50,"In intravenous single-dose studies in mice, the LD50 was 731.26 microg/kg and 676.03 microg/kg in male and female mice respectively.",A recombinant protein LHRH-PE40 for tumour therapy: preclinical safety studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17169119/),[μg] / [kg],676.03,80846,DB00052,Somatropin recombinant
,9267949,Peak IGF-I concentrations,Peak IGF-I concentrations were sustained from 2 hrs (90.5 ng/mL [23 to 228]) to 5 hrs (88.5 ng/mL [29 to 300]).,Administration of human recombinant insulin-like growth factor-I in critically ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9267949/),[ng] / [ml],90.5,82086,DB00052,Somatropin recombinant
,9267949,Peak IGF-I concentrations,Peak IGF-I concentrations were sustained from 2 hrs (90.5 ng/mL [23 to 228]) to 5 hrs (88.5 ng/mL [29 to 300]).,Administration of human recombinant insulin-like growth factor-I in critically ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9267949/),[ng] / [ml],88.5,82087,DB00052,Somatropin recombinant
,6092407,MCR,The difference in duration of effect between hCRF and oCRF may be attributed to an approximately 3-4 times higher MCR of hCRF [7.9 +/- 1.2 (+/- SE) ml/kg min; n = 14] than oCRF (1.9 +/- 0.1 ml/kg min; n = 9) in man.,Human corticotropin-releasing factor in man: pharmacokinetic properties and dose-response of plasma adrenocorticotropin and cortisol secretion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6092407/),[ml] / [kg·min],7.9,82497,DB00052,Somatropin recombinant
,6092407,MCR,The difference in duration of effect between hCRF and oCRF may be attributed to an approximately 3-4 times higher MCR of hCRF [7.9 +/- 1.2 (+/- SE) ml/kg min; n = 14] than oCRF (1.9 +/- 0.1 ml/kg min; n = 9) in man.,Human corticotropin-releasing factor in man: pharmacokinetic properties and dose-response of plasma adrenocorticotropin and cortisol secretion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6092407/),[ml] / [kg·min],1.9,82498,DB00052,Somatropin recombinant
,3107967,distribution,"The disappearance of IR-hGHRH from plasma was characterized by a biexponential decay curve, with initial distribution and subsequent metabolic t1/2 value of 5.0 +/- 1.0 and 29.6 +/- 5.4 min (mean +/- SE), respectively.",Plasma disappearance half-time and metabolic clearance rate of exogenous human growth hormone-releasing hormone-(1-44)-NH2 in normal subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3107967/),min,5.0,83890,DB00052,Somatropin recombinant
,3107967,metabolic t1/2,"The disappearance of IR-hGHRH from plasma was characterized by a biexponential decay curve, with initial distribution and subsequent metabolic t1/2 value of 5.0 +/- 1.0 and 29.6 +/- 5.4 min (mean +/- SE), respectively.",Plasma disappearance half-time and metabolic clearance rate of exogenous human growth hormone-releasing hormone-(1-44)-NH2 in normal subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3107967/),min,29.6,83891,DB00052,Somatropin recombinant
,3107967,MCR,The MCR of IR-hGHRH was 6.1 +/- 1.2 ml/min X kg.,Plasma disappearance half-time and metabolic clearance rate of exogenous human growth hormone-releasing hormone-(1-44)-NH2 in normal subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3107967/),[ml] / [kg·min],6.1,83892,DB00052,Somatropin recombinant
,3107967,volume of distribution,The volume of distribution of IR-hGHRH was 3.3 +/- 0.4 liters.,Plasma disappearance half-time and metabolic clearance rate of exogenous human growth hormone-releasing hormone-(1-44)-NH2 in normal subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3107967/),l,3.3,83893,DB00052,Somatropin recombinant
,19293342,area under the curve for 0 to 24 hours,Results are given as mean +/- SEM: The area under the curve for 0 to 24 hours is approximately twice as high without food (27.8 +/- 4.1) than with food (13.7 +/- 1.2; P = .002).,Effect of food on the pharmacokinetics and pharmacodynamics of an oral ghrelin agonist (ARD-07) in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19293342/),,27.8,85728,DB00052,Somatropin recombinant
,19293342,area under the curve for 0 to 24 hours,Results are given as mean +/- SEM: The area under the curve for 0 to 24 hours is approximately twice as high without food (27.8 +/- 4.1) than with food (13.7 +/- 1.2; P = .002).,Effect of food on the pharmacokinetics and pharmacodynamics of an oral ghrelin agonist (ARD-07) in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19293342/),,13.7,85729,DB00052,Somatropin recombinant
,19293342,maximum observed ARD-07 concentration relative to dose administration (C(max)),The maximum observed ARD-07 concentration relative to dose administration (C(max)) is more than twice as high without food (10.6 +/- 1.6 ng/mL) than with food (4.4 +/- 0.5 ng/mL; P = .001).,Effect of food on the pharmacokinetics and pharmacodynamics of an oral ghrelin agonist (ARD-07) in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19293342/),[ng] / [ml],10.6,85730,DB00052,Somatropin recombinant
,19293342,maximum observed ARD-07 concentration relative to dose administration (C(max)),The maximum observed ARD-07 concentration relative to dose administration (C(max)) is more than twice as high without food (10.6 +/- 1.6 ng/mL) than with food (4.4 +/- 0.5 ng/mL; P = .001).,Effect of food on the pharmacokinetics and pharmacodynamics of an oral ghrelin agonist (ARD-07) in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19293342/),[ng] / [ml],4.4,85731,DB00052,Somatropin recombinant
,19293342,C(max),C(max) of growth hormone occurs at a significantly (P = .001) later stage with food (C(max) = 13.0 +/- 3.5 ng/mL) than without food (37.1 +/- 5.3 ng/mL).,Effect of food on the pharmacokinetics and pharmacodynamics of an oral ghrelin agonist (ARD-07) in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19293342/),[ng] / [ml],13.0,85732,DB00052,Somatropin recombinant
,19293342,C(max),C(max) of growth hormone occurs at a significantly (P = .001) later stage with food (C(max) = 13.0 +/- 3.5 ng/mL) than without food (37.1 +/- 5.3 ng/mL).,Effect of food on the pharmacokinetics and pharmacodynamics of an oral ghrelin agonist (ARD-07) in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19293342/),[ng] / [ml],37.1,85733,DB00052,Somatropin recombinant
,9824264,Trough serum growth hormone,Trough serum growth hormone (microg/l) was higher in both patient groups (5.3+/-3.6) than in controls (1.0+/-0.3; p<0.01).,Spontaneous pulsatility and pharmacokinetics of growth hormone in liver cirrhotic patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9824264/),[μg] / [l],5.3,87271,DB00052,Somatropin recombinant
,9824264,Trough serum growth hormone,Trough serum growth hormone (microg/l) was higher in both patient groups (5.3+/-3.6) than in controls (1.0+/-0.3; p<0.01).,Spontaneous pulsatility and pharmacokinetics of growth hormone in liver cirrhotic patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9824264/),[μg] / [l],1.0,87272,DB00052,Somatropin recombinant
,9824264,area under the curve over 24 h,"After subcutaneous recombinant human growth hormone injection, maximal growth hormone was higher in cirrhotic patients and the area under the curve over 24 h was greater (626+/-120) than in controls (330+/-54; p<0.01).",Spontaneous pulsatility and pharmacokinetics of growth hormone in liver cirrhotic patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9824264/),,626,87273,DB00052,Somatropin recombinant
,9824264,area under the curve over 24 h,"After subcutaneous recombinant human growth hormone injection, maximal growth hormone was higher in cirrhotic patients and the area under the curve over 24 h was greater (626+/-120) than in controls (330+/-54; p<0.01).",Spontaneous pulsatility and pharmacokinetics of growth hormone in liver cirrhotic patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9824264/),,330,87274,DB00052,Somatropin recombinant
,26497877,Rates of progression-free survival,"Rates of progression-free survival at 6 months were 17 and 8 % in the pilaralisib and voxtalisib arms, respectively.",Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26497877/),%,17,90896,DB00052,Somatropin recombinant
,26497877,Rates of progression-free survival,"Rates of progression-free survival at 6 months were 17 and 8 % in the pilaralisib and voxtalisib arms, respectively.",Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26497877/),%,8,90897,DB00052,Somatropin recombinant
,8132756,renal fraction,"Allowing for the linear dependence of MCR on GFR and assuming single-compartment distribution, the estimated renal fraction of total MCR was 25-53 and 4-15% in controls and patients, respectively.",Metabolic clearance of recombinant human growth hormone in health and chronic renal failure. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8132756/),,4,93635,DB00052,Somatropin recombinant
,1619029,Peak plasma total T concentration,"Peak plasma total T concentration was achieved at 255 +/- 51 (SEM) min after the first 40 mg dose of TU, 300 +/- 76 min at 3 months, and 293 +/- 103 min at 6 months, the levels remaining elevated above baseline for at least 8 h after a single oral dose.",Oral testosterone undecanoate in the management of delayed puberty in boys: pharmacokinetics and effects on sexual maturation and growth. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1619029/),min,255,94387,DB00052,Somatropin recombinant
,1619029,Peak plasma total T concentration,"Peak plasma total T concentration was achieved at 255 +/- 51 (SEM) min after the first 40 mg dose of TU, 300 +/- 76 min at 3 months, and 293 +/- 103 min at 6 months, the levels remaining elevated above baseline for at least 8 h after a single oral dose.",Oral testosterone undecanoate in the management of delayed puberty in boys: pharmacokinetics and effects on sexual maturation and growth. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1619029/),min,300,94388,DB00052,Somatropin recombinant
,1619029,Peak plasma total T concentration,"Peak plasma total T concentration was achieved at 255 +/- 51 (SEM) min after the first 40 mg dose of TU, 300 +/- 76 min at 3 months, and 293 +/- 103 min at 6 months, the levels remaining elevated above baseline for at least 8 h after a single oral dose.",Oral testosterone undecanoate in the management of delayed puberty in boys: pharmacokinetics and effects on sexual maturation and growth. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1619029/),min,293,94389,DB00052,Somatropin recombinant
,1619029,peak,"Plasma dihydrotestosterone concentrations were elevated after the first dose (mean 5.4 +/- 1.3; peak 11.0 +/- 2.5 nmol/L), the extent of this rise being less after 6 months (mean 4.1 +/- 0.8; peak 7.1 +/- 1.1 nmol/L) as was the case with mean estradiol (51.5 +/- 8.9 to 38.1 +/- 3.7 pmol/L).",Oral testosterone undecanoate in the management of delayed puberty in boys: pharmacokinetics and effects on sexual maturation and growth. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1619029/),,7.1,94390,DB00052,Somatropin recombinant
,1619029,Height velocity,Height velocity rose from 3.2 +/- 0.3 cm/yr (pretreatment) to 7.2 +/- 1.0 cm/yr in the first year and was maintained at 7.3 +/- 0.4 cm/yr despite cessation of therapy during the second year.,Oral testosterone undecanoate in the management of delayed puberty in boys: pharmacokinetics and effects on sexual maturation and growth. ,Vmax velocity-Q2,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1619029/),[cm] / [yr],3.2,94391,DB00052,Somatropin recombinant
,1619029,Height velocity,Height velocity rose from 3.2 +/- 0.3 cm/yr (pretreatment) to 7.2 +/- 1.0 cm/yr in the first year and was maintained at 7.3 +/- 0.4 cm/yr despite cessation of therapy during the second year.,Oral testosterone undecanoate in the management of delayed puberty in boys: pharmacokinetics and effects on sexual maturation and growth. ,Vmax velocity-Q2,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1619029/),[cm] / [yr],7.2,94392,DB00052,Somatropin recombinant
,1619029,Height velocity,Height velocity rose from 3.2 +/- 0.3 cm/yr (pretreatment) to 7.2 +/- 1.0 cm/yr in the first year and was maintained at 7.3 +/- 0.4 cm/yr despite cessation of therapy during the second year.,Oral testosterone undecanoate in the management of delayed puberty in boys: pharmacokinetics and effects on sexual maturation and growth. ,Vmax velocity-Q2,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1619029/),,7.3,94393,DB00052,Somatropin recombinant
,11883648,Km,"The Km values were similar in male and female human, female rat liver microsomes, and expressed CYP3A4 and CYP3A5 (0.39, 0.27, 0.28, 0.25, and 0.26 microM, respectively).",Effect of testosterone suppression on the pharmacokinetics of a potent gnRH receptor antagonist. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11883648/),μM,0.39,99307,DB00052,Somatropin recombinant
,11883648,Km,"The Km values were similar in male and female human, female rat liver microsomes, and expressed CYP3A4 and CYP3A5 (0.39, 0.27, 0.28, 0.25, and 0.26 microM, respectively).",Effect of testosterone suppression on the pharmacokinetics of a potent gnRH receptor antagonist. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11883648/),μM,0.27,99308,DB00052,Somatropin recombinant
,11883648,Km,"The Km values were similar in male and female human, female rat liver microsomes, and expressed CYP3A4 and CYP3A5 (0.39, 0.27, 0.28, 0.25, and 0.26 microM, respectively).",Effect of testosterone suppression on the pharmacokinetics of a potent gnRH receptor antagonist. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11883648/),μM,0.28,99309,DB00052,Somatropin recombinant
,11883648,Km,"The Km values were similar in male and female human, female rat liver microsomes, and expressed CYP3A4 and CYP3A5 (0.39, 0.27, 0.28, 0.25, and 0.26 microM, respectively).",Effect of testosterone suppression on the pharmacokinetics of a potent gnRH receptor antagonist. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11883648/),μM,0.25,99310,DB00052,Somatropin recombinant
,11883648,Km,"The Km values were similar in male and female human, female rat liver microsomes, and expressed CYP3A4 and CYP3A5 (0.39, 0.27, 0.28, 0.25, and 0.26 microM, respectively).",Effect of testosterone suppression on the pharmacokinetics of a potent gnRH receptor antagonist. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11883648/),μM,0.26,99311,DB00052,Somatropin recombinant
,11883648,Km,"The Km in male rat liver microsomes was 1.5 microM, suggesting that in male and female rats AG-045572 is metabolized by different CYP3A isozymes.",Effect of testosterone suppression on the pharmacokinetics of a potent gnRH receptor antagonist. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11883648/),μM,1.5,99312,DB00052,Somatropin recombinant
,11883648,oral bioavailability,"The oral bioavailability of AG-045572 in intact male rats was 8%, while in female or castrated male rats it was 24%.",Effect of testosterone suppression on the pharmacokinetics of a potent gnRH receptor antagonist. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11883648/),%,8,99313,DB00052,Somatropin recombinant
,11883648,oral bioavailability,"The oral bioavailability of AG-045572 in intact male rats was 8%, while in female or castrated male rats it was 24%.",Effect of testosterone suppression on the pharmacokinetics of a potent gnRH receptor antagonist. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11883648/),%,24,99314,DB00052,Somatropin recombinant
,11883648,oral bioavailability,"Pretreatment of intact male rats with AG-045572 i.m. for 4 days resulted in suppression of testosterone to castrate levels, accompanied by an increase in oral bioavailability of AG-045572 to 27%.",Effect of testosterone suppression on the pharmacokinetics of a potent gnRH receptor antagonist. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11883648/),%,27,99315,DB00052,Somatropin recombinant
,8767407,T1/2kle,"T1/2kle was 19.6 +/- 2.3 min, Cltot 2.9 +/- 0.4 ml/kg/bw/min and DS 76.4 +/- 3.8 ml/kg/bw for 90 min.",Human growth hormone kinetics in critically ill patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8767407/),min,19.6,99347,DB00052,Somatropin recombinant
,8767407,Cltot,"T1/2kle was 19.6 +/- 2.3 min, Cltot 2.9 +/- 0.4 ml/kg/bw/min and DS 76.4 +/- 3.8 ml/kg/bw for 90 min.",Human growth hormone kinetics in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8767407/),[ml] / [bw·kg·min],2.9,99348,DB00052,Somatropin recombinant
,8767407,DS,"T1/2kle was 19.6 +/- 2.3 min, Cltot 2.9 +/- 0.4 ml/kg/bw/min and DS 76.4 +/- 3.8 ml/kg/bw for 90 min.",Human growth hormone kinetics in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8767407/),[ml] / [bw·kg],76.4,99349,DB00052,Somatropin recombinant
,16003295,apparent clearance,The apparent clearance for SOM230 is approximately half of that for octreotide (8.0 L/h versus 15.8 L/h).,"Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16003295/),[l] / [h],8.0,99429,DB00052,Somatropin recombinant
,16003295,apparent clearance,The apparent clearance for SOM230 is approximately half of that for octreotide (8.0 L/h versus 15.8 L/h).,"Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16003295/),[l] / [h],15.8,99430,DB00052,Somatropin recombinant
,16003295,elimination half-life,The elimination half-life for SOM230 is about 5 times longer than that for octreotide (11.8 hours versus 2.3 hours).,"Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16003295/),h,11.8,99431,DB00052,Somatropin recombinant
,16003295,elimination half-life,The elimination half-life for SOM230 is about 5 times longer than that for octreotide (11.8 hours versus 2.3 hours).,"Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16003295/),h,2.3,99432,DB00052,Somatropin recombinant
,16003295,half of the maximum drug effect is observed (EC50),"The test drug concentration level at which half of the maximum drug effect is observed (EC50) is 46 and 553 pg/mL for octreotide and SOM230, respectively, with large interpatient variability (coefficients of variation, 164% and 65%, respectively), mainly attributable to the heterogeneous responses among patients.","Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16003295/),[pg] / [ml],46,99433,DB00052,Somatropin recombinant
,16003295,half of the maximum drug effect is observed (EC50),"The test drug concentration level at which half of the maximum drug effect is observed (EC50) is 46 and 553 pg/mL for octreotide and SOM230, respectively, with large interpatient variability (coefficients of variation, 164% and 65%, respectively), mainly attributable to the heterogeneous responses among patients.","Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16003295/),[pg] / [ml],553,99434,DB00052,Somatropin recombinant
,10663217,insulin sensitivity,"During steady-state euglycaemia (0500-0730 hours), insulin sensitivity mean (SEM) plasma insulin 0.020 (0.002) mU/l[ and insulin clearance rates 19.1 (1.8) ml.kg-1.min[ varied with age non-linearly and in a reciprocal fashion to each other (cubic regression F = 4.09, p = 0.01; F = 3.55, p = 0.02, respectively).",Both insulin sensitivity and insulin clearance in children and young adults with type I (insulin-dependent) diabetes vary with growth hormone concentrations and with age. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10663217/),[mu] / [l],0.020,99629,DB00052,Somatropin recombinant
,10663217,insulin clearance rates,"During steady-state euglycaemia (0500-0730 hours), insulin sensitivity mean (SEM) plasma insulin 0.020 (0.002) mU/l[ and insulin clearance rates 19.1 (1.8) ml.kg-1.min[ varied with age non-linearly and in a reciprocal fashion to each other (cubic regression F = 4.09, p = 0.01; F = 3.55, p = 0.02, respectively).",Both insulin sensitivity and insulin clearance in children and young adults with type I (insulin-dependent) diabetes vary with growth hormone concentrations and with age. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10663217/),[min·ml] / [kg],19.1,99630,DB00052,Somatropin recombinant
,14499707,half-life,"The main drawbacks associated with the pharmaceutical use of hGRF1-29 relate to its short half-life in plasma, about 10-20 min in humans, which is caused mostly by renal ultrafiltration and enzymatic degradation at the N terminus.",PEGylation of growth hormone-releasing hormone (GRF) analogues. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14499707/),min,10-20,99966,DB00052,Somatropin recombinant
,19477256,absolute bioavailability,Nasal administration of Amioca/Carbopol 974P powders without heat treatment resulted in an absolute bioavailability in rabbits of 8.2+/-3.0% for insulin.,Influence of heat treatment on spray-dried mixtures of Amioca starch and Carbopol 974P used as carriers for nasal drug delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19477256/),%,8.2,102369,DB00052,Somatropin recombinant
,19477256,bioavailability,"Due to the difference in water-absorbing capacity (which opened the tight junctions of the nasal mucosa), elasticity and plasticity (which reduced mucociliairy clearance and prolonged residence time) heat treatment at 120 degrees C improved the bioavailability: 26.4+/-21.9, 36.5+/-11.0 and 19.3+/-17.3% after heat treatment during 30 min, 1 h and 4 h, respectively.",Influence of heat treatment on spray-dried mixtures of Amioca starch and Carbopol 974P used as carriers for nasal drug delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19477256/),%,26.4,102370,DB00052,Somatropin recombinant
,19477256,bioavailability,"Due to the difference in water-absorbing capacity (which opened the tight junctions of the nasal mucosa), elasticity and plasticity (which reduced mucociliairy clearance and prolonged residence time) heat treatment at 120 degrees C improved the bioavailability: 26.4+/-21.9, 36.5+/-11.0 and 19.3+/-17.3% after heat treatment during 30 min, 1 h and 4 h, respectively.",Influence of heat treatment on spray-dried mixtures of Amioca starch and Carbopol 974P used as carriers for nasal drug delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19477256/),%,36.5,102371,DB00052,Somatropin recombinant
,19477256,bioavailability,"Due to the difference in water-absorbing capacity (which opened the tight junctions of the nasal mucosa), elasticity and plasticity (which reduced mucociliairy clearance and prolonged residence time) heat treatment at 120 degrees C improved the bioavailability: 26.4+/-21.9, 36.5+/-11.0 and 19.3+/-17.3% after heat treatment during 30 min, 1 h and 4 h, respectively.",Influence of heat treatment on spray-dried mixtures of Amioca starch and Carbopol 974P used as carriers for nasal drug delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19477256/),%,19.3,102372,DB00052,Somatropin recombinant
,27638053,peak (maximum) concentration (C max),FSH after single subcutaneous and intramuscular injections of menotrophin or urofollitrophin attained a systemic peak (maximum) concentration (C max) that was on average consistent throughout the first four studies and ranged from 4.98 to 7.50 IU/L.,Pharmacokinetics and Pharmacodynamics of Follicle-Stimulating Hormone in Healthy Women Receiving Single and Multiple Doses of Highly Purified Human Menotrophin and Urofollitrophin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27638053/),[iu] / [l],4.98 to 7.50,103820,DB00052,Somatropin recombinant
,27638053,area under the plasma concentration-time curve (AUC) from administration to the last observed concentration time t (AUCt),The area under the plasma concentration-time curve (AUC) from administration to the last observed concentration time t (AUCt) ranged from 409.71 to 486.16 IU/L·h and the elimination half-life (t ½) ranged from 39.02 to 53.63 h.,Pharmacokinetics and Pharmacodynamics of Follicle-Stimulating Hormone in Healthy Women Receiving Single and Multiple Doses of Highly Purified Human Menotrophin and Urofollitrophin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27638053/),[iu] / [h·l],409.71 to 486.16,103821,DB00052,Somatropin recombinant
,27638053,elimination half-life (t ½),The area under the plasma concentration-time curve (AUC) from administration to the last observed concentration time t (AUCt) ranged from 409.71 to 486.16 IU/L·h and the elimination half-life (t ½) ranged from 39.02 to 53.63 h.,Pharmacokinetics and Pharmacodynamics of Follicle-Stimulating Hormone in Healthy Women Receiving Single and Multiple Doses of Highly Purified Human Menotrophin and Urofollitrophin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27638053/),h,39.02 to 53.63,103822,DB00052,Somatropin recombinant
,27638053,C max,"After multiple doses of urofollitrophin (225 IU) for 5 days, FSH attained a mean C max of 14.93 ± 2.92 IU/L and had an AUC during the time interval τ between two consecutive doses at steady state (AUCτ) of 322.59 ± 57.92 IU/L·h, which was similar to the mean AUCt after a single subcutaneous dose of 225 IU of urofollitrophin in study 5 (306.82 ± 68.37 IU/L·h).",Pharmacokinetics and Pharmacodynamics of Follicle-Stimulating Hormone in Healthy Women Receiving Single and Multiple Doses of Highly Purified Human Menotrophin and Urofollitrophin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27638053/),[iu] / [l],14.93,103823,DB00052,Somatropin recombinant
,27638053,AUC during the time interval τ between two consecutive doses at steady state (AUCτ),"After multiple doses of urofollitrophin (225 IU) for 5 days, FSH attained a mean C max of 14.93 ± 2.92 IU/L and had an AUC during the time interval τ between two consecutive doses at steady state (AUCτ) of 322.59 ± 57.92 IU/L·h, which was similar to the mean AUCt after a single subcutaneous dose of 225 IU of urofollitrophin in study 5 (306.82 ± 68.37 IU/L·h).",Pharmacokinetics and Pharmacodynamics of Follicle-Stimulating Hormone in Healthy Women Receiving Single and Multiple Doses of Highly Purified Human Menotrophin and Urofollitrophin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27638053/),[iu] / [h·l],322.59,103824,DB00052,Somatropin recombinant
,27638053,AUCt,"After multiple doses of urofollitrophin (225 IU) for 5 days, FSH attained a mean C max of 14.93 ± 2.92 IU/L and had an AUC during the time interval τ between two consecutive doses at steady state (AUCτ) of 322.59 ± 57.92 IU/L·h, which was similar to the mean AUCt after a single subcutaneous dose of 225 IU of urofollitrophin in study 5 (306.82 ± 68.37 IU/L·h).",Pharmacokinetics and Pharmacodynamics of Follicle-Stimulating Hormone in Healthy Women Receiving Single and Multiple Doses of Highly Purified Human Menotrophin and Urofollitrophin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27638053/),[iu] / [h·l],306.82,103825,DB00052,Somatropin recombinant
,33797023,PFS,"At final PFS analysis (February 14, 2017), median PFS was 21.2 and 14.3 months, respectively, in the abemaciclib and placebo groups (hazard ratio: 0.672; 95% confidence interval: 0.380-1.189).","Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33797023/),month,21.2,105288,DB00052,Somatropin recombinant
,33797023,PFS,"At final PFS analysis (February 14, 2017), median PFS was 21.2 and 14.3 months, respectively, in the abemaciclib and placebo groups (hazard ratio: 0.672; 95% confidence interval: 0.380-1.189).","Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33797023/),month,14,105289,DB00052,Somatropin recombinant
,33797023,objective response rate,Abemaciclib had a higher objective response rate (37.5%) than placebo (12.9%).,"Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33797023/),%,37.5,105290,DB00052,Somatropin recombinant
,33797023,objective response rate,Abemaciclib had a higher objective response rate (37.5%) than placebo (12.9%).,"Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33797023/),%,12.9,105291,DB00052,Somatropin recombinant
,3371267,clearance,"Comparison of the pharmacokinetic parameters indicated that the clearance after iv administration (rhGH, 15 ml/min; Met-hGH, 13 ml/min) and the sc bioavailability (rhGH, 0.72 +/- 0.21; Met-hGH, 0.59 +/- 0.21) were not significantly different for the 2 forms of hGH.",Equivalent potency and pharmacokinetics of recombinant human growth hormones with or without an N-terminal methionine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3371267/),[ml] / [min],15,105710,DB00052,Somatropin recombinant
,3371267,clearance,"Comparison of the pharmacokinetic parameters indicated that the clearance after iv administration (rhGH, 15 ml/min; Met-hGH, 13 ml/min) and the sc bioavailability (rhGH, 0.72 +/- 0.21; Met-hGH, 0.59 +/- 0.21) were not significantly different for the 2 forms of hGH.",Equivalent potency and pharmacokinetics of recombinant human growth hormones with or without an N-terminal methionine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3371267/),[ml] / [min],13,105711,DB00052,Somatropin recombinant
,3371267,bioavailability,"Comparison of the pharmacokinetic parameters indicated that the clearance after iv administration (rhGH, 15 ml/min; Met-hGH, 13 ml/min) and the sc bioavailability (rhGH, 0.72 +/- 0.21; Met-hGH, 0.59 +/- 0.21) were not significantly different for the 2 forms of hGH.",Equivalent potency and pharmacokinetics of recombinant human growth hormones with or without an N-terminal methionine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3371267/),,0.72,105712,DB00052,Somatropin recombinant
,3371267,bioavailability,"Comparison of the pharmacokinetic parameters indicated that the clearance after iv administration (rhGH, 15 ml/min; Met-hGH, 13 ml/min) and the sc bioavailability (rhGH, 0.72 +/- 0.21; Met-hGH, 0.59 +/- 0.21) were not significantly different for the 2 forms of hGH.",Equivalent potency and pharmacokinetics of recombinant human growth hormones with or without an N-terminal methionine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3371267/),,0.59,105713,DB00052,Somatropin recombinant
,17929148,peak concentrations,Testing the microspheres in healthy volunteers showed an increase (over 7-8 days) in hGH serum concentrations (peak concentrations: 1-2.5 ng/ml).,Preclinical and clinical in vitro in vivo correlation of an hGH dextran microsphere formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17929148/),[ng] / [ml],1-2.5,107704,DB00052,Somatropin recombinant
,10806600,Cmin,"After the injection, mean serum octreotide concentration initially increased rapidly, reached the maximum (Cmax, day 1 = 0.96 +/- 0.25 ng/ml) approximately 1.5 hours after dosing, and declined thereafter until 24 hours postdose (Cmin, 24 h = 0.088 +/- 0.093 ng/ml).","Pharmacokinetics, pharmacodynamics, and safety of microencapsulated octreotide acetate in healthy subjects. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10806600/),[ng] / [ml],0.088,108464,DB00052,Somatropin recombinant
,10806600,plateau height (Cplateau (2-112d,"The plateau height (Cplateau (2-112d, 60%)) was 1.68 +/- 0.88 ng/ml, and the duration (delta plateau, 60%) was 30.2 +/- 15.7 days.","Pharmacokinetics, pharmacodynamics, and safety of microencapsulated octreotide acetate in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10806600/),[ng] / [ml],60,108465,DB00052,Somatropin recombinant
,10806600,plateau height (Cplateau (2-112d,"The plateau height (Cplateau (2-112d, 60%)) was 1.68 +/- 0.88 ng/ml, and the duration (delta plateau, 60%) was 30.2 +/- 15.7 days.","Pharmacokinetics, pharmacodynamics, and safety of microencapsulated octreotide acetate in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10806600/),[ng] / [ml],1.68,108466,DB00052,Somatropin recombinant
,10806600,duration (delta plateau,"The plateau height (Cplateau (2-112d, 60%)) was 1.68 +/- 0.88 ng/ml, and the duration (delta plateau, 60%) was 30.2 +/- 15.7 days.","Pharmacokinetics, pharmacodynamics, and safety of microencapsulated octreotide acetate in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10806600/),%,60,108467,DB00052,Somatropin recombinant
,10806600,duration (delta plateau,"The plateau height (Cplateau (2-112d, 60%)) was 1.68 +/- 0.88 ng/ml, and the duration (delta plateau, 60%) was 30.2 +/- 15.7 days.","Pharmacokinetics, pharmacodynamics, and safety of microencapsulated octreotide acetate in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10806600/),d,30.2,108468,DB00052,Somatropin recombinant
,10806600,"integrated concentration-time curve, AUC0-112d","The integrated concentration-time curve, AUC0-112d, was 2819 +/- 782 (ng.h/ml), and the apparent half-life (t1/2) was 169 hours.","Pharmacokinetics, pharmacodynamics, and safety of microencapsulated octreotide acetate in healthy subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10806600/),[h·ng] / [ml],2819,108469,DB00052,Somatropin recombinant
,10806600,apparent half-life (t1/2),"The integrated concentration-time curve, AUC0-112d, was 2819 +/- 782 (ng.h/ml), and the apparent half-life (t1/2) was 169 hours.","Pharmacokinetics, pharmacodynamics, and safety of microencapsulated octreotide acetate in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10806600/),h,169,108470,DB00052,Somatropin recombinant
,10806600,"concentration, Cavg","To assess the variability, the drug concentrations were determined hourly for 8 hours on day 28, and the mean octreotide concentration, Cavg, day 28' was 1.55 +/- 1.26 ng/ml.","Pharmacokinetics, pharmacodynamics, and safety of microencapsulated octreotide acetate in healthy subjects. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10806600/),[ng] / [ml],1.55,108471,DB00052,Somatropin recombinant
,16154424,minimum lanreotide concentrations (Cmin) at steady state,"Average minimum lanreotide concentrations (Cmin) at steady state were 1.949 +/- 0.619, 2.685 +/- 0.783, and 3.575 +/- 1.271 ng/mL for 60, 90, and 120 mg of lanreotide Autogel, respectively, showing a dose-proportional increase.",Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16154424/),[ng] / [ml],1.949,113230,DB00052,Somatropin recombinant
,16154424,minimum lanreotide concentrations (Cmin) at steady state,"Average minimum lanreotide concentrations (Cmin) at steady state were 1.949 +/- 0.619, 2.685 +/- 0.783, and 3.575 +/- 1.271 ng/mL for 60, 90, and 120 mg of lanreotide Autogel, respectively, showing a dose-proportional increase.",Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16154424/),[ng] / [ml],2.685,113231,DB00052,Somatropin recombinant
,16154424,minimum lanreotide concentrations (Cmin) at steady state,"Average minimum lanreotide concentrations (Cmin) at steady state were 1.949 +/- 0.619, 2.685 +/- 0.783, and 3.575 +/- 1.271 ng/mL for 60, 90, and 120 mg of lanreotide Autogel, respectively, showing a dose-proportional increase.",Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16154424/),[ng] / [ml],3.575,113232,DB00052,Somatropin recombinant
,16154424,half of the Emax (EC50),"The serum concentration that elicited half of the Emax (EC50) was estimated as 0.206 ng/mL, showing a high sensitivity to lanreotide, with a predictably high interpatient variability of 200.75% reflecting the range of dosing regimens needed to control GH.",Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16154424/),[ng] / [ml],0.206,113233,DB00052,Somatropin recombinant
,9056052,tmax,"MK-462 was rapidly absorbed with a median tmax of 1.3 h (range 1-3 h) vs a tmax for sumatriptan of 2.5 h (range 1-4 h, P < 0.001).",Initial human experience with MK-462 (rizatriptan): a novel 5-HT1D agonist. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9056052/),h,1.3,115982,DB00052,Somatropin recombinant
,9056052,tmax,"MK-462 was rapidly absorbed with a median tmax of 1.3 h (range 1-3 h) vs a tmax for sumatriptan of 2.5 h (range 1-4 h, P < 0.001).",Initial human experience with MK-462 (rizatriptan): a novel 5-HT1D agonist. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9056052/),h,2.5,115983,DB00052,Somatropin recombinant
,24569459,t1/2,The mean t1/2 of KRN23 was 8-12 days after i.v. administration and 13-19 days after s.c. administration.,Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24569459/),d,8-12,116535,DB00052,Somatropin recombinant
,24569459,t1/2,The mean t1/2 of KRN23 was 8-12 days after i.v. administration and 13-19 days after s.c. administration.,Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24569459/),d,13-19,116536,DB00052,Somatropin recombinant
,22527887,"T(max,ss)","Pasireotide demonstrated fast absorption (T(max,ss): 0.25-0.5 h), low clearance (CL/F(ss): 8.10-9.03 L/h), long effective half-life (T(½,eff): ~12 h, on average between 9.7 and 13.1 h for 50, 200, and 600 μg sc qd), and large volume of distribution (V(z)/F(ss): 251-1,091 L) at steady state.","Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22527887/),h,0.25-0.5,123655,DB00052,Somatropin recombinant
,22527887,clearance (CL/F(ss),"Pasireotide demonstrated fast absorption (T(max,ss): 0.25-0.5 h), low clearance (CL/F(ss): 8.10-9.03 L/h), long effective half-life (T(½,eff): ~12 h, on average between 9.7 and 13.1 h for 50, 200, and 600 μg sc qd), and large volume of distribution (V(z)/F(ss): 251-1,091 L) at steady state.","Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22527887/),[l] / [h],8.10-9.03,123656,DB00052,Somatropin recombinant
,22527887,"effective half-life (T(½,eff)","Pasireotide demonstrated fast absorption (T(max,ss): 0.25-0.5 h), low clearance (CL/F(ss): 8.10-9.03 L/h), long effective half-life (T(½,eff): ~12 h, on average between 9.7 and 13.1 h for 50, 200, and 600 μg sc qd), and large volume of distribution (V(z)/F(ss): 251-1,091 L) at steady state.","Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22527887/),h,12,123657,DB00052,Somatropin recombinant
,22527887,"effective half-life (T(½,eff)","Pasireotide demonstrated fast absorption (T(max,ss): 0.25-0.5 h), low clearance (CL/F(ss): 8.10-9.03 L/h), long effective half-life (T(½,eff): ~12 h, on average between 9.7 and 13.1 h for 50, 200, and 600 μg sc qd), and large volume of distribution (V(z)/F(ss): 251-1,091 L) at steady state.","Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22527887/),h,9.7 and 13.1,123658,DB00052,Somatropin recombinant
,22527887,V(z)/F(ss),"Pasireotide demonstrated fast absorption (T(max,ss): 0.25-0.5 h), low clearance (CL/F(ss): 8.10-9.03 L/h), long effective half-life (T(½,eff): ~12 h, on average between 9.7 and 13.1 h for 50, 200, and 600 μg sc qd), and large volume of distribution (V(z)/F(ss): 251-1,091 L) at steady state.","Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22527887/),l,"251-1,091",123659,DB00052,Somatropin recombinant
,17535864,Cmax,Serum GH maximal concentration (Cmax) and area under the time-concentration curve (AUC) were higher after i.m. than s.c. administration of 0.033 mg/kg (Cmax 35.5 and 12.0 microg/l; AUC 196.2 and 123.8).,Pharmacokinetics and pharmacodynamics of GH: dependence on route and dosage of administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17535864/),[μg] / [l],35.5,124742,DB00052,Somatropin recombinant
,17535864,Cmax,Serum GH maximal concentration (Cmax) and area under the time-concentration curve (AUC) were higher after i.m. than s.c. administration of 0.033 mg/kg (Cmax 35.5 and 12.0 microg/l; AUC 196.2 and 123.8).,Pharmacokinetics and pharmacodynamics of GH: dependence on route and dosage of administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17535864/),[μg] / [l],12.0,124743,DB00052,Somatropin recombinant
,17535864,AUC,Serum GH maximal concentration (Cmax) and area under the time-concentration curve (AUC) were higher after i.m. than s.c. administration of 0.033 mg/kg (Cmax 35.5 and 12.0 microg/l; AUC 196.2 and 123.8).,Pharmacokinetics and pharmacodynamics of GH: dependence on route and dosage of administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17535864/),,196.2,124744,DB00052,Somatropin recombinant
,17535864,AUC,Serum GH maximal concentration (Cmax) and area under the time-concentration curve (AUC) were higher after i.m. than s.c. administration of 0.033 mg/kg (Cmax 35.5 and 12.0 microg/l; AUC 196.2 and 123.8).,Pharmacokinetics and pharmacodynamics of GH: dependence on route and dosage of administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17535864/),,123.8,124745,DB00052,Somatropin recombinant
,26672637,HVs,"Mean annualized HVs for somavaratan administered monthly, twice monthly, or weekly (7.86 ± 2.5, 8.61 ± 2.7, and 7.58 ± 2.5 cm/y, respectively) were similar between groups.","A Randomized Safety and Efficacy Study of Somavaratan (VRS-317), a Long-Acting rhGH, in Pediatric Growth Hormone Deficiency. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26672637/),[cm] / [y],7.86,127951,DB00052,Somatropin recombinant
,26672637,HVs,"Mean annualized HVs for somavaratan administered monthly, twice monthly, or weekly (7.86 ± 2.5, 8.61 ± 2.7, and 7.58 ± 2.5 cm/y, respectively) were similar between groups.","A Randomized Safety and Efficacy Study of Somavaratan (VRS-317), a Long-Acting rhGH, in Pediatric Growth Hormone Deficiency. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26672637/),[cm] / [y],8.61,127952,DB00052,Somatropin recombinant
,26672637,HVs,"Mean annualized HVs for somavaratan administered monthly, twice monthly, or weekly (7.86 ± 2.5, 8.61 ± 2.7, and 7.58 ± 2.5 cm/y, respectively) were similar between groups.","A Randomized Safety and Efficacy Study of Somavaratan (VRS-317), a Long-Acting rhGH, in Pediatric Growth Hormone Deficiency. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26672637/),[cm] / [y],7.58,127953,DB00052,Somatropin recombinant
,33148479,PFS,"The median PFS was 9.1 months for A+T versus 7.4 months for A-200 (hazard ratio, 0.815; 95% confidence interval, 0.556-1.193; P = .293).",nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33148479/),month,9.1,130282,DB00052,Somatropin recombinant
,33148479,PFS,"The median PFS was 9.1 months for A+T versus 7.4 months for A-200 (hazard ratio, 0.815; 95% confidence interval, 0.556-1.193; P = .293).",nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33148479/),month,7.4,130283,DB00052,Somatropin recombinant
,32706937,oral bioavailability,"The oral bioavailability of the 600-mg ribociclib tablet was 65.8% (90% confidence interval [CI], 59.1-73.2%).","Evaluation of Absolute Oral Bioavailability and Bioequivalence of Ribociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, in Healthy Subjects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32706937/),%,65.8,132451,DB00052,Somatropin recombinant
,32706937,systemic clearance,"The geometric mean systemic clearance of ribociclib was moderate (40.2 L/h; 27.4% intersubject variability [CV%]) compared with hepatic blood flow, and the geometric mean volume of distribution was high (979 L; 25.2 CV%).","Evaluation of Absolute Oral Bioavailability and Bioequivalence of Ribociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, in Healthy Subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32706937/),[l] / [h],40.2,132452,DB00052,Somatropin recombinant
,32706937,volume of distribution,"The geometric mean systemic clearance of ribociclib was moderate (40.2 L/h; 27.4% intersubject variability [CV%]) compared with hepatic blood flow, and the geometric mean volume of distribution was high (979 L; 25.2 CV%).","Evaluation of Absolute Oral Bioavailability and Bioequivalence of Ribociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, in Healthy Subjects. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32706937/),l,979,132453,DB00052,Somatropin recombinant
,32706937,metabolic ratios,LEQ803-to-ribociclib metabolic ratios were 0.198 for the oral administration and 0.125 for intravenous infusion.,"Evaluation of Absolute Oral Bioavailability and Bioequivalence of Ribociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, in Healthy Subjects. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32706937/),,0.198,132454,DB00052,Somatropin recombinant
,32706937,metabolic ratios,LEQ803-to-ribociclib metabolic ratios were 0.198 for the oral administration and 0.125 for intravenous infusion.,"Evaluation of Absolute Oral Bioavailability and Bioequivalence of Ribociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, in Healthy Subjects. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32706937/),,0.125,132455,DB00052,Somatropin recombinant
,32706937,time to reach maximum concentration,The median time to reach maximum concentration was 3 hours with both formulations.,"Evaluation of Absolute Oral Bioavailability and Bioequivalence of Ribociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, in Healthy Subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32706937/),h,3,132456,DB00052,Somatropin recombinant
,8325945,t1/2,"The GH elimination half-life was shorter in the morning: for endogenous GH, t1/2 was 23 +/- 1.1 min (mean +/- SE) in the morning compared to 26 +/- 1.7 min in the evening (P < 0.02).","Diurnal variation in the elimination rate of human growth hormone (GH): the half-life of serum GH is prolonged in the evening, and affected by the source of the hormone, as well as by body size and serum estradiol. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8325945/),min,23,135935,DB00052,Somatropin recombinant
,8325945,t1/2,"The GH elimination half-life was shorter in the morning: for endogenous GH, t1/2 was 23 +/- 1.1 min (mean +/- SE) in the morning compared to 26 +/- 1.7 min in the evening (P < 0.02).","Diurnal variation in the elimination rate of human growth hormone (GH): the half-life of serum GH is prolonged in the evening, and affected by the source of the hormone, as well as by body size and serum estradiol. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8325945/),min,26,135936,DB00052,Somatropin recombinant
,8325945,t1/2,"The half-life of exogenous 22-kilodalton GH was shorter compared to endogenous GH (P < 0.002), and diurnal variation was even more pronounced: t1/2 was 14 +/- 1.0 min in the morning and 19 +/- 1.0 min in the evening (P < 0.01).","Diurnal variation in the elimination rate of human growth hormone (GH): the half-life of serum GH is prolonged in the evening, and affected by the source of the hormone, as well as by body size and serum estradiol. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8325945/),min,14,135937,DB00052,Somatropin recombinant
,8325945,t1/2,"The half-life of exogenous 22-kilodalton GH was shorter compared to endogenous GH (P < 0.002), and diurnal variation was even more pronounced: t1/2 was 14 +/- 1.0 min in the morning and 19 +/- 1.0 min in the evening (P < 0.01).","Diurnal variation in the elimination rate of human growth hormone (GH): the half-life of serum GH is prolonged in the evening, and affected by the source of the hormone, as well as by body size and serum estradiol. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8325945/),min,19,135938,DB00052,Somatropin recombinant
,10427162,peak GH concentration,"At the highest dose (20 micromol/kg), a 35-fold increase in peak GH concentration was observed (49.5+/-17.8 ng/ml, mean+/-s.e.m.).","Pharmacological characterisation of a new oral GH secretagogue, NN703. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10427162/),[ng] / [ml],49.5,136029,DB00052,Somatropin recombinant
,10427162,peak GH plasma concentration,After a single i.v. dose of 1 micromol/kg the peak GH plasma concentration was elevated to 38.5+/-19.6 ng/ml (mean+/-s.e.m.) approximately 30 min after dosing and returned to basal level after 360 min.,"Pharmacological characterisation of a new oral GH secretagogue, NN703. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10427162/),[ng] / [ml],38.5,136030,DB00052,Somatropin recombinant
,10427162,oral bioavailability,The oral bioavailability was 30%.,"Pharmacological characterisation of a new oral GH secretagogue, NN703. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10427162/),%,30,136031,DB00052,Somatropin recombinant
,10427162,plasma half-life,The plasma half-life of NN703 was 4.1+/-0.4 h.,"Pharmacological characterisation of a new oral GH secretagogue, NN703. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10427162/),h,4.1,136032,DB00052,Somatropin recombinant
,23585663,terminal elimination half-life,"At 0.80 mg/kg, VRS-317 had a mean terminal elimination half-life of 131 hours.","A long-acting human growth hormone with delayed clearance (VRS-317): results of a double-blind, placebo-controlled, single ascending dose study in growth hormone-deficient adults. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23585663/),h,131,137107,DB00052,Somatropin recombinant
,20300802,"absorption half-lives, t (1/2a)","The absorption half-lives, t (1/2a), of rhGH and DDAVP from dissolving microneedles were 23.7 ± 4.3-28.9 ± 5.2 and 14.4 ± 2.9-14.1 ± 1.1 min; the extents of bioavailability were 72.8 ± 4.2-89.9 ± 10.0% and 90.0 ± 15.4-93.1 ± 10.3%, respectively.",Two-layered dissolving microneedles for percutaneous delivery of peptide/protein drugs in rats. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20300802/),min,23.7,137251,DB00052,Somatropin recombinant
,20300802,"absorption half-lives, t (1/2a)","The absorption half-lives, t (1/2a), of rhGH and DDAVP from dissolving microneedles were 23.7 ± 4.3-28.9 ± 5.2 and 14.4 ± 2.9-14.1 ± 1.1 min; the extents of bioavailability were 72.8 ± 4.2-89.9 ± 10.0% and 90.0 ± 15.4-93.1 ± 10.3%, respectively.",Two-layered dissolving microneedles for percutaneous delivery of peptide/protein drugs in rats. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20300802/),min,28.9,137252,DB00052,Somatropin recombinant
,20300802,"absorption half-lives, t (1/2a)","The absorption half-lives, t (1/2a), of rhGH and DDAVP from dissolving microneedles were 23.7 ± 4.3-28.9 ± 5.2 and 14.4 ± 2.9-14.1 ± 1.1 min; the extents of bioavailability were 72.8 ± 4.2-89.9 ± 10.0% and 90.0 ± 15.4-93.1 ± 10.3%, respectively.",Two-layered dissolving microneedles for percutaneous delivery of peptide/protein drugs in rats. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20300802/),min,14.4,137253,DB00052,Somatropin recombinant
,20300802,"absorption half-lives, t (1/2a)","The absorption half-lives, t (1/2a), of rhGH and DDAVP from dissolving microneedles were 23.7 ± 4.3-28.9 ± 5.2 and 14.4 ± 2.9-14.1 ± 1.1 min; the extents of bioavailability were 72.8 ± 4.2-89.9 ± 10.0% and 90.0 ± 15.4-93.1 ± 10.3%, respectively.",Two-layered dissolving microneedles for percutaneous delivery of peptide/protein drugs in rats. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20300802/),min,14.1,137254,DB00052,Somatropin recombinant
,20300802,bioavailability,"The absorption half-lives, t (1/2a), of rhGH and DDAVP from dissolving microneedles were 23.7 ± 4.3-28.9 ± 5.2 and 14.4 ± 2.9-14.1 ± 1.1 min; the extents of bioavailability were 72.8 ± 4.2-89.9 ± 10.0% and 90.0 ± 15.4-93.1 ± 10.3%, respectively.",Two-layered dissolving microneedles for percutaneous delivery of peptide/protein drugs in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20300802/),%,72.8,137255,DB00052,Somatropin recombinant
,20300802,bioavailability,"The absorption half-lives, t (1/2a), of rhGH and DDAVP from dissolving microneedles were 23.7 ± 4.3-28.9 ± 5.2 and 14.4 ± 2.9-14.1 ± 1.1 min; the extents of bioavailability were 72.8 ± 4.2-89.9 ± 10.0% and 90.0 ± 15.4-93.1 ± 10.3%, respectively.",Two-layered dissolving microneedles for percutaneous delivery of peptide/protein drugs in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20300802/),%,89.9,137256,DB00052,Somatropin recombinant
,20300802,bioavailability,"The absorption half-lives, t (1/2a), of rhGH and DDAVP from dissolving microneedles were 23.7 ± 4.3-28.9 ± 5.2 and 14.4 ± 2.9-14.1 ± 1.1 min; the extents of bioavailability were 72.8 ± 4.2-89.9 ± 10.0% and 90.0 ± 15.4-93.1 ± 10.3%, respectively.",Two-layered dissolving microneedles for percutaneous delivery of peptide/protein drugs in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20300802/),%,90.0,137257,DB00052,Somatropin recombinant
,20300802,bioavailability,"The absorption half-lives, t (1/2a), of rhGH and DDAVP from dissolving microneedles were 23.7 ± 4.3-28.9 ± 5.2 and 14.4 ± 2.9-14.1 ± 1.1 min; the extents of bioavailability were 72.8 ± 4.2-89.9 ± 10.0% and 90.0 ± 15.4-93.1 ± 10.3%, respectively.",Two-layered dissolving microneedles for percutaneous delivery of peptide/protein drugs in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20300802/),%,93.1,137258,DB00052,Somatropin recombinant
,23099431,distribution,"Averaging all three dose levels, the distribution and elimination half-life of GHRP-6 were 7.6 ± 1.9 min and 2.5 ± 1.1h, respectively.",Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23099431/),min,7.6,138752,DB00052,Somatropin recombinant
,23099431,elimination half-life,"Averaging all three dose levels, the distribution and elimination half-life of GHRP-6 were 7.6 ± 1.9 min and 2.5 ± 1.1h, respectively.",Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23099431/),h,2.5,138753,DB00052,Somatropin recombinant
,27489211,tmax,"TV-1106 demonstrated relatively slow absorption (median tmax , 10-30 hours) and a mean elimination half-life of 26-36 hours.","Assessment of the Pharmacokinetics, Pharmacodynamics, and Safety of Single Doses of TV-1106, a Long-Acting Growth Hormone, in Healthy Japanese and Caucasian Subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27489211/),h,10-30,139017,DB00052,Somatropin recombinant
,27489211,elimination half-life,"TV-1106 demonstrated relatively slow absorption (median tmax , 10-30 hours) and a mean elimination half-life of 26-36 hours.","Assessment of the Pharmacokinetics, Pharmacodynamics, and Safety of Single Doses of TV-1106, a Long-Acting Growth Hormone, in Healthy Japanese and Caucasian Subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27489211/),h,26-36,139018,DB00052,Somatropin recombinant
above,11218239,Holman index,"Only 1 of 8 patients, who did not receive parenteral lipids, had a Holman index above 0.2, indicative of EFA deficiency.","Effect of high-dose growth hormone and glutamine on body composition, urine creatinine excretion, fatty acid absorption, and essential fatty acids status in short bowel patients: a randomized, double-blind, crossover, placebo-controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11218239/),,0.2,140016,DB00052,Somatropin recombinant
,26286586,terminal elimination half-life,"TV-1106 showed pharmacokinetic characteristics of a long-acting hGH as demonstrated by a terminal elimination half-life of 23-35 h, delayed time of peak concentration, and systemic levels seen up to 7 days after dosing.","Safety, pharmacokinetic and pharmacodynamic properties of TV-1106, a long-acting GH treatment for GH deficiency. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26286586/),h,23-35,141551,DB00052,Somatropin recombinant
,7891298,absolute bioavailability,"Plasma concentrations of the hormone were determined until 240 min post administration by ELISA, and the absolute bioavailability was estimated to be in the vicinity of 20%.",Epithelial transport and bioavailability of intranasally administered human growth hormone formulated with the absorption enhancers didecanoyl-L-alpha-phosphatidylcholine and alpha-cyclodextrin in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7891298/),%,20,142427,DB00052,Somatropin recombinant
,1490668,apparent elimination half-life,"Following i.v. administration, apparent elimination half-life of rhGH was 18 min.",Pharmacokinetics and short-term metabolic effects of mammalian cell-derived biosynthetic human growth hormone in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1490668/),min,18,142663,DB00052,Somatropin recombinant
,1490668,peak serum concentration,"Following i.m. administration, a mean peak serum concentration of 36.9 ng/ml (range 13-61 ng/ml) occurred at 3 h, and following s.c. administration, more sustained but lower serum concentrations occurred, with mean peak concentrations of 16.4 and 16.3 ng/ml at 4 and 6 h (ranges 9.0-27.5 ng/ml and 6.5-35.5 ng/ml at 4 and 6 h, respectively).",Pharmacokinetics and short-term metabolic effects of mammalian cell-derived biosynthetic human growth hormone in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1490668/),[ng] / [ml],36.9,142664,DB00052,Somatropin recombinant
,1490668,peak concentrations,"Following i.m. administration, a mean peak serum concentration of 36.9 ng/ml (range 13-61 ng/ml) occurred at 3 h, and following s.c. administration, more sustained but lower serum concentrations occurred, with mean peak concentrations of 16.4 and 16.3 ng/ml at 4 and 6 h (ranges 9.0-27.5 ng/ml and 6.5-35.5 ng/ml at 4 and 6 h, respectively).",Pharmacokinetics and short-term metabolic effects of mammalian cell-derived biosynthetic human growth hormone in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1490668/),[ng] / [ml],16.4,142665,DB00052,Somatropin recombinant
,1490668,peak concentrations,"Following i.m. administration, a mean peak serum concentration of 36.9 ng/ml (range 13-61 ng/ml) occurred at 3 h, and following s.c. administration, more sustained but lower serum concentrations occurred, with mean peak concentrations of 16.4 and 16.3 ng/ml at 4 and 6 h (ranges 9.0-27.5 ng/ml and 6.5-35.5 ng/ml at 4 and 6 h, respectively).",Pharmacokinetics and short-term metabolic effects of mammalian cell-derived biosynthetic human growth hormone in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1490668/),[ng] / [ml],16.3,142666,DB00052,Somatropin recombinant
,1490668,peak concentrations,"Following i.m. administration, a mean peak serum concentration of 36.9 ng/ml (range 13-61 ng/ml) occurred at 3 h, and following s.c. administration, more sustained but lower serum concentrations occurred, with mean peak concentrations of 16.4 and 16.3 ng/ml at 4 and 6 h (ranges 9.0-27.5 ng/ml and 6.5-35.5 ng/ml at 4 and 6 h, respectively).",Pharmacokinetics and short-term metabolic effects of mammalian cell-derived biosynthetic human growth hormone in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1490668/),[ng] / [ml],6.5-35.5,142667,DB00052,Somatropin recombinant
,1490668,area under the curves,The mean area under the curves was lower after s.c. (134 +/- 48 ng.h.ml-1) than after i.m. (194 +/- 48 ng.h.ml-1) injections (p < 0.03).,Pharmacokinetics and short-term metabolic effects of mammalian cell-derived biosynthetic human growth hormone in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1490668/),[h·ng] / [ml],134,142668,DB00052,Somatropin recombinant
,1490668,area under the curves,The mean area under the curves was lower after s.c. (134 +/- 48 ng.h.ml-1) than after i.m. (194 +/- 48 ng.h.ml-1) injections (p < 0.03).,Pharmacokinetics and short-term metabolic effects of mammalian cell-derived biosynthetic human growth hormone in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1490668/),[h·ng] / [ml],194,142669,DB00052,Somatropin recombinant
,3481177,Cmax,"Cmax was 53.4 and 62.9 mIU/litre and Tmax was 5.3 and 4.0 hours for Genotropin and Somatonorm, respectively.",Bioequivalence of Genotropin and Somatonorm. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3481177/),[miu] / [l],53.4,142918,DB00052,Somatropin recombinant
,3481177,Cmax,"Cmax was 53.4 and 62.9 mIU/litre and Tmax was 5.3 and 4.0 hours for Genotropin and Somatonorm, respectively.",Bioequivalence of Genotropin and Somatonorm. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3481177/),[miu] / [l],62.9,142919,DB00052,Somatropin recombinant
,3481177,Tmax,"Cmax was 53.4 and 62.9 mIU/litre and Tmax was 5.3 and 4.0 hours for Genotropin and Somatonorm, respectively.",Bioequivalence of Genotropin and Somatonorm. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3481177/),h,5.3,142920,DB00052,Somatropin recombinant
,3481177,Tmax,"Cmax was 53.4 and 62.9 mIU/litre and Tmax was 5.3 and 4.0 hours for Genotropin and Somatonorm, respectively.",Bioequivalence of Genotropin and Somatonorm. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3481177/),h,4.0,142921,DB00052,Somatropin recombinant
,3481177,bioavailability,The measured bioavailability of 71% could be an overestimate due to interference by endogenous hGH.,Bioequivalence of Genotropin and Somatonorm. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3481177/),%,71,142922,DB00052,Somatropin recombinant
,17207107,peak GH concentration,"Compared with placebo, alcohol significantly decreased the APO-induced GH release (mean and SEM peak GH concentration 19.9+/-3.2 vs 6.2+/-1.9 ng/mL, p=0.002).",Apomorphine-induced growth hormone response is attenuated by ethanol but not dextromethorphan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17207107/),[ng] / [ml],19.9,143867,DB00052,Somatropin recombinant
,17207107,peak GH concentration,"Compared with placebo, alcohol significantly decreased the APO-induced GH release (mean and SEM peak GH concentration 19.9+/-3.2 vs 6.2+/-1.9 ng/mL, p=0.002).",Apomorphine-induced growth hormone response is attenuated by ethanol but not dextromethorphan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17207107/),[ng] / [ml],6.2,143868,DB00052,Somatropin recombinant
,17207107,response,"Dextromethorphan did not change APO-induced GH response (22.5+/-5.4 vs 21.0+/-5.8 ng/mL, p=0.105).",Apomorphine-induced growth hormone response is attenuated by ethanol but not dextromethorphan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17207107/),[ng] / [ml],22.5,143869,DB00052,Somatropin recombinant
,17207107,response,"Dextromethorphan did not change APO-induced GH response (22.5+/-5.4 vs 21.0+/-5.8 ng/mL, p=0.105).",Apomorphine-induced growth hormone response is attenuated by ethanol but not dextromethorphan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17207107/),[ng] / [ml],21.0,143870,DB00052,Somatropin recombinant
,2395807,relative bioavailability,"A lysophospholipid, lysophosphatidylcholine, gave the highest peak concentration, with an increase in peak height of 450% and a relative bioavailability of 25.8%.",Nasal absorption enhancers for biosynthetic human growth hormone in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2395807/),%,25.8,144697,DB00052,Somatropin recombinant
,2395807,relative bioavailability,"However, the greatest increase in AUC (291%) was achieved with the aminopeptidase inhibitor, amastatin, which gave a relative bioavailability of 28.9%.",Nasal absorption enhancers for biosynthetic human growth hormone in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2395807/),%,28.9,144698,DB00052,Somatropin recombinant
,2395807,relative bioavailabilities,"A mucolytic agent, N-acetyl-L-cysteine, and a transmembrane fatty acid transporter, palmitoyl-DL-carnitine, were also found to promote the nasal absorption of hGH in this model, with relative bioavailabilities of 12.2 and 22.1%, respectively.",Nasal absorption enhancers for biosynthetic human growth hormone in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2395807/),%,12.2,144699,DB00052,Somatropin recombinant
,2395807,relative bioavailabilities,"A mucolytic agent, N-acetyl-L-cysteine, and a transmembrane fatty acid transporter, palmitoyl-DL-carnitine, were also found to promote the nasal absorption of hGH in this model, with relative bioavailabilities of 12.2 and 22.1%, respectively.",Nasal absorption enhancers for biosynthetic human growth hormone in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2395807/),%,22.1,144700,DB00052,Somatropin recombinant
,10381769,Cmax,"Cmax values for 125-mg and 75-mg MDMA doses were 236.4 and 130.9 ng/ml, and Tmax was observed at 2.4 and 1.8 h, respectively.","Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381769/),[ng] / [ml],236.4,146037,DB00052,Somatropin recombinant
,10381769,Cmax,"Cmax values for 125-mg and 75-mg MDMA doses were 236.4 and 130.9 ng/ml, and Tmax was observed at 2.4 and 1.8 h, respectively.","Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381769/),[ng] / [ml],130.9,146038,DB00052,Somatropin recombinant
,10381769,Tmax,"Cmax values for 125-mg and 75-mg MDMA doses were 236.4 and 130.9 ng/ml, and Tmax was observed at 2.4 and 1.8 h, respectively.","Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381769/),h,2.4,146039,DB00052,Somatropin recombinant
,10381769,Tmax,"Cmax values for 125-mg and 75-mg MDMA doses were 236.4 and 130.9 ng/ml, and Tmax was observed at 2.4 and 1.8 h, respectively.","Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381769/),h,1.8,146040,DB00052,Somatropin recombinant
,10381769,Elimination half-life,"Elimination half-life was 8.6 h and 7.7 h for high and low MDMA doses, respectively.","Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381769/),h,8.6,146041,DB00052,Somatropin recombinant
,10381769,Elimination half-life,"Elimination half-life was 8.6 h and 7.7 h for high and low MDMA doses, respectively.","Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381769/),h,7.7,146042,DB00052,Somatropin recombinant
,10381769,half-life,Amphetamine half-life was 15 h.,"Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381769/),h,15,146043,DB00052,Somatropin recombinant
,7957536,half-life,"Plasma growth hormone concentrations increased dose-dependently after the injection of the peptide, peaking at about 30 min and then decreasing to baseline values within 240 min with a half-life of about 55 min.",Growth hormone-releasing activity of hexarelin in humans. A dose-response study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957536/),min,55,151693,DB00052,Somatropin recombinant
,7957536,peak plasma growth hormone concentrations (Cmax),"The mean peak plasma growth hormone concentrations (Cmax) were 3.9, 26.9, 52.3, 55.0 ng.ml-1 after 0, 0.5, 1 and 2 micrograms.",Growth hormone-releasing activity of hexarelin in humans. A dose-response study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957536/),[ng] / [ml],3.9,151694,DB00052,Somatropin recombinant
,7957536,peak plasma growth hormone concentrations (Cmax),"The mean peak plasma growth hormone concentrations (Cmax) were 3.9, 26.9, 52.3, 55.0 ng.ml-1 after 0, 0.5, 1 and 2 micrograms.",Growth hormone-releasing activity of hexarelin in humans. A dose-response study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957536/),[ng] / [ml],26.9,151695,DB00052,Somatropin recombinant
,7957536,peak plasma growth hormone concentrations (Cmax),"The mean peak plasma growth hormone concentrations (Cmax) were 3.9, 26.9, 52.3, 55.0 ng.ml-1 after 0, 0.5, 1 and 2 micrograms.",Growth hormone-releasing activity of hexarelin in humans. A dose-response study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957536/),[ng] / [ml],52.3,151696,DB00052,Somatropin recombinant
,7957536,peak plasma growth hormone concentrations (Cmax),"The mean peak plasma growth hormone concentrations (Cmax) were 3.9, 26.9, 52.3, 55.0 ng.ml-1 after 0, 0.5, 1 and 2 micrograms.",Growth hormone-releasing activity of hexarelin in humans. A dose-response study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957536/),[ng] / [ml],55.0,151697,DB00052,Somatropin recombinant
,7957536,areas under the curve,"The corresponding areas under the curve of growth hormone plasma levels from drug injection to 180 min (AUC0-180) were 0.135, 1.412, 2.918 and 3.695 micrograms.min.ml-1.",Growth hormone-releasing activity of hexarelin in humans. A dose-response study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957536/),[min·μg] / [ml],0.135,151698,DB00052,Somatropin recombinant
,7957536,areas under the curve,"The corresponding areas under the curve of growth hormone plasma levels from drug injection to 180 min (AUC0-180) were 0.135, 1.412, 2.918 and 3.695 micrograms.min.ml-1.",Growth hormone-releasing activity of hexarelin in humans. A dose-response study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957536/),[min·μg] / [ml],1.412,151699,DB00052,Somatropin recombinant
,7957536,areas under the curve,"The corresponding areas under the curve of growth hormone plasma levels from drug injection to 180 min (AUC0-180) were 0.135, 1.412, 2.918 and 3.695 micrograms.min.ml-1.",Growth hormone-releasing activity of hexarelin in humans. A dose-response study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957536/),[min·μg] / [ml],2.918,151700,DB00052,Somatropin recombinant
,7957536,areas under the curve,"The corresponding areas under the curve of growth hormone plasma levels from drug injection to 180 min (AUC0-180) were 0.135, 1.412, 2.918 and 3.695 micrograms.min.ml-1.",Growth hormone-releasing activity of hexarelin in humans. A dose-response study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957536/),[min·μg] / [ml],3.695,151701,DB00052,Somatropin recombinant
,7957536,ED50,The calculated ED50 values were 0.50 and 0.64 microgram.,Growth hormone-releasing activity of hexarelin in humans. A dose-response study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957536/),μg,0.50,151702,DB00052,Somatropin recombinant
,7957536,ED50,The calculated ED50 values were 0.50 and 0.64 microgram.,Growth hormone-releasing activity of hexarelin in humans. A dose-response study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957536/),μg,0.64,151703,DB00052,Somatropin recombinant
,7957536,Emaxs,The corresponding Emaxs were 55.1 ng.,Growth hormone-releasing activity of hexarelin in humans. A dose-response study. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957536/),ng,55.1,151704,DB00052,Somatropin recombinant
,15080773,elimination half life (t(1/2)),"Acylated ghrelin disappeared more rapidly from plasma than total ghrelin, with elimination half life (t(1/2)) of 9-13 and 27-31 min respectively.","Pharmacokinetics, safety, and endocrine and appetite effects of ghrelin administration in young healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080773/),min,9-13,153522,DB00052,Somatropin recombinant
,15080773,elimination half life (t(1/2)),"Acylated ghrelin disappeared more rapidly from plasma than total ghrelin, with elimination half life (t(1/2)) of 9-13 and 27-31 min respectively.","Pharmacokinetics, safety, and endocrine and appetite effects of ghrelin administration in young healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080773/),min,27-31,153523,DB00052,Somatropin recombinant
,15080773,"peak plasma concentration (C(max,0-90 min)","Both the low and high doses of ghrelin strongly stimulated GH release (peak plasma concentration (C(max,0-90 min)): 124.2+/-63.9 and 153.2+/-52.2 ng/ml for 1 and 5 microg/kg ghrelin respectively).","Pharmacokinetics, safety, and endocrine and appetite effects of ghrelin administration in young healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080773/),[ng] / [ml],124.2,153524,DB00052,Somatropin recombinant
,15080773,"peak plasma concentration (C(max,0-90 min)","Both the low and high doses of ghrelin strongly stimulated GH release (peak plasma concentration (C(max,0-90 min)): 124.2+/-63.9 and 153.2+/-52.2 ng/ml for 1 and 5 microg/kg ghrelin respectively).","Pharmacokinetics, safety, and endocrine and appetite effects of ghrelin administration in young healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080773/),[ng] / [ml],153.2,153525,DB00052,Somatropin recombinant
,28110155,half-life,PEGylation resulted in long exposure to RO5046013 with a half-life of 140-200h.,First-in-man study with a novel PEGylated recombinant human insulin-like growth factor-I. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28110155/),h,140-200,155975,DB00052,Somatropin recombinant
up to,21036718,Plasma stability,Plasma stability of (177)Lu-AMBA could be maintained up to 55.67±6.07% at 24 h in a protection buffer.,Multimodality imaging and preclinical evaluation of 177Lu-AMBA for human prostate tumours in a murine model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21036718/),%,55.67,157400,DB00052,Somatropin recombinant
,21036718,distribution half-life (t(1/2α)),"The distribution half-life (t(1/2α)) and the elimination half-life (t(1/2β)) of (177) Lu-AMBA in mice were 0.52 h and 26.6 h, respectively.",Multimodality imaging and preclinical evaluation of 177Lu-AMBA for human prostate tumours in a murine model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21036718/),h,0.52,157401,DB00052,Somatropin recombinant
,21036718,elimination half-life (t(1/2β)),"The distribution half-life (t(1/2α)) and the elimination half-life (t(1/2β)) of (177) Lu-AMBA in mice were 0.52 h and 26.6 h, respectively.",Multimodality imaging and preclinical evaluation of 177Lu-AMBA for human prostate tumours in a murine model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21036718/),h,26.6,157402,DB00052,Somatropin recombinant
,16403822,half-life,The IGF-I half-life in four subjects after a dose of 0.5 mg/kg rhIGF-I/rhIGFBP-3 was estimated to be 21+/- 4 h.,Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I)/rhIGF-binding protein-3 complex administered to patients with growth hormone insensitivity syndrome. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16403822/),h,21,157405,DB00052,Somatropin recombinant
,3186618,plasma half lives,The plasma half lives were estimated to be about 3-7 min.,Pharmacokinetics of biosynthetic and pituitary human growth hormones in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3186618/),min,3-7,157433,DB00052,Somatropin recombinant
,3186618,beta 1/2,(alpha 1/2) and 29 min. (beta 1/2).,Pharmacokinetics of biosynthetic and pituitary human growth hormones in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3186618/),min,29,157434,DB00052,Somatropin recombinant
,26946443,Clearance,Clearance in non-anesthetized rats was 290 ml/h/kg.,The kidneys play a central role in the clearance of rhGH in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26946443/),[ml] / [h·kg],290,159150,DB00052,Somatropin recombinant
,2022713,elimination rate constant,"Plasma concentration vs. time data were curve fit using a nonlinear weighted least squares algorithm which permitted calculation of the following PK parameters (mean +/- SEM; FD vs. MD group): elimination rate constant (0.23 +/- 0.04 vs. 0.25 +/- 0.04 h-1), absorption rate constant (0.43 +/- 0.05 vs. 0.48 +/- 0.04 h-1), elimination half-life (t1/2; 3.01 vs. 2.77 h), total plasma clearance (CL/F; 0.32 +/- 0.02 vs. 0.54 +/- 0.09 L/h.kg), and apparent volume of distribution (VDss/F; 2.2 +/- 0.14 vs. 3.15 +/- 0.28 L/kg).",Single and multiple dose pharmacokinetics of methionyl growth hormone in children with idiopathic growth hormone deficiency. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2022713/),1/[h],0.23,161082,DB00052,Somatropin recombinant
,2022713,elimination rate constant,"Plasma concentration vs. time data were curve fit using a nonlinear weighted least squares algorithm which permitted calculation of the following PK parameters (mean +/- SEM; FD vs. MD group): elimination rate constant (0.23 +/- 0.04 vs. 0.25 +/- 0.04 h-1), absorption rate constant (0.43 +/- 0.05 vs. 0.48 +/- 0.04 h-1), elimination half-life (t1/2; 3.01 vs. 2.77 h), total plasma clearance (CL/F; 0.32 +/- 0.02 vs. 0.54 +/- 0.09 L/h.kg), and apparent volume of distribution (VDss/F; 2.2 +/- 0.14 vs. 3.15 +/- 0.28 L/kg).",Single and multiple dose pharmacokinetics of methionyl growth hormone in children with idiopathic growth hormone deficiency. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2022713/),1/[h],0.25,161083,DB00052,Somatropin recombinant
,2022713,absorption rate constant,"Plasma concentration vs. time data were curve fit using a nonlinear weighted least squares algorithm which permitted calculation of the following PK parameters (mean +/- SEM; FD vs. MD group): elimination rate constant (0.23 +/- 0.04 vs. 0.25 +/- 0.04 h-1), absorption rate constant (0.43 +/- 0.05 vs. 0.48 +/- 0.04 h-1), elimination half-life (t1/2; 3.01 vs. 2.77 h), total plasma clearance (CL/F; 0.32 +/- 0.02 vs. 0.54 +/- 0.09 L/h.kg), and apparent volume of distribution (VDss/F; 2.2 +/- 0.14 vs. 3.15 +/- 0.28 L/kg).",Single and multiple dose pharmacokinetics of methionyl growth hormone in children with idiopathic growth hormone deficiency. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2022713/),1/[h],0.43,161084,DB00052,Somatropin recombinant
,2022713,absorption rate constant,"Plasma concentration vs. time data were curve fit using a nonlinear weighted least squares algorithm which permitted calculation of the following PK parameters (mean +/- SEM; FD vs. MD group): elimination rate constant (0.23 +/- 0.04 vs. 0.25 +/- 0.04 h-1), absorption rate constant (0.43 +/- 0.05 vs. 0.48 +/- 0.04 h-1), elimination half-life (t1/2; 3.01 vs. 2.77 h), total plasma clearance (CL/F; 0.32 +/- 0.02 vs. 0.54 +/- 0.09 L/h.kg), and apparent volume of distribution (VDss/F; 2.2 +/- 0.14 vs. 3.15 +/- 0.28 L/kg).",Single and multiple dose pharmacokinetics of methionyl growth hormone in children with idiopathic growth hormone deficiency. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2022713/),1/[h],0.48,161085,DB00052,Somatropin recombinant
,2022713,elimination half-life (t1/2,"Plasma concentration vs. time data were curve fit using a nonlinear weighted least squares algorithm which permitted calculation of the following PK parameters (mean +/- SEM; FD vs. MD group): elimination rate constant (0.23 +/- 0.04 vs. 0.25 +/- 0.04 h-1), absorption rate constant (0.43 +/- 0.05 vs. 0.48 +/- 0.04 h-1), elimination half-life (t1/2; 3.01 vs. 2.77 h), total plasma clearance (CL/F; 0.32 +/- 0.02 vs. 0.54 +/- 0.09 L/h.kg), and apparent volume of distribution (VDss/F; 2.2 +/- 0.14 vs. 3.15 +/- 0.28 L/kg).",Single and multiple dose pharmacokinetics of methionyl growth hormone in children with idiopathic growth hormone deficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2022713/),h,3.01,161086,DB00052,Somatropin recombinant
,2022713,elimination half-life (t1/2,"Plasma concentration vs. time data were curve fit using a nonlinear weighted least squares algorithm which permitted calculation of the following PK parameters (mean +/- SEM; FD vs. MD group): elimination rate constant (0.23 +/- 0.04 vs. 0.25 +/- 0.04 h-1), absorption rate constant (0.43 +/- 0.05 vs. 0.48 +/- 0.04 h-1), elimination half-life (t1/2; 3.01 vs. 2.77 h), total plasma clearance (CL/F; 0.32 +/- 0.02 vs. 0.54 +/- 0.09 L/h.kg), and apparent volume of distribution (VDss/F; 2.2 +/- 0.14 vs. 3.15 +/- 0.28 L/kg).",Single and multiple dose pharmacokinetics of methionyl growth hormone in children with idiopathic growth hormone deficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2022713/),h,2.77,161087,DB00052,Somatropin recombinant
,2022713,total plasma clearance (CL/F,"Plasma concentration vs. time data were curve fit using a nonlinear weighted least squares algorithm which permitted calculation of the following PK parameters (mean +/- SEM; FD vs. MD group): elimination rate constant (0.23 +/- 0.04 vs. 0.25 +/- 0.04 h-1), absorption rate constant (0.43 +/- 0.05 vs. 0.48 +/- 0.04 h-1), elimination half-life (t1/2; 3.01 vs. 2.77 h), total plasma clearance (CL/F; 0.32 +/- 0.02 vs. 0.54 +/- 0.09 L/h.kg), and apparent volume of distribution (VDss/F; 2.2 +/- 0.14 vs. 3.15 +/- 0.28 L/kg).",Single and multiple dose pharmacokinetics of methionyl growth hormone in children with idiopathic growth hormone deficiency. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2022713/),[l] / [h·kg],0.32,161088,DB00052,Somatropin recombinant
,2022713,total plasma clearance (CL/F,"Plasma concentration vs. time data were curve fit using a nonlinear weighted least squares algorithm which permitted calculation of the following PK parameters (mean +/- SEM; FD vs. MD group): elimination rate constant (0.23 +/- 0.04 vs. 0.25 +/- 0.04 h-1), absorption rate constant (0.43 +/- 0.05 vs. 0.48 +/- 0.04 h-1), elimination half-life (t1/2; 3.01 vs. 2.77 h), total plasma clearance (CL/F; 0.32 +/- 0.02 vs. 0.54 +/- 0.09 L/h.kg), and apparent volume of distribution (VDss/F; 2.2 +/- 0.14 vs. 3.15 +/- 0.28 L/kg).",Single and multiple dose pharmacokinetics of methionyl growth hormone in children with idiopathic growth hormone deficiency. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2022713/),[l] / [h·kg],0.54,161089,DB00052,Somatropin recombinant
,2022713,apparent volume of distribution (VDss/F,"Plasma concentration vs. time data were curve fit using a nonlinear weighted least squares algorithm which permitted calculation of the following PK parameters (mean +/- SEM; FD vs. MD group): elimination rate constant (0.23 +/- 0.04 vs. 0.25 +/- 0.04 h-1), absorption rate constant (0.43 +/- 0.05 vs. 0.48 +/- 0.04 h-1), elimination half-life (t1/2; 3.01 vs. 2.77 h), total plasma clearance (CL/F; 0.32 +/- 0.02 vs. 0.54 +/- 0.09 L/h.kg), and apparent volume of distribution (VDss/F; 2.2 +/- 0.14 vs. 3.15 +/- 0.28 L/kg).",Single and multiple dose pharmacokinetics of methionyl growth hormone in children with idiopathic growth hormone deficiency. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2022713/),[l] / [kg],2.2,161090,DB00052,Somatropin recombinant
,2022713,apparent volume of distribution (VDss/F,"Plasma concentration vs. time data were curve fit using a nonlinear weighted least squares algorithm which permitted calculation of the following PK parameters (mean +/- SEM; FD vs. MD group): elimination rate constant (0.23 +/- 0.04 vs. 0.25 +/- 0.04 h-1), absorption rate constant (0.43 +/- 0.05 vs. 0.48 +/- 0.04 h-1), elimination half-life (t1/2; 3.01 vs. 2.77 h), total plasma clearance (CL/F; 0.32 +/- 0.02 vs. 0.54 +/- 0.09 L/h.kg), and apparent volume of distribution (VDss/F; 2.2 +/- 0.14 vs. 3.15 +/- 0.28 L/kg).",Single and multiple dose pharmacokinetics of methionyl growth hormone in children with idiopathic growth hormone deficiency. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2022713/),[l] / [kg],3.15,161091,DB00052,Somatropin recombinant
,2022713,VDss/F,"With the exception of a larger VDss/F in subjects who received daily (3.6 +/- 0.4 L/kg) vs. TIW metGH (2.4 +/- 0.2 L/kg), no significant differences were found for the PK parameters between the D and TIW dosing groups.",Single and multiple dose pharmacokinetics of methionyl growth hormone in children with idiopathic growth hormone deficiency. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2022713/),[l] / [kg],3.6,161092,DB00052,Somatropin recombinant
,2022713,VDss/F,"With the exception of a larger VDss/F in subjects who received daily (3.6 +/- 0.4 L/kg) vs. TIW metGH (2.4 +/- 0.2 L/kg), no significant differences were found for the PK parameters between the D and TIW dosing groups.",Single and multiple dose pharmacokinetics of methionyl growth hormone in children with idiopathic growth hormone deficiency. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2022713/),[l] / [kg],2.4,161093,DB00052,Somatropin recombinant
,2022713,time to reach maximum concentration (Tmax),"In all subjects, absorption of metGH was slow, with an average time to reach maximum concentration (Tmax) of 4.4 h and an absorption t1/2 that ranged from 1.4-1.8 h.",Single and multiple dose pharmacokinetics of methionyl growth hormone in children with idiopathic growth hormone deficiency. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2022713/),h,4.4,161094,DB00052,Somatropin recombinant
,2022713,absorption t1/2,"In all subjects, absorption of metGH was slow, with an average time to reach maximum concentration (Tmax) of 4.4 h and an absorption t1/2 that ranged from 1.4-1.8 h.",Single and multiple dose pharmacokinetics of methionyl growth hormone in children with idiopathic growth hormone deficiency. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2022713/),h,1.4-1.8,161095,DB00052,Somatropin recombinant
,11505794,metabolic half-life,Somatropin has a known metabolic half-life of ca. 20-30 min while the observed terminal half-lives were 2-4 h.,Pharmacokinetics of human growth hormone administered subcutaneously with two different injection systems. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11505794/),min,20-30,161485,DB00052,Somatropin recombinant
,11505794,terminal half-lives,Somatropin has a known metabolic half-life of ca. 20-30 min while the observed terminal half-lives were 2-4 h.,Pharmacokinetics of human growth hormone administered subcutaneously with two different injection systems. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11505794/),h,2-4,161486,DB00052,Somatropin recombinant
,22481061,maximum solubility,The maximum solubility of aPPD in ethanol was 68.4 mg/ml.,A novel oral dosage formulation of the ginsenoside aglycone protopanaxadiol exhibits therapeutic activity against a hormone-insensitive model of prostate cancer. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22481061/),[mg] / [ml],68.4,161610,DB00052,Somatropin recombinant
,22481061,T(max),"aPPD administered at a dose of 70 mg/kg yielded a T(max) of approximately 40 min and a C(max) value of 3.9 ± 1.4 μg/ml, and no toxicity was observed.",A novel oral dosage formulation of the ginsenoside aglycone protopanaxadiol exhibits therapeutic activity against a hormone-insensitive model of prostate cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22481061/),min,40,161611,DB00052,Somatropin recombinant
,22481061,C(max),"aPPD administered at a dose of 70 mg/kg yielded a T(max) of approximately 40 min and a C(max) value of 3.9 ± 1.4 μg/ml, and no toxicity was observed.",A novel oral dosage formulation of the ginsenoside aglycone protopanaxadiol exhibits therapeutic activity against a hormone-insensitive model of prostate cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22481061/),[μg] / [ml],3.9,161612,DB00052,Somatropin recombinant
,11741481,EC(50),"(+)-6-Carbamoyl-3-(2-chlorophenyl)-(2-diethylaminoethyl)-4-trifluoromethyloxindole (SM-130686, 37S) was found to have potent activity (EC(50) = 3.0 nM), while the other enantiomer 37R had reduced activity.",Oxindole derivatives as orally active potent growth hormone secretagogues. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11741481/),nM,3.0,162320,DB00052,Somatropin recombinant
,11741481,oral bioavailability,Compound 37S showed a good pharmacokinetic profile in rats with 28% oral bioavailability at 10 mg/kg and excellent in vivo activity as evidenced by a significant weight gain after 4 days of oral administration at 10 mg/kg twice a day.,Oxindole derivatives as orally active potent growth hormone secretagogues. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11741481/),%,28,162321,DB00052,Somatropin recombinant
,11741481,IC(50),Compound 37S displaced the binding of (35)S-MK-677 to human GHS-R with an IC(50) value of 1.2 +/- 0.2 nM.,Oxindole derivatives as orally active potent growth hormone secretagogues. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11741481/),nM,1.2,162322,DB00052,Somatropin recombinant
,15970435,bioavailabilities,"Mean bioavailabilities of hGH from Formulations A and B were 14 and 15%, respectively relative to subcutaneous injection.",Intranasal delivery of recombinant human growth hormone (somatropin) in sheep using chitosan-based powder formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15970435/),%,14,163194,DB00052,Somatropin recombinant
,15970435,bioavailabilities,"Mean bioavailabilities of hGH from Formulations A and B were 14 and 15%, respectively relative to subcutaneous injection.",Intranasal delivery of recombinant human growth hormone (somatropin) in sheep using chitosan-based powder formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15970435/),%,15,163195,DB00052,Somatropin recombinant
,3802551,peak plasma level,The peak plasma level of hGH (62 +/- 20 mU/l) occurred between 3.0 and 3.5 h.,"An open-labelled study of the safety, acute metabolic activity and pharmacokinetic profile of a short-term course of recombinant human growth hormone in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3802551/),[mu] / [l],62,163597,DB00052,Somatropin recombinant
,17634080,AUC(0-24 h),GH AUC(0-24 h) was greater for patients (387.91 +/- 134.13 microg h/l) than healthy subjects (225.35 +/- 59.63 microg h/l) and the 90% confidence interval (CI) for the estimated patient : healthy subject ratio (1.40-2.07) was not within the acceptance interval (0.67-1.50).,"Pharmacokinetics and pharmacodynamics of growth hormone in patients on chronic haemodialysis compared with matched healthy subjects: an open, nonrandomized, parallel-group trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17634080/),[h·μg] / [l],387.91,167860,DB00052,Somatropin recombinant
,17634080,AUC(0-24 h),GH AUC(0-24 h) was greater for patients (387.91 +/- 134.13 microg h/l) than healthy subjects (225.35 +/- 59.63 microg h/l) and the 90% confidence interval (CI) for the estimated patient : healthy subject ratio (1.40-2.07) was not within the acceptance interval (0.67-1.50).,"Pharmacokinetics and pharmacodynamics of growth hormone in patients on chronic haemodialysis compared with matched healthy subjects: an open, nonrandomized, parallel-group trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17634080/),[h·μg] / [l],225.35,167861,DB00052,Somatropin recombinant
,17634080,AUC(18-24 h),"GH AUC(18-24 h) for patients and healthy subjects (3.03 +/- 2.71 microg h/l and 6.37 +/- 4.21 microg h/l) returned approximately to baseline (2.86 +/- 3.91 microg h/l and 1.09 +/- 1.43 microg h/l); terminal half-life (t(1/2,z)) was shorter for patients (2.28 +/- 00.43 h vs. 3.23 +/- 00.75 h).","Pharmacokinetics and pharmacodynamics of growth hormone in patients on chronic haemodialysis compared with matched healthy subjects: an open, nonrandomized, parallel-group trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17634080/),[h·μg] / [l],3.03,167862,DB00052,Somatropin recombinant
,17634080,AUC(18-24 h),"GH AUC(18-24 h) for patients and healthy subjects (3.03 +/- 2.71 microg h/l and 6.37 +/- 4.21 microg h/l) returned approximately to baseline (2.86 +/- 3.91 microg h/l and 1.09 +/- 1.43 microg h/l); terminal half-life (t(1/2,z)) was shorter for patients (2.28 +/- 00.43 h vs. 3.23 +/- 00.75 h).","Pharmacokinetics and pharmacodynamics of growth hormone in patients on chronic haemodialysis compared with matched healthy subjects: an open, nonrandomized, parallel-group trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17634080/),[h·μg] / [l],6.37,167863,DB00052,Somatropin recombinant
,17634080,AUC(18-24 h),"GH AUC(18-24 h) for patients and healthy subjects (3.03 +/- 2.71 microg h/l and 6.37 +/- 4.21 microg h/l) returned approximately to baseline (2.86 +/- 3.91 microg h/l and 1.09 +/- 1.43 microg h/l); terminal half-life (t(1/2,z)) was shorter for patients (2.28 +/- 00.43 h vs. 3.23 +/- 00.75 h).","Pharmacokinetics and pharmacodynamics of growth hormone in patients on chronic haemodialysis compared with matched healthy subjects: an open, nonrandomized, parallel-group trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17634080/),[h·μg] / [l],2.86,167864,DB00052,Somatropin recombinant
,17634080,AUC(18-24 h),"GH AUC(18-24 h) for patients and healthy subjects (3.03 +/- 2.71 microg h/l and 6.37 +/- 4.21 microg h/l) returned approximately to baseline (2.86 +/- 3.91 microg h/l and 1.09 +/- 1.43 microg h/l); terminal half-life (t(1/2,z)) was shorter for patients (2.28 +/- 00.43 h vs. 3.23 +/- 00.75 h).","Pharmacokinetics and pharmacodynamics of growth hormone in patients on chronic haemodialysis compared with matched healthy subjects: an open, nonrandomized, parallel-group trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17634080/),[h·μg] / [l],1.09,167865,DB00052,Somatropin recombinant
,17634080,"terminal half-life (t(1/2,z))","GH AUC(18-24 h) for patients and healthy subjects (3.03 +/- 2.71 microg h/l and 6.37 +/- 4.21 microg h/l) returned approximately to baseline (2.86 +/- 3.91 microg h/l and 1.09 +/- 1.43 microg h/l); terminal half-life (t(1/2,z)) was shorter for patients (2.28 +/- 00.43 h vs. 3.23 +/- 00.75 h).","Pharmacokinetics and pharmacodynamics of growth hormone in patients on chronic haemodialysis compared with matched healthy subjects: an open, nonrandomized, parallel-group trial. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17634080/),h,2.28,167866,DB00052,Somatropin recombinant
,17634080,"terminal half-life (t(1/2,z))","GH AUC(18-24 h) for patients and healthy subjects (3.03 +/- 2.71 microg h/l and 6.37 +/- 4.21 microg h/l) returned approximately to baseline (2.86 +/- 3.91 microg h/l and 1.09 +/- 1.43 microg h/l); terminal half-life (t(1/2,z)) was shorter for patients (2.28 +/- 00.43 h vs. 3.23 +/- 00.75 h).","Pharmacokinetics and pharmacodynamics of growth hormone in patients on chronic haemodialysis compared with matched healthy subjects: an open, nonrandomized, parallel-group trial. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17634080/),h,3.23,167867,DB00052,Somatropin recombinant
,17822889,protein loading,"The protein loading (protein/polymer, w/w, %) was 12.1+/-1.3% and 8.5+/-0.4% with PHEA-C16 and PHEA-PEG 5000-C16, respectively.",Supramolecular association of recombinant human growth hormone with hydrophobized polyhydroxyethylaspartamides. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17822889/),%,12.1,169154,DB00052,Somatropin recombinant
,17822889,protein loading,"The protein loading (protein/polymer, w/w, %) was 12.1+/-1.3% and 8.5+/-0.4% with PHEA-C16 and PHEA-PEG 5000-C16, respectively.",Supramolecular association of recombinant human growth hormone with hydrophobized polyhydroxyethylaspartamides. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17822889/),%,8.5,169155,DB00052,Somatropin recombinant
,17822889,association constant,The rh-GH/polymer association constant calculated by Scatchard analysis was 1.87 x 10(5)M(-1) with PHEA-C(16) and 0.27 x 10(5)M(-1) with PHEA-PEG 5000-C16.,Supramolecular association of recombinant human growth hormone with hydrophobized polyhydroxyethylaspartamides. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17822889/),1/[M],1.87 x 10(5),169156,DB00052,Somatropin recombinant
,17822889,association constant,The rh-GH/polymer association constant calculated by Scatchard analysis was 1.87 x 10(5)M(-1) with PHEA-C(16) and 0.27 x 10(5)M(-1) with PHEA-PEG 5000-C16.,Supramolecular association of recombinant human growth hormone with hydrophobized polyhydroxyethylaspartamides. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17822889/),1/[M],0.27 x 10(5),169157,DB00052,Somatropin recombinant
,31835495,clinical benefit rate,The clinical benefit rate was 27.9% among 43 patients treated at the R2D.,Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31835495/),%,27.9,174682,DB00052,Somatropin recombinant
,22678811,terminal elimination half-life,"In monkeys, VRS-317, having a terminal elimination half-life of approximately 110 h, was rapidly and near-completely absorbed, and was well tolerated with no observed adverse effects after every alternate week subcutaneous dosing for 14 weeks.",A novel long-acting human growth hormone fusion protein (VRS-317): enhanced in vivo potency and half-life. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22678811/),h,110,177188,DB00052,Somatropin recombinant
,16720652,maximal serum GH concentration,The observed maximal serum GH concentration was approximately doubled after LB03002 (6.1 +/- 3.2 and 4.5 +/- 2.2 microg/liter at first and fifth doses) compared with daily GH (2.7 +/- 2.2 microg/liter).,"Comparative pharmacokinetics and pharmacodynamics of a new sustained-release growth hormone (GH), LB03002, versus daily GH in adults with GH deficiency. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16720652/),[μg] / [l],6.1,178369,DB00052,Somatropin recombinant
,16720652,maximal serum GH concentration,The observed maximal serum GH concentration was approximately doubled after LB03002 (6.1 +/- 3.2 and 4.5 +/- 2.2 microg/liter at first and fifth doses) compared with daily GH (2.7 +/- 2.2 microg/liter).,"Comparative pharmacokinetics and pharmacodynamics of a new sustained-release growth hormone (GH), LB03002, versus daily GH in adults with GH deficiency. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16720652/),[μg] / [l],4.5,178370,DB00052,Somatropin recombinant
,16720652,maximal serum GH concentration,The observed maximal serum GH concentration was approximately doubled after LB03002 (6.1 +/- 3.2 and 4.5 +/- 2.2 microg/liter at first and fifth doses) compared with daily GH (2.7 +/- 2.2 microg/liter).,"Comparative pharmacokinetics and pharmacodynamics of a new sustained-release growth hormone (GH), LB03002, versus daily GH in adults with GH deficiency. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16720652/),[μg] / [l],2.7,178371,DB00052,Somatropin recombinant
,31548064,half-life,"After bolus administration, human FGF21 circulated with a half-life of 194 min, and its constant infusion increased total plasma concentration 117-fold over levels in excipient-infused cows.","Fibroblast growth factor-21 (FGF21) administration to early-lactating dairy cows. Pharmacokinetics, whole-animal performance, and lipid metabolism. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31548064/),min,194,178974,DB00052,Somatropin recombinant
,10336548,clearance,Disposition profiles of rhGH from two short-term i.v. infusion studies were described by a two-compartment model yielding a clearance of 16.1 ml/min and T1/2 of 2.0 h.,A pharmacokinetic/pharmacodynamic model for recombinant human growth hormone effects on induction of insulin-like growth factor I in monkeys. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10336548/),[ml] / [min],16.1,182644,DB00052,Somatropin recombinant
,10336548,T1/2,Disposition profiles of rhGH from two short-term i.v. infusion studies were described by a two-compartment model yielding a clearance of 16.1 ml/min and T1/2 of 2.0 h.,A pharmacokinetic/pharmacodynamic model for recombinant human growth hormone effects on induction of insulin-like growth factor I in monkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10336548/),h,2.0,182645,DB00052,Somatropin recombinant
,10336548,Smax,"Parameter values obtained included Smax = 2.2, SC50 = 6.5 ng/ml, and gamma (slope coefficient) = 6.8, which were applicable to all treatments.",A pharmacokinetic/pharmacodynamic model for recombinant human growth hormone effects on induction of insulin-like growth factor I in monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10336548/),,2.2,182646,DB00052,Somatropin recombinant
,10336548,SC50,"Parameter values obtained included Smax = 2.2, SC50 = 6.5 ng/ml, and gamma (slope coefficient) = 6.8, which were applicable to all treatments.",A pharmacokinetic/pharmacodynamic model for recombinant human growth hormone effects on induction of insulin-like growth factor I in monkeys. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10336548/),[ng] / [ml],6.5,182647,DB00052,Somatropin recombinant
,8219484,clearance,"IGF-I was thus characterized as a low-clearance peptide, with a clearance and half-life estimated at about 0.20 ml/minute/kg and 20 hours, respectively, in healthy volunteers.",Pharmacokinetics of recombinant human insulin-like growth factor I given subcutaneously to healthy volunteers and to patients with growth hormone receptor deficiency. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8219484/),[ml] / [kg·min],0.20,182789,DB00052,Somatropin recombinant
,8219484,half-life,"IGF-I was thus characterized as a low-clearance peptide, with a clearance and half-life estimated at about 0.20 ml/minute/kg and 20 hours, respectively, in healthy volunteers.",Pharmacokinetics of recombinant human insulin-like growth factor I given subcutaneously to healthy volunteers and to patients with growth hormone receptor deficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8219484/),h,20,182790,DB00052,Somatropin recombinant
,8219484,volume of distribution,"The volume of distribution was low, about 0.20-0.36 litres/kg, the bioavailability of subcutaneously administered rhIGF-I was 100%, and the rate of production of IGF-I was estimated to be about 50 micrograms/kg/day (3.5 mg/day).",Pharmacokinetics of recombinant human insulin-like growth factor I given subcutaneously to healthy volunteers and to patients with growth hormone receptor deficiency. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8219484/),[l] / [kg],0.20-0.36,182791,DB00052,Somatropin recombinant
,8219484,bioavailability,"The volume of distribution was low, about 0.20-0.36 litres/kg, the bioavailability of subcutaneously administered rhIGF-I was 100%, and the rate of production of IGF-I was estimated to be about 50 micrograms/kg/day (3.5 mg/day).",Pharmacokinetics of recombinant human insulin-like growth factor I given subcutaneously to healthy volunteers and to patients with growth hormone receptor deficiency. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8219484/),%,100,182792,DB00052,Somatropin recombinant
,8219484,rate of production,"The volume of distribution was low, about 0.20-0.36 litres/kg, the bioavailability of subcutaneously administered rhIGF-I was 100%, and the rate of production of IGF-I was estimated to be about 50 micrograms/kg/day (3.5 mg/day).",Pharmacokinetics of recombinant human insulin-like growth factor I given subcutaneously to healthy volunteers and to patients with growth hormone receptor deficiency. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8219484/),[μg] / [d·kg],50,182793,DB00052,Somatropin recombinant
,8219484,clearance,"The clearance and half-life of IGF-I were estimated to be about 0.60 ml/minute/kg and 6 hours, respectively.",Pharmacokinetics of recombinant human insulin-like growth factor I given subcutaneously to healthy volunteers and to patients with growth hormone receptor deficiency. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8219484/),[ml] / [kg·min],0.60,182794,DB00052,Somatropin recombinant
,8219484,half-life,"The clearance and half-life of IGF-I were estimated to be about 0.60 ml/minute/kg and 6 hours, respectively.",Pharmacokinetics of recombinant human insulin-like growth factor I given subcutaneously to healthy volunteers and to patients with growth hormone receptor deficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8219484/),h,6,182795,DB00052,Somatropin recombinant
,8219484,maximum increase,"The maximum increase in IGF-I levels was 111 +/- 12 micrograms/l and 150 +/- 3 micrograms/l following daily subcutaneous injections of 40 x 1 and 40 x 2 micrograms/kg for 7 days, respectively.",Pharmacokinetics of recombinant human insulin-like growth factor I given subcutaneously to healthy volunteers and to patients with growth hormone receptor deficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8219484/),[μg] / [l],111,182796,DB00052,Somatropin recombinant
,8219484,maximum increase,"The maximum increase in IGF-I levels was 111 +/- 12 micrograms/l and 150 +/- 3 micrograms/l following daily subcutaneous injections of 40 x 1 and 40 x 2 micrograms/kg for 7 days, respectively.",Pharmacokinetics of recombinant human insulin-like growth factor I given subcutaneously to healthy volunteers and to patients with growth hormone receptor deficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8219484/),[μg] / [l],150,182797,DB00052,Somatropin recombinant
>or=,12699438,serum peak GH concentration,"Nine of the 83 patients (11%) responded with a serum peak GH concentration >or= 5 micro g/l after the first and/or last NN703 administration, whereas no patient responded after placebo administration.",Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12699438/),[μg] / [l],5,182886,DB00052,Somatropin recombinant
,12699438,serum peak GH concentration,"Mean serum peak GH concentration after GHRH administration was 2.1 micro g/l (+/-0.3, SEM), which was higher than that after the first NN703 administration (1.32 +/- 0.3, P < 0.05).",Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12699438/),[μg] / [l],2.1,182887,DB00052,Somatropin recombinant
,12699438,serum peak GH concentration,"Mean serum peak GH concentration after GHRH administration was 2.1 micro g/l (+/-0.3, SEM), which was higher than that after the first NN703 administration (1.32 +/- 0.3, P < 0.05).",Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12699438/),[μg] / [l],1.32,182888,DB00052,Somatropin recombinant
>or=,12699438,peak GH response,Eleven per cent of the GHD adult patients responded with a peak GH response >or= 5 micro g/l after the first and/or last administration of oral NN703.,Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12699438/),[μg] / [l],5,182889,DB00052,Somatropin recombinant
,15113616,bioavailability,"The bioavailability by the inhaled route was 41% relative to subcutaneous dosing, with an absolute bioavailability estimated at 13%.","Pulmonary delivery of TH9507, a growth hormone releasing factor analogue, in the dog. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15113616/),%,41,185784,DB00052,Somatropin recombinant
,15113616,absolute bioavailability,"The bioavailability by the inhaled route was 41% relative to subcutaneous dosing, with an absolute bioavailability estimated at 13%.","Pulmonary delivery of TH9507, a growth hormone releasing factor analogue, in the dog. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15113616/),%,13,185785,DB00052,Somatropin recombinant
,15113616,mean residence time (MRT),The mean residence time (MRT) was greater following intratracheal administration (74min versus 52min; P<0.01).,"Pulmonary delivery of TH9507, a growth hormone releasing factor analogue, in the dog. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15113616/),min,74,185786,DB00052,Somatropin recombinant
,15113616,mean residence time (MRT),The mean residence time (MRT) was greater following intratracheal administration (74min versus 52min; P<0.01).,"Pulmonary delivery of TH9507, a growth hormone releasing factor analogue, in the dog. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15113616/),min,52,185787,DB00052,Somatropin recombinant
,3063133,respiratory rate,"Ventilation was performed mechanically during the entire operative period (N2O/O2 - FiO2:0.33, tidal volume 10 ml/kg, respiratory rate: 14/min).",[Response of human growth hormone to anesthesia induction with propofol]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3063133/),1/[min],14,187266,DB00052,Somatropin recombinant
,18670103,weight,"The mean weight, length and diameter were 0.68+/-0.05 mg, 3.2+/-0.5 mm and 0.6+/-0.2 microm, respectively.",Self-dissolving micropiles for the percutaneous absorption of recombinant human growth hormone in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18670103/),mg,0.68,189048,DB00052,Somatropin recombinant
,18670103,length,"The mean weight, length and diameter were 0.68+/-0.05 mg, 3.2+/-0.5 mm and 0.6+/-0.2 microm, respectively.",Self-dissolving micropiles for the percutaneous absorption of recombinant human growth hormone in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18670103/),mm,3.2,189049,DB00052,Somatropin recombinant
,18670103,length,"The mean weight, length and diameter were 0.68+/-0.05 mg, 3.2+/-0.5 mm and 0.6+/-0.2 microm, respectively.",Self-dissolving micropiles for the percutaneous absorption of recombinant human growth hormone in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18670103/),μm,0.6,189050,DB00052,Somatropin recombinant
,18670103,diameter,"The mean weight, length and diameter were 0.68+/-0.05 mg, 3.2+/-0.5 mm and 0.6+/-0.2 microm, respectively.",Self-dissolving micropiles for the percutaneous absorption of recombinant human growth hormone in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18670103/),μm,0.6,189051,DB00052,Somatropin recombinant
,18670103,Peak plasma rhGH level,"Peak plasma rhGH level, 132.8+/-11.8 ng ml(-1), appeared at 0.8+/-0.2 h.",Self-dissolving micropiles for the percutaneous absorption of recombinant human growth hormone in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18670103/),[ng] / [ml],132.8,189052,DB00052,Somatropin recombinant
,2866222,half-lives of the initial distribution phase (alpha),Analysis of the biphasic disappearance curve of IR-hGRF-1-29NH2 from plasma after i.v. injection (10 micrograms) gave values for the half-lives of the initial distribution phase (alpha) and for the elimination phase (beta) of 1.9 +/- 0.2 min and 10.4 +/- 0.2 min respectively.,Growth hormone-releasing factor analogue (hGRF1-29NH2): immunoreactive-GRF plasma levels after intravenous and subcutaneous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866222/),min,1.9,190118,DB00052,Somatropin recombinant
,2866222,elimination phase (beta),Analysis of the biphasic disappearance curve of IR-hGRF-1-29NH2 from plasma after i.v. injection (10 micrograms) gave values for the half-lives of the initial distribution phase (alpha) and for the elimination phase (beta) of 1.9 +/- 0.2 min and 10.4 +/- 0.2 min respectively.,Growth hormone-releasing factor analogue (hGRF1-29NH2): immunoreactive-GRF plasma levels after intravenous and subcutaneous administration. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866222/),min,10.4,190119,DB00052,Somatropin recombinant
,10650345,t(1/2),"The fast compartment with t(1/2) of 14.4 min or 25.2 min, for hGH and bGH represents 30.3% and 18.9% of total radioactivity, respectively, at hypothetical time zero (not experi mental).",Pharmacokinetics of radioiodinated growth hormones in the turtle Chrysemys dorbigni. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10650345/),min,14.4,190485,DB00052,Somatropin recombinant
,10650345,t(1/2),"The fast compartment with t(1/2) of 14.4 min or 25.2 min, for hGH and bGH represents 30.3% and 18.9% of total radioactivity, respectively, at hypothetical time zero (not experi mental).",Pharmacokinetics of radioiodinated growth hormones in the turtle Chrysemys dorbigni. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10650345/),min,25.2,190486,DB00052,Somatropin recombinant
,10650345,L/B ratio,"The labeled hGH or bGH binds to turtle serum in similar proportion, but maximal liver uptake of these hormones are completely different (L/B ratio of 9.2 +/- 0.6 (n = 5) for ( 125)I-hGH and 4.8 +/- 0.3 (n = 7) for (125)I-bGH).",Pharmacokinetics of radioiodinated growth hormones in the turtle Chrysemys dorbigni. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10650345/),,9.2,190487,DB00052,Somatropin recombinant
,10650345,L/B ratio,"The labeled hGH or bGH binds to turtle serum in similar proportion, but maximal liver uptake of these hormones are completely different (L/B ratio of 9.2 +/- 0.6 (n = 5) for ( 125)I-hGH and 4.8 +/- 0.3 (n = 7) for (125)I-bGH).",Pharmacokinetics of radioiodinated growth hormones in the turtle Chrysemys dorbigni. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10650345/),,4.8,190488,DB00052,Somatropin recombinant
,22573933,t(max),"Pasireotide demonstrated a favorable PK profile with fast absorption (t(max): 0.25-0.5 hours), low clearance (CL/F: 8-13 L/hour), long effective elimination half-life (mean t(½,β): 7-11 hours), and a proportional dose-exposure relationship.","A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22573933/),h,0.25-0.5,191434,DB00052,Somatropin recombinant
,22573933,clearance (CL/F,"Pasireotide demonstrated a favorable PK profile with fast absorption (t(max): 0.25-0.5 hours), low clearance (CL/F: 8-13 L/hour), long effective elimination half-life (mean t(½,β): 7-11 hours), and a proportional dose-exposure relationship.","A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22573933/),[l] / [h],8-13,191435,DB00052,Somatropin recombinant
,22573933,"t(½,β)","Pasireotide demonstrated a favorable PK profile with fast absorption (t(max): 0.25-0.5 hours), low clearance (CL/F: 8-13 L/hour), long effective elimination half-life (mean t(½,β): 7-11 hours), and a proportional dose-exposure relationship.","A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22573933/),h,7-11,191436,DB00052,Somatropin recombinant
,18802875,Cl/F,"The renal clearance is reduced due to the increased size of the molecule (Cl/F reduced from 9.6 to 0.1 l h(-1) for somatropin and PHA-794428, respectively).",PEGylation of somatropin (recombinant human growth hormone): impact on its clearance in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18802875/),[l] / [h],9.6,192863,DB00052,Somatropin recombinant
,18802875,Cl/F,"The renal clearance is reduced due to the increased size of the molecule (Cl/F reduced from 9.6 to 0.1 l h(-1) for somatropin and PHA-794428, respectively).",PEGylation of somatropin (recombinant human growth hormone): impact on its clearance in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18802875/),[l] / [h],0.1,192864,DB00052,Somatropin recombinant
,18802875,Km,"In addition, the reduction in growth hormone receptor affinity has reduced the clearance mediated by interaction with this receptor (somatropin Km = 3.6 microg l(-1) and Vmax = 104 microg h(-1)/PHA-794428 Km = 53 microg l(-1) and Vmax = 84 microg h(-1)).",PEGylation of somatropin (recombinant human growth hormone): impact on its clearance in humans. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18802875/),[μg] / [l],3.6,192865,DB00052,Somatropin recombinant
,18802875,Vmax,"In addition, the reduction in growth hormone receptor affinity has reduced the clearance mediated by interaction with this receptor (somatropin Km = 3.6 microg l(-1) and Vmax = 104 microg h(-1)/PHA-794428 Km = 53 microg l(-1) and Vmax = 84 microg h(-1)).",PEGylation of somatropin (recombinant human growth hormone): impact on its clearance in humans. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18802875/),[μg] / [h],104,192866,DB00052,Somatropin recombinant
,18802875,Km,"In addition, the reduction in growth hormone receptor affinity has reduced the clearance mediated by interaction with this receptor (somatropin Km = 3.6 microg l(-1) and Vmax = 104 microg h(-1)/PHA-794428 Km = 53 microg l(-1) and Vmax = 84 microg h(-1)).",PEGylation of somatropin (recombinant human growth hormone): impact on its clearance in humans. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18802875/),[μg] / [l],53,192867,DB00052,Somatropin recombinant
,18802875,Vmax,"In addition, the reduction in growth hormone receptor affinity has reduced the clearance mediated by interaction with this receptor (somatropin Km = 3.6 microg l(-1) and Vmax = 104 microg h(-1)/PHA-794428 Km = 53 microg l(-1) and Vmax = 84 microg h(-1)).",PEGylation of somatropin (recombinant human growth hormone): impact on its clearance in humans. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18802875/),[μg] / [h],84,192868,DB00052,Somatropin recombinant
,29422321,Cmax,"In the Clinical-setting, median Cmax was 71 mU/L and AUC was 534 mU/L ∗ h, with coefficients of variation for intra-individual variation of 39% and 36%, respectively, and inter-individual variation of 44% and 42%, respectively.",Broad variability in pharmacokinetics of GH following rhGH injections in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29422321/),[mu] / [l],71,194147,DB00052,Somatropin recombinant
,29422321,AUC,"In the Clinical-setting, median Cmax was 71 mU/L and AUC was 534 mU/L ∗ h, with coefficients of variation for intra-individual variation of 39% and 36%, respectively, and inter-individual variation of 44% and 42%, respectively.",Broad variability in pharmacokinetics of GH following rhGH injections in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29422321/),[mu] / [h·l·∗],534,194148,DB00052,Somatropin recombinant
,12914551,Emax,"Emax values were 246 (121), 180 (107), 205 (139) ng/mL, respectively, and EC50 were 0.98 (48.1), 1.70 (62.3), 3.67 (65.2) ng/mL, respectively at dose 5, 10, and 20 micro g/kg (P < 10-4).",Pharmacokinetic-pharmacodynamic study of apomorphine's effect on growth hormone secretion in healthy subjects. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12914551/),[ng] / [ml],246,194495,DB00052,Somatropin recombinant
,12914551,Emax,"Emax values were 246 (121), 180 (107), 205 (139) ng/mL, respectively, and EC50 were 0.98 (48.1), 1.70 (62.3), 3.67 (65.2) ng/mL, respectively at dose 5, 10, and 20 micro g/kg (P < 10-4).",Pharmacokinetic-pharmacodynamic study of apomorphine's effect on growth hormone secretion in healthy subjects. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12914551/),[ng] / [ml],180,194496,DB00052,Somatropin recombinant
,12914551,Emax,"Emax values were 246 (121), 180 (107), 205 (139) ng/mL, respectively, and EC50 were 0.98 (48.1), 1.70 (62.3), 3.67 (65.2) ng/mL, respectively at dose 5, 10, and 20 micro g/kg (P < 10-4).",Pharmacokinetic-pharmacodynamic study of apomorphine's effect on growth hormone secretion in healthy subjects. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12914551/),[ng] / [ml],205,194497,DB00052,Somatropin recombinant
,12914551,EC50,"Emax values were 246 (121), 180 (107), 205 (139) ng/mL, respectively, and EC50 were 0.98 (48.1), 1.70 (62.3), 3.67 (65.2) ng/mL, respectively at dose 5, 10, and 20 micro g/kg (P < 10-4).",Pharmacokinetic-pharmacodynamic study of apomorphine's effect on growth hormone secretion in healthy subjects. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12914551/),[ng] / [ml],0.98,194498,DB00052,Somatropin recombinant
,12914551,EC50,"Emax values were 246 (121), 180 (107), 205 (139) ng/mL, respectively, and EC50 were 0.98 (48.1), 1.70 (62.3), 3.67 (65.2) ng/mL, respectively at dose 5, 10, and 20 micro g/kg (P < 10-4).",Pharmacokinetic-pharmacodynamic study of apomorphine's effect on growth hormone secretion in healthy subjects. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12914551/),[ng] / [ml],1.70,194499,DB00052,Somatropin recombinant
,12914551,EC50,"Emax values were 246 (121), 180 (107), 205 (139) ng/mL, respectively, and EC50 were 0.98 (48.1), 1.70 (62.3), 3.67 (65.2) ng/mL, respectively at dose 5, 10, and 20 micro g/kg (P < 10-4).",Pharmacokinetic-pharmacodynamic study of apomorphine's effect on growth hormone secretion in healthy subjects. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12914551/),[ng] / [ml],3.67,194500,DB00052,Somatropin recombinant
,11060749,IC(50),Satraplatin was selected for clinical study on the basis of possessing several promising preclinical features the first of which is it's potent in vitro growth inhibitory properties against several tumour types (mean IC(50) approximately 1 microM).,An update on satraplatin: the first orally available platinum anticancer drug. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11060749/),μM,1,196447,DB00052,Somatropin recombinant
,12412826,maximum,The maximum hGH serum concentration of around 20 ng/ml was observed 3.5 to 4 hours after drug administration.,"Pharmacokinetics and pharmacodynamics of a new formulation of recombinant human growth hormone administered by ZomaJet 2 Vision, a new needle-free device, compared to subcutaneous administration using a conventional syringe. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12412826/),[ng] / [ml],20,197367,DB00052,Somatropin recombinant
,12412826,terminal half-life,The terminal half-life was found to be around 2.5 hours.,"Pharmacokinetics and pharmacodynamics of a new formulation of recombinant human growth hormone administered by ZomaJet 2 Vision, a new needle-free device, compared to subcutaneous administration using a conventional syringe. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12412826/),h,2.5,197368,DB00052,Somatropin recombinant
,17622531,TGI,"Antitumor activity was highly significant in both human hormone-independent breast (MDA-MB-231) and prostate (PC-3) xenografts, resulting in TGI of 72 and 100%, respectively.","Identification, characterization and potent antitumor activity of ECO-4601, a novel peripheral benzodiazepine receptor ligand. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17622531/),%,72,200664,DB00052,Somatropin recombinant
,17622531,TGI,"Antitumor activity was highly significant in both human hormone-independent breast (MDA-MB-231) and prostate (PC-3) xenografts, resulting in TGI of 72 and 100%, respectively.","Identification, characterization and potent antitumor activity of ECO-4601, a novel peripheral benzodiazepine receptor ligand. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17622531/),%,100,200665,DB00052,Somatropin recombinant
,9436668,terminal half-life,"The maximum FSH concentration was reached 9-11 h post-injection, the terminal half-life was 43-47 h.",Pharmacodynamics and pharmacokinetics after repeated subcutaneous administration of three gonadotrophin preparations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9436668/),h,43-47,201256,DB00052,Somatropin recombinant
,28201598,height velocity,"Annualized mean height velocity for the three TransCon GH doses ranged from 11.9 cm to 13.9 cm, which was not statistically different from 11.6 cm for Genotropin.",A Randomized Phase 2 Study of Long-Acting TransCon GH vs Daily GH in Childhood GH Deficiency. ,Vmax velocity-Q2,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28201598/),cm,11.9,205767,DB00052,Somatropin recombinant
,28201598,height velocity,"Annualized mean height velocity for the three TransCon GH doses ranged from 11.9 cm to 13.9 cm, which was not statistically different from 11.6 cm for Genotropin.",A Randomized Phase 2 Study of Long-Acting TransCon GH vs Daily GH in Childhood GH Deficiency. ,Vmax velocity-Q2,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28201598/),cm,13.9,205768,DB00052,Somatropin recombinant
,28201598,height velocity,"Annualized mean height velocity for the three TransCon GH doses ranged from 11.9 cm to 13.9 cm, which was not statistically different from 11.6 cm for Genotropin.",A Randomized Phase 2 Study of Long-Acting TransCon GH vs Daily GH in Childhood GH Deficiency. ,Vmax velocity-Q2,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28201598/),cm,11.6,205769,DB00052,Somatropin recombinant
,3924685,half-life,"A plot of the disappearance of IR-hGRF from plasma after a single intravenous injection was fitted by a biexponential curve, analysis of which gave a half-life of 3.2 +/- 0.2 min for the initial distribution phase and 57.3 +/- 1.5 min for the elimination phase.",Radioimmunoassay for human growth hormone-releasing factor (hGRF 1-40): comparison of plasma immunoreactive GRF after intravenous and subcutaneous administration to rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3924685/),min,3.2,206265,DB00052,Somatropin recombinant
,3924685,half-life,"A plot of the disappearance of IR-hGRF from plasma after a single intravenous injection was fitted by a biexponential curve, analysis of which gave a half-life of 3.2 +/- 0.2 min for the initial distribution phase and 57.3 +/- 1.5 min for the elimination phase.",Radioimmunoassay for human growth hormone-releasing factor (hGRF 1-40): comparison of plasma immunoreactive GRF after intravenous and subcutaneous administration to rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3924685/),min,57.3,206266,DB00052,Somatropin recombinant
,291954,terminal half-life,"The mean terminal half-life after intravenous administration of 5 or 10 mg of human beta-endorphin to three patients was 37 min; the mean volume of distribution was 178 ml/kg, and the metabolic clearance rate was 3.2 (ml/min)/kg.",beta-Endorphin: analgesic and hormonal effects in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/291954/),min,37,206720,DB00052,Somatropin recombinant
,291954,volume of distribution,"The mean terminal half-life after intravenous administration of 5 or 10 mg of human beta-endorphin to three patients was 37 min; the mean volume of distribution was 178 ml/kg, and the metabolic clearance rate was 3.2 (ml/min)/kg.",beta-Endorphin: analgesic and hormonal effects in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/291954/),[ml] / [kg],178,206721,DB00052,Somatropin recombinant
,291954,metabolic clearance rate,"The mean terminal half-life after intravenous administration of 5 or 10 mg of human beta-endorphin to three patients was 37 min; the mean volume of distribution was 178 ml/kg, and the metabolic clearance rate was 3.2 (ml/min)/kg.",beta-Endorphin: analgesic and hormonal effects in humans. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/291954/),[ml] / [kg·min)],3.2,206722,DB00052,Somatropin recombinant
,291954,half-life,"The half-life of beta-endorphin in cerebrospinal fluid after intracerebroventricular administration was 93 min, and the volume of distribution was 0.74 ml/kg.",beta-Endorphin: analgesic and hormonal effects in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/291954/),min,93,206723,DB00052,Somatropin recombinant
,291954,volume of distribution,"The half-life of beta-endorphin in cerebrospinal fluid after intracerebroventricular administration was 93 min, and the volume of distribution was 0.74 ml/kg.",beta-Endorphin: analgesic and hormonal effects in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/291954/),[ml] / [kg],0.74,206724,DB00052,Somatropin recombinant
,9241042,Vd,"In most queens (> 90%) given single gonadotropins (i.m. or i.v.), eCG and hCG persisted in circulation for at least 120 h and 96 h after injection, respectively, reflecting similar (p > 0.05) pharmacokinetic (i.v.) values for Vd (eCG, 91.4 +/- 24.8 ml/kg; hCG, 59.1 +/- 7.9 ml/kg), t1/2beta (eCG, 23.0 +/- 2.4 h; hCG, 22.9 +/- 4.1 h), and Clr (eCG, 2.7 +/- 0.5 ml/h per kg; hCG, 1.8 +/- 0.1 ml/h per kg).",Pharmacokinetics and ovarian-stimulatory effects of equine and human chorionic gonadotropins administered singly and in combination in the domestic cat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241042/),[ml] / [kg],91.4,208805,DB00052,Somatropin recombinant
,9241042,Vd,"In most queens (> 90%) given single gonadotropins (i.m. or i.v.), eCG and hCG persisted in circulation for at least 120 h and 96 h after injection, respectively, reflecting similar (p > 0.05) pharmacokinetic (i.v.) values for Vd (eCG, 91.4 +/- 24.8 ml/kg; hCG, 59.1 +/- 7.9 ml/kg), t1/2beta (eCG, 23.0 +/- 2.4 h; hCG, 22.9 +/- 4.1 h), and Clr (eCG, 2.7 +/- 0.5 ml/h per kg; hCG, 1.8 +/- 0.1 ml/h per kg).",Pharmacokinetics and ovarian-stimulatory effects of equine and human chorionic gonadotropins administered singly and in combination in the domestic cat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241042/),[ml] / [kg],59.1,208806,DB00052,Somatropin recombinant
,9241042,t1/2beta,"In most queens (> 90%) given single gonadotropins (i.m. or i.v.), eCG and hCG persisted in circulation for at least 120 h and 96 h after injection, respectively, reflecting similar (p > 0.05) pharmacokinetic (i.v.) values for Vd (eCG, 91.4 +/- 24.8 ml/kg; hCG, 59.1 +/- 7.9 ml/kg), t1/2beta (eCG, 23.0 +/- 2.4 h; hCG, 22.9 +/- 4.1 h), and Clr (eCG, 2.7 +/- 0.5 ml/h per kg; hCG, 1.8 +/- 0.1 ml/h per kg).",Pharmacokinetics and ovarian-stimulatory effects of equine and human chorionic gonadotropins administered singly and in combination in the domestic cat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241042/),h,23.0,208807,DB00052,Somatropin recombinant
,9241042,t1/2beta,"In most queens (> 90%) given single gonadotropins (i.m. or i.v.), eCG and hCG persisted in circulation for at least 120 h and 96 h after injection, respectively, reflecting similar (p > 0.05) pharmacokinetic (i.v.) values for Vd (eCG, 91.4 +/- 24.8 ml/kg; hCG, 59.1 +/- 7.9 ml/kg), t1/2beta (eCG, 23.0 +/- 2.4 h; hCG, 22.9 +/- 4.1 h), and Clr (eCG, 2.7 +/- 0.5 ml/h per kg; hCG, 1.8 +/- 0.1 ml/h per kg).",Pharmacokinetics and ovarian-stimulatory effects of equine and human chorionic gonadotropins administered singly and in combination in the domestic cat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241042/),h,22.9,208808,DB00052,Somatropin recombinant
,9241042,Clr,"In most queens (> 90%) given single gonadotropins (i.m. or i.v.), eCG and hCG persisted in circulation for at least 120 h and 96 h after injection, respectively, reflecting similar (p > 0.05) pharmacokinetic (i.v.) values for Vd (eCG, 91.4 +/- 24.8 ml/kg; hCG, 59.1 +/- 7.9 ml/kg), t1/2beta (eCG, 23.0 +/- 2.4 h; hCG, 22.9 +/- 4.1 h), and Clr (eCG, 2.7 +/- 0.5 ml/h per kg; hCG, 1.8 +/- 0.1 ml/h per kg).",Pharmacokinetics and ovarian-stimulatory effects of equine and human chorionic gonadotropins administered singly and in combination in the domestic cat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241042/),[ml] / [h·kg],2.7,208809,DB00052,Somatropin recombinant
,9241042,Clr,"In most queens (> 90%) given single gonadotropins (i.m. or i.v.), eCG and hCG persisted in circulation for at least 120 h and 96 h after injection, respectively, reflecting similar (p > 0.05) pharmacokinetic (i.v.) values for Vd (eCG, 91.4 +/- 24.8 ml/kg; hCG, 59.1 +/- 7.9 ml/kg), t1/2beta (eCG, 23.0 +/- 2.4 h; hCG, 22.9 +/- 4.1 h), and Clr (eCG, 2.7 +/- 0.5 ml/h per kg; hCG, 1.8 +/- 0.1 ml/h per kg).",Pharmacokinetics and ovarian-stimulatory effects of equine and human chorionic gonadotropins administered singly and in combination in the domestic cat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9241042/),[ml] / [h·kg],1.8,208810,DB00052,Somatropin recombinant
,3113974,distribution half-life,The distribution half-life was 6.6 min and the elimination half-life was 39.0 min (harmonic means).,Pharmacokinetics of human growth hormone releasing factor (hGRF-44 NH2) in normal men after intravenous administration of a large range of doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3113974/),min,6.6,209219,DB00052,Somatropin recombinant
,3113974,elimination half-life,The distribution half-life was 6.6 min and the elimination half-life was 39.0 min (harmonic means).,Pharmacokinetics of human growth hormone releasing factor (hGRF-44 NH2) in normal men after intravenous administration of a large range of doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3113974/),min,39.0,209220,DB00052,Somatropin recombinant
,3113974,Total clearance,Total clearance was 0.12 +/- 0.01 microgram/l/min.,Pharmacokinetics of human growth hormone releasing factor (hGRF-44 NH2) in normal men after intravenous administration of a large range of doses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3113974/),[μg] / [l·min],0.12,209221,DB00052,Somatropin recombinant
,2778036,MCR,We found that adult men have a significantly more rapid MCR of human GH than women (125.2 +/- 7.6 mL/min.m2 in men; 89.4 +/- 7.7 mL/min.m2 in women) and that both men and women have a significantly more rapid MCR of human GH than prepubertal children (66.8 +/- 7.7 mL/min.m2).,"Metabolic clearance rates of synthetic human growth hormone in children, adult women, and adult men. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778036/),[ml] / [m2·min],125.2,211563,DB00052,Somatropin recombinant
,2778036,MCR,We found that adult men have a significantly more rapid MCR of human GH than women (125.2 +/- 7.6 mL/min.m2 in men; 89.4 +/- 7.7 mL/min.m2 in women) and that both men and women have a significantly more rapid MCR of human GH than prepubertal children (66.8 +/- 7.7 mL/min.m2).,"Metabolic clearance rates of synthetic human growth hormone in children, adult women, and adult men. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778036/),[ml] / [m2·min],89.4,211564,DB00052,Somatropin recombinant
,2778036,MCR,We found that adult men have a significantly more rapid MCR of human GH than women (125.2 +/- 7.6 mL/min.m2 in men; 89.4 +/- 7.7 mL/min.m2 in women) and that both men and women have a significantly more rapid MCR of human GH than prepubertal children (66.8 +/- 7.7 mL/min.m2).,"Metabolic clearance rates of synthetic human growth hormone in children, adult women, and adult men. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778036/),[ml] / [m2·min],66.8,211565,DB00052,Somatropin recombinant
,19893921,AUC,"The AUC obtained after rhTSH was 4.6 times smaller than that obtained after L-T4 withdrawal (532 versus 2,423 mIU/L per day).",Area under the curve of TSH after levothyroxine withdrawal versus administration of recombinant human TSH (rhTSH): possible implications for tumor growth. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19893921/),[miu] / [d·l],532,211819,DB00052,Somatropin recombinant
,19893921,AUC,"The AUC obtained after rhTSH was 4.6 times smaller than that obtained after L-T4 withdrawal (532 versus 2,423 mIU/L per day).",Area under the curve of TSH after levothyroxine withdrawal versus administration of recombinant human TSH (rhTSH): possible implications for tumor growth. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19893921/),[miu] / [d·l],"2,423",211820,DB00052,Somatropin recombinant
,18199894,clearance,"Pharmacokinetic analysis revealed less than dose-proportional behavior of drug with low clearance (approximately 7 mL/h/kg), small volume of distribution (approximately 114 mL/kg), and half-life values of approximately 13 hours, which were independent of dose.","Ghrelin agonist (TZP-101): safety, pharmacokinetics and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18199894/),[ml] / [h·kg],7,213405,DB00052,Somatropin recombinant
,18199894,volume of distribution,"Pharmacokinetic analysis revealed less than dose-proportional behavior of drug with low clearance (approximately 7 mL/h/kg), small volume of distribution (approximately 114 mL/kg), and half-life values of approximately 13 hours, which were independent of dose.","Ghrelin agonist (TZP-101): safety, pharmacokinetics and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18199894/),[ml] / [kg],114,213406,DB00052,Somatropin recombinant
,18199894,half-life,"Pharmacokinetic analysis revealed less than dose-proportional behavior of drug with low clearance (approximately 7 mL/h/kg), small volume of distribution (approximately 114 mL/kg), and half-life values of approximately 13 hours, which were independent of dose.","Ghrelin agonist (TZP-101): safety, pharmacokinetics and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18199894/),h,13,213407,DB00052,Somatropin recombinant
,7617520,bioavailable fraction,The bioavailable fraction for aerosolized hGH (45%) was greater than for instilled hGH (16%).,The influence of regional deposition on the pharmacokinetics of pulmonary-delivered human growth hormone in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7617520/),%,45,213660,DB00052,Somatropin recombinant
,7617520,bioavailable fraction,The bioavailable fraction for aerosolized hGH (45%) was greater than for instilled hGH (16%).,The influence of regional deposition on the pharmacokinetics of pulmonary-delivered human growth hormone in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7617520/),%,16,213661,DB00052,Somatropin recombinant
,7617520,elimination half-life,Absorption rate limited pharmacokinetics prevailed for both hGH formulations with post-peak half-lives approximately 10-fold greater than the intravenous elimination half-life of 40 min.,The influence of regional deposition on the pharmacokinetics of pulmonary-delivered human growth hormone in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7617520/),min,40,213662,DB00052,Somatropin recombinant
,7617520,Apparent absorption rate constants,"Apparent absorption rate constants resulting from instillation and aerosolization were equivalent (0.0012 min-1 and 0.0020 min-1 respectively), however lung-to-blood transfer rate constants for aerosol delivery (0.00071 min-1) were greater than for instillation (0.00018 min-1).",The influence of regional deposition on the pharmacokinetics of pulmonary-delivered human growth hormone in rabbits. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7617520/),1/[min],0.0012,213663,DB00052,Somatropin recombinant
,7617520,Apparent absorption rate constants,"Apparent absorption rate constants resulting from instillation and aerosolization were equivalent (0.0012 min-1 and 0.0020 min-1 respectively), however lung-to-blood transfer rate constants for aerosol delivery (0.00071 min-1) were greater than for instillation (0.00018 min-1).",The influence of regional deposition on the pharmacokinetics of pulmonary-delivered human growth hormone in rabbits. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7617520/),1/[min],0.0020,213664,DB00052,Somatropin recombinant
,7617520,lung-to-blood transfer rate constants,"Apparent absorption rate constants resulting from instillation and aerosolization were equivalent (0.0012 min-1 and 0.0020 min-1 respectively), however lung-to-blood transfer rate constants for aerosol delivery (0.00071 min-1) were greater than for instillation (0.00018 min-1).",The influence of regional deposition on the pharmacokinetics of pulmonary-delivered human growth hormone in rabbits. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7617520/),1/[min],0.00071,213665,DB00052,Somatropin recombinant
,7617520,lung-to-blood transfer rate constants,"Apparent absorption rate constants resulting from instillation and aerosolization were equivalent (0.0012 min-1 and 0.0020 min-1 respectively), however lung-to-blood transfer rate constants for aerosol delivery (0.00071 min-1) were greater than for instillation (0.00018 min-1).",The influence of regional deposition on the pharmacokinetics of pulmonary-delivered human growth hormone in rabbits. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7617520/),1/[min],0.00018,213666,DB00052,Somatropin recombinant
,12740741,VO 2 max,"Eight healthy male subjects (age: 22.1 +/- 0.8 yr, body mass index: 22.2 +/- 0.9 kg/m 2, .VO 2 max: 52.2 +/- 0.5 ml/min/kg [mean +/- SEM]) were exposed to incremental EX until volitional exhaustion (cycle ergometry), and in random order to a maximally stimulating bolus injection of 100 microg GHRH, or to combined administration of 100 microg GHRH and EX (GHRH+EX).",Involvement of endogenous growth hormone-releasing hormone (GHRH) in the exercise-related response of growth hormone. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12740741/),[ml] / [kg·min],52.2,213903,DB00052,Somatropin recombinant
,12740741,peak serum GH levels,The results showed that peak serum GH levels to GHRH alone and EX alone were not significantly different: 41.5 +/- 9.0 microg/l and 64.1 +/- 8.1(mean +/- SEM).,Involvement of endogenous growth hormone-releasing hormone (GHRH) in the exercise-related response of growth hormone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12740741/),[μg] / [l],41.5,213904,DB00052,Somatropin recombinant
,12740741,peak serum GH levels,The results showed that peak serum GH levels to GHRH alone and EX alone were not significantly different: 41.5 +/- 9.0 microg/l and 64.1 +/- 8.1(mean +/- SEM).,Involvement of endogenous growth hormone-releasing hormone (GHRH) in the exercise-related response of growth hormone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12740741/),,64.1,213905,DB00052,Somatropin recombinant
,12740741,Peak GH level,"Peak GH level to GHRH+EX was 156.1 +/- 19.9 microg/l, which was significantly greater than to either stimulus alone (p < 0.02) or additively (105.6 +/- 17.1 microg/l, p < 0.02).",Involvement of endogenous growth hormone-releasing hormone (GHRH) in the exercise-related response of growth hormone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12740741/),[μg] / [l],156.1,213906,DB00052,Somatropin recombinant
,12740741,Peak GH level,"Peak GH level to GHRH+EX was 156.1 +/- 19.9 microg/l, which was significantly greater than to either stimulus alone (p < 0.02) or additively (105.6 +/- 17.1 microg/l, p < 0.02).",Involvement of endogenous growth hormone-releasing hormone (GHRH) in the exercise-related response of growth hormone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12740741/),[μg] / [l],105.6,213907,DB00052,Somatropin recombinant
,12740741,AUC's,AUC's to GHRH alone and EX alone were not significantly different (3242 +/- 839 vs. 2472 +/- 408 microg/l x 120 min).,Involvement of endogenous growth hormone-releasing hormone (GHRH) in the exercise-related response of growth hormone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12740741/),[μg] / [120·l·min],3242,213908,DB00052,Somatropin recombinant
,12740741,AUC's,AUC's to GHRH alone and EX alone were not significantly different (3242 +/- 839 vs. 2472 +/- 408 microg/l x 120 min).,Involvement of endogenous growth hormone-releasing hormone (GHRH) in the exercise-related response of growth hormone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12740741/),[μg] / [120·l·min],2472,213909,DB00052,Somatropin recombinant
,12740741,AUC,"AUC to GHRH+EX (7807 +/- 1221 microg/l x 120 min) was greater than to either stimulus alone (p < 0.02) or additively (5714 +/- 1247 microg/l x 120 min, p < 0.02).",Involvement of endogenous growth hormone-releasing hormone (GHRH) in the exercise-related response of growth hormone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12740741/),[μg] / [120·l·min],7807,213910,DB00052,Somatropin recombinant
,12740741,AUC,"AUC to GHRH+EX (7807 +/- 1221 microg/l x 120 min) was greater than to either stimulus alone (p < 0.02) or additively (5714 +/- 1247 microg/l x 120 min, p < 0.02).",Involvement of endogenous growth hormone-releasing hormone (GHRH) in the exercise-related response of growth hormone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12740741/),[μg] / [120·l·min],5714,213911,DB00052,Somatropin recombinant
,17458505,half-life,The pharmacokinetic profile revealed an effective half-life of approximately 27 h.,"Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17458505/),h,27,214331,DB00052,Somatropin recombinant
,17458505,Plasma concentrations,Plasma concentrations were maximum 2-8 h post dosing with an overall median value of 2 h.,"Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17458505/),h,2,214332,DB00052,Somatropin recombinant
,6425363,MCR,The calculated MCR during the single injection study was 194 +/- 17.5 liters/m2 per d and was not significantly different from the calculated value during the constant infusion study (202 +/- 16 liters/m2 per d).,Metabolic clearance and plasma disappearance rates of human pancreatic tumor growth hormone releasing factor in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6425363/),[l] / [d·m2],194,215958,DB00052,Somatropin recombinant
,6425363,MCR,The calculated MCR during the single injection study was 194 +/- 17.5 liters/m2 per d and was not significantly different from the calculated value during the constant infusion study (202 +/- 16 liters/m2 per d).,Metabolic clearance and plasma disappearance rates of human pancreatic tumor growth hormone releasing factor in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6425363/),[l] / [d·m2],202,215959,DB00052,Somatropin recombinant
,6425363,disappearance rate,The disappearance rate during the single injection study was subdivided into two linear phases: an initial equilibration phase (7.6 +/- 1.2 min) and a subsequent elimination phase (51.8 +/- 5.4 min).,Metabolic clearance and plasma disappearance rates of human pancreatic tumor growth hormone releasing factor in man. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6425363/),min,7.6,215960,DB00052,Somatropin recombinant
,6425363,disappearance rate,The disappearance rate during the single injection study was subdivided into two linear phases: an initial equilibration phase (7.6 +/- 1.2 min) and a subsequent elimination phase (51.8 +/- 5.4 min).,Metabolic clearance and plasma disappearance rates of human pancreatic tumor growth hormone releasing factor in man. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6425363/),min,51.8,215961,DB00052,Somatropin recombinant
,6425363,linear disappearance rate,The latter was similar to the linear disappearance rate observed (41.3 +/- 3.0 min) after cessation of the constant infusion.,Metabolic clearance and plasma disappearance rates of human pancreatic tumor growth hormone releasing factor in man. ,km-Q51,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6425363/),min,41.3,215962,DB00052,Somatropin recombinant
,23735833,Peak clonidine concentrations,Peak clonidine concentrations of 0.846 ± 0.288 ng/ml were reached after 1 h.,Pharmacokinetics and pharmacodynamics of orally administered clonidine: a model-based approach. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23735833/),[ng] / [ml],0.846,219950,DB00052,Somatropin recombinant
,15853836,C(max),"PK analysis showed a smaller early serum hGH peak followed by a broad sustained second peak of hGH (C(max) 1.20 microg/l at 7.2 days), and hGH levels were maintained above baseline for at least 14 days.","A new sustained-release preparation of human growth hormone and its pharmacokinetic, pharmacodynamic and safety profile. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15853836/),[μg] / [l],1.20,221389,DB00052,Somatropin recombinant
,15853836,C(max),"Resultant IGF-I concentrations were characterized by sustained elevation at a level near C(max) of 103 microg/l (at t(max) of 9.7 days), equal to an SD score of +0.8.","A new sustained-release preparation of human growth hormone and its pharmacokinetic, pharmacodynamic and safety profile. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15853836/),[μg] / [l],103,221390,DB00052,Somatropin recombinant
,15853836,t(max),"Resultant IGF-I concentrations were characterized by sustained elevation at a level near C(max) of 103 microg/l (at t(max) of 9.7 days), equal to an SD score of +0.8.","A new sustained-release preparation of human growth hormone and its pharmacokinetic, pharmacodynamic and safety profile. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15853836/),d,9.7,221391,DB00052,Somatropin recombinant
,27552669,elimination half-lives,Exposure increased in a dose-dependent manner with peak concentrations at approximately 24h post-dosing and elimination half-lives in the range of 12 to 24h.,"Safety and PK/PD correlation of TV-1106, a recombinant fused human albumin-growth hormone, following repeat dose administration to monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27552669/),h,12 to 24,225226,DB00052,Somatropin recombinant
,10984300,t1/2,"The fast compartment with t1/2 of 1-2 min was virtually absent in dwarf mice, and chromatographic studies revealed the disappearance of free GH in these mice.",Specific interactions of growth hormone (GH) with GH-receptors and GH-binding proteins in vivo in genetically GH-deficient Ames dwarf mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984300/),min,1-2,225714,DB00052,Somatropin recombinant
,10984300,uptake,"The second step of processing labeled GH in vivo is the uptake by the liver, which was slower in dwarf than in normal mice (30-45 vs 15 min).",Specific interactions of growth hormone (GH) with GH-receptors and GH-binding proteins in vivo in genetically GH-deficient Ames dwarf mice. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984300/),min,30-45,225715,DB00052,Somatropin recombinant
,10984300,uptake,"The second step of processing labeled GH in vivo is the uptake by the liver, which was slower in dwarf than in normal mice (30-45 vs 15 min).",Specific interactions of growth hormone (GH) with GH-receptors and GH-binding proteins in vivo in genetically GH-deficient Ames dwarf mice. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984300/),min,15,225716,DB00052,Somatropin recombinant
,10984300,UB ratio,"Moreover, a lower GH uptake was found in dwarf than in normal mice (UB ratio of 1.75+/-0.29 [30 min] vs L/B ratio of 3.68+/-0.33 [15 min], respectively) due to lower concentration of free GH in plasma and to the reduced number of GH-receptors (GHRs).",Specific interactions of growth hormone (GH) with GH-receptors and GH-binding proteins in vivo in genetically GH-deficient Ames dwarf mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984300/),,1.75,225717,DB00052,Somatropin recombinant
,10984300,L/B ratio,"Moreover, a lower GH uptake was found in dwarf than in normal mice (UB ratio of 1.75+/-0.29 [30 min] vs L/B ratio of 3.68+/-0.33 [15 min], respectively) due to lower concentration of free GH in plasma and to the reduced number of GH-receptors (GHRs).",Specific interactions of growth hormone (GH) with GH-receptors and GH-binding proteins in vivo in genetically GH-deficient Ames dwarf mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984300/),,3.68,225718,DB00052,Somatropin recombinant
,10984300,Stokes radius,The radioactive material present in the liver was compatible with 125I-hGH-GHR complexes with Stokes radius of 59A.,Specific interactions of growth hormone (GH) with GH-receptors and GH-binding proteins in vivo in genetically GH-deficient Ames dwarf mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984300/),a,59,225719,DB00052,Somatropin recombinant
,22106937,Ki,"Early hits such as 1 (Ki=86 nM, EC50=134 nM) though potent in vitro displayed poor pharmacokinetic properties that required optimization.",Optimization of the potency and pharmacokinetic properties of a macrocyclic ghrelin receptor agonist (Part I): Development of ulimorelin (TZP-101) from hit to clinic. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22106937/),nM,86,226031,DB00052,Somatropin recombinant
,22106937,EC50,"Early hits such as 1 (Ki=86 nM, EC50=134 nM) though potent in vitro displayed poor pharmacokinetic properties that required optimization.",Optimization of the potency and pharmacokinetic properties of a macrocyclic ghrelin receptor agonist (Part I): Development of ulimorelin (TZP-101) from hit to clinic. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22106937/),nM,134,226032,DB00052,Somatropin recombinant
,22106937,Ki,"Extensive SAR led to the identification of 2 (Ki=16 nM, EC50=29 nM), also known as ulimorelin or TZP-101, which has progressed to phase III human clinical trials for the treatment of postoperative ileus.",Optimization of the potency and pharmacokinetic properties of a macrocyclic ghrelin receptor agonist (Part I): Development of ulimorelin (TZP-101) from hit to clinic. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22106937/),nM,16,226033,DB00052,Somatropin recombinant
,22106937,EC50,"Extensive SAR led to the identification of 2 (Ki=16 nM, EC50=29 nM), also known as ulimorelin or TZP-101, which has progressed to phase III human clinical trials for the treatment of postoperative ileus.",Optimization of the potency and pharmacokinetic properties of a macrocyclic ghrelin receptor agonist (Part I): Development of ulimorelin (TZP-101) from hit to clinic. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22106937/),nM,29,226034,DB00052,Somatropin recombinant
,22106937,orally bioavailable,Compound 2 is 24% orally bioavailable in both rats and monkeys.,Optimization of the potency and pharmacokinetic properties of a macrocyclic ghrelin receptor agonist (Part I): Development of ulimorelin (TZP-101) from hit to clinic. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22106937/),%,24,226035,DB00052,Somatropin recombinant
,11134132,area under the curve (AUC),"The area under the curve (AUC) of the GH response after GHRP-2 alone was 4.8 times higher compared with GHRH alone (1834 +/- 255 vs. 382 +/- 78 microg/L.60 min, P: < 0.001).",Reduction of free fatty acids by acipimox enhances the growth hormone (GH) responses to GH-releasing peptide 2 in elderly men. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11134132/),[μg] / [60·l·min],1834,227362,DB00052,Somatropin recombinant
,11134132,area under the curve (AUC),"The area under the curve (AUC) of the GH response after GHRP-2 alone was 4.8 times higher compared with GHRH alone (1834 +/- 255 vs. 382 +/- 78 microg/L.60 min, P: < 0.001).",Reduction of free fatty acids by acipimox enhances the growth hormone (GH) responses to GH-releasing peptide 2 in elderly men. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11134132/),[μg] / [60·l·min],382,227363,DB00052,Somatropin recombinant
,11134132,AUC,"Acipimox, which reduced FFAs from 607 micromol/L to 180 micromol/L, increased the GH AUC to 1087 after GHRH and to 2956 microg/L.60 min after GHRP-2 (P: < 0.01).",Reduction of free fatty acids by acipimox enhances the growth hormone (GH) responses to GH-releasing peptide 2 in elderly men. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11134132/),[μg] / [l],1087,227364,DB00052,Somatropin recombinant
,11134132,AUC,"Acipimox, which reduced FFAs from 607 micromol/L to 180 micromol/L, increased the GH AUC to 1087 after GHRH and to 2956 microg/L.60 min after GHRP-2 (P: < 0.01).",Reduction of free fatty acids by acipimox enhances the growth hormone (GH) responses to GH-releasing peptide 2 in elderly men. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11134132/),[μg] / [l],2956,227365,DB00052,Somatropin recombinant
,3818897,Vd,"14 mL/min X kg), Vd was 4-fold smaller for complexed hGH than for free hGH (71 vs. 256 mL/kg), and initial degradation rate was 4.5-fold lower for complexed than for free hGH (13.2% vs. 59.9%/15 min).","The effect of circulating growth hormone-binding protein on metabolic clearance, distribution, and degradation of human growth hormone. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3818897/),[ml] / [kg],71,229634,DB00052,Somatropin recombinant
,3818897,Vd,"14 mL/min X kg), Vd was 4-fold smaller for complexed hGH than for free hGH (71 vs. 256 mL/kg), and initial degradation rate was 4.5-fold lower for complexed than for free hGH (13.2% vs. 59.9%/15 min).","The effect of circulating growth hormone-binding protein on metabolic clearance, distribution, and degradation of human growth hormone. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3818897/),[ml] / [kg],256,229635,DB00052,Somatropin recombinant
,3818897,initial degradation rate,"14 mL/min X kg), Vd was 4-fold smaller for complexed hGH than for free hGH (71 vs. 256 mL/kg), and initial degradation rate was 4.5-fold lower for complexed than for free hGH (13.2% vs. 59.9%/15 min).","The effect of circulating growth hormone-binding protein on metabolic clearance, distribution, and degradation of human growth hormone. ",Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3818897/),%,13.2,229636,DB00052,Somatropin recombinant
,3818897,initial degradation rate,"14 mL/min X kg), Vd was 4-fold smaller for complexed hGH than for free hGH (71 vs. 256 mL/kg), and initial degradation rate was 4.5-fold lower for complexed than for free hGH (13.2% vs. 59.9%/15 min).","The effect of circulating growth hormone-binding protein on metabolic clearance, distribution, and degradation of human growth hormone. ",Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3818897/),[%] / [15·min],59.9,229637,DB00052,Somatropin recombinant
,8438807,Integrated concentration of growth hormone,Integrated concentration of growth hormone was 2.2 +/- 0.9 micrograms/L before therapy.,Plasma integrated concentration of growth hormone after recombinant human growth hormone injection. Implications for determining an optimal dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8438807/),[μg] / [l],2.2,230660,DB00052,Somatropin recombinant
,8438807,integrated concentration of growth hormone,The integrated concentration of growth hormone after treatment (14.6 +/- 4.2 micrograms/L) was significantly higher than that before treatment and that of normally growing children (P < .001).,Plasma integrated concentration of growth hormone after recombinant human growth hormone injection. Implications for determining an optimal dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8438807/),[μg] / [l],14.6,230661,DB00052,Somatropin recombinant
,8438807,peak growth hormone level,"After injection, peak growth hormone level was 53.7 +/- 24.1 micrograms/L; time to peak growth hormone level, 4.8 +/- 1.2 hours; constant of elimination, 0.24 +/- 0.06 per hour; half life, 3.0 +/- 0.7 hours; area under the curve, 328 +/- 85 (microgram.h)/L; clearance rate, 107.6 +/- 34.3 mL/min (3.2 +/- 0.8 mL/min per kilogram based on weight, 95.2 +/- 24.2 mL/min per meter squared based on surface area).",Plasma integrated concentration of growth hormone after recombinant human growth hormone injection. Implications for determining an optimal dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8438807/),[μg] / [l],53.7,230662,DB00052,Somatropin recombinant
,8438807,time to peak growth hormone level,"After injection, peak growth hormone level was 53.7 +/- 24.1 micrograms/L; time to peak growth hormone level, 4.8 +/- 1.2 hours; constant of elimination, 0.24 +/- 0.06 per hour; half life, 3.0 +/- 0.7 hours; area under the curve, 328 +/- 85 (microgram.h)/L; clearance rate, 107.6 +/- 34.3 mL/min (3.2 +/- 0.8 mL/min per kilogram based on weight, 95.2 +/- 24.2 mL/min per meter squared based on surface area).",Plasma integrated concentration of growth hormone after recombinant human growth hormone injection. Implications for determining an optimal dose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8438807/),h,4.8,230663,DB00052,Somatropin recombinant
,8438807,constant of elimination,"After injection, peak growth hormone level was 53.7 +/- 24.1 micrograms/L; time to peak growth hormone level, 4.8 +/- 1.2 hours; constant of elimination, 0.24 +/- 0.06 per hour; half life, 3.0 +/- 0.7 hours; area under the curve, 328 +/- 85 (microgram.h)/L; clearance rate, 107.6 +/- 34.3 mL/min (3.2 +/- 0.8 mL/min per kilogram based on weight, 95.2 +/- 24.2 mL/min per meter squared based on surface area).",Plasma integrated concentration of growth hormone after recombinant human growth hormone injection. Implications for determining an optimal dose. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8438807/),1/[h],0.24,230664,DB00052,Somatropin recombinant
,8438807,half life,"After injection, peak growth hormone level was 53.7 +/- 24.1 micrograms/L; time to peak growth hormone level, 4.8 +/- 1.2 hours; constant of elimination, 0.24 +/- 0.06 per hour; half life, 3.0 +/- 0.7 hours; area under the curve, 328 +/- 85 (microgram.h)/L; clearance rate, 107.6 +/- 34.3 mL/min (3.2 +/- 0.8 mL/min per kilogram based on weight, 95.2 +/- 24.2 mL/min per meter squared based on surface area).",Plasma integrated concentration of growth hormone after recombinant human growth hormone injection. Implications for determining an optimal dose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8438807/),h,3.0,230665,DB00052,Somatropin recombinant
,8438807,area under the curve,"After injection, peak growth hormone level was 53.7 +/- 24.1 micrograms/L; time to peak growth hormone level, 4.8 +/- 1.2 hours; constant of elimination, 0.24 +/- 0.06 per hour; half life, 3.0 +/- 0.7 hours; area under the curve, 328 +/- 85 (microgram.h)/L; clearance rate, 107.6 +/- 34.3 mL/min (3.2 +/- 0.8 mL/min per kilogram based on weight, 95.2 +/- 24.2 mL/min per meter squared based on surface area).",Plasma integrated concentration of growth hormone after recombinant human growth hormone injection. Implications for determining an optimal dose. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8438807/),[h·μg] / [l],328,230666,DB00052,Somatropin recombinant
,8438807,clearance rate,"After injection, peak growth hormone level was 53.7 +/- 24.1 micrograms/L; time to peak growth hormone level, 4.8 +/- 1.2 hours; constant of elimination, 0.24 +/- 0.06 per hour; half life, 3.0 +/- 0.7 hours; area under the curve, 328 +/- 85 (microgram.h)/L; clearance rate, 107.6 +/- 34.3 mL/min (3.2 +/- 0.8 mL/min per kilogram based on weight, 95.2 +/- 24.2 mL/min per meter squared based on surface area).",Plasma integrated concentration of growth hormone after recombinant human growth hormone injection. Implications for determining an optimal dose. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8438807/),[ml] / [min],107.6,230667,DB00052,Somatropin recombinant
,8438807,clearance rate,"After injection, peak growth hormone level was 53.7 +/- 24.1 micrograms/L; time to peak growth hormone level, 4.8 +/- 1.2 hours; constant of elimination, 0.24 +/- 0.06 per hour; half life, 3.0 +/- 0.7 hours; area under the curve, 328 +/- 85 (microgram.h)/L; clearance rate, 107.6 +/- 34.3 mL/min (3.2 +/- 0.8 mL/min per kilogram based on weight, 95.2 +/- 24.2 mL/min per meter squared based on surface area).",Plasma integrated concentration of growth hormone after recombinant human growth hormone injection. Implications for determining an optimal dose. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8438807/),[ml] / [kg·min],3.2,230668,DB00052,Somatropin recombinant
,8438807,Integrated concentration,"Integrated concentration of insulin before treatment was 19.0 +/- 10.9 mU/L, which was significantly lower than that after injection of growth hormone (33.4 +/- 9.5 mU/L; n = 9, P < .0008).",Plasma integrated concentration of growth hormone after recombinant human growth hormone injection. Implications for determining an optimal dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8438807/),[mu] / [l],19.0,230669,DB00052,Somatropin recombinant
,8438807,Integrated concentration,"Integrated concentration of insulin before treatment was 19.0 +/- 10.9 mU/L, which was significantly lower than that after injection of growth hormone (33.4 +/- 9.5 mU/L; n = 9, P < .0008).",Plasma integrated concentration of growth hormone after recombinant human growth hormone injection. Implications for determining an optimal dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8438807/),[mu] / [l],33.4,230670,DB00052,Somatropin recombinant
,2562650,absolute bioavailability,"The mean absolute bioavailability was approximately 36% after 18h and was similar for doses of 0.75, 1.5, and 3 mg/kg.",Absorption of human growth hormone from the rat lung. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2562650/),%,36,235722,DB00052,Somatropin recombinant
,2562650,elimination half-life,Disappearance was linear with time and by 24 h approximately 70% of the radioactivity was gone from the lungs (elimination half-life = approximately 10.5h).,Absorption of human growth hormone from the rat lung. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2562650/),h,10.5,235723,DB00052,Somatropin recombinant
,19303337,maximum absorption rate (VMA),"The following estimates were obtained: maximum absorption rate (VMA) - 11.3 microg/kg/h (both groups); amount of drug corresponding to half-maximum absorption rate (KMA) - 1.06 and 18.8 microg/kg (ESRD patients and HVs, respectively; P<0.001); maximum elimination rate (VM) - 9.37 and 13.0 microg/kg/h (ESRD patients and HVs, respectively; P<0.001); amount of drug corresponding to half-maximum elimination rate - 18.9 microg/kg (both groups).",Population pharmacokinetic model for human growth hormone in adult patients in chronic dialysis compared with healthy subjects. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19303337/),[μg] / [h·kg],11.3,236729,DB00052,Somatropin recombinant
,19303337,half-maximum absorption rate (KMA),"The following estimates were obtained: maximum absorption rate (VMA) - 11.3 microg/kg/h (both groups); amount of drug corresponding to half-maximum absorption rate (KMA) - 1.06 and 18.8 microg/kg (ESRD patients and HVs, respectively; P<0.001); maximum elimination rate (VM) - 9.37 and 13.0 microg/kg/h (ESRD patients and HVs, respectively; P<0.001); amount of drug corresponding to half-maximum elimination rate - 18.9 microg/kg (both groups).",Population pharmacokinetic model for human growth hormone in adult patients in chronic dialysis compared with healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19303337/),[μg] / [kg],1.06,236730,DB00052,Somatropin recombinant
,19303337,half-maximum absorption rate (KMA),"The following estimates were obtained: maximum absorption rate (VMA) - 11.3 microg/kg/h (both groups); amount of drug corresponding to half-maximum absorption rate (KMA) - 1.06 and 18.8 microg/kg (ESRD patients and HVs, respectively; P<0.001); maximum elimination rate (VM) - 9.37 and 13.0 microg/kg/h (ESRD patients and HVs, respectively; P<0.001); amount of drug corresponding to half-maximum elimination rate - 18.9 microg/kg (both groups).",Population pharmacokinetic model for human growth hormone in adult patients in chronic dialysis compared with healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19303337/),[μg] / [kg],18.8,236731,DB00052,Somatropin recombinant
,19303337,maximum elimination rate (VM),"The following estimates were obtained: maximum absorption rate (VMA) - 11.3 microg/kg/h (both groups); amount of drug corresponding to half-maximum absorption rate (KMA) - 1.06 and 18.8 microg/kg (ESRD patients and HVs, respectively; P<0.001); maximum elimination rate (VM) - 9.37 and 13.0 microg/kg/h (ESRD patients and HVs, respectively; P<0.001); amount of drug corresponding to half-maximum elimination rate - 18.9 microg/kg (both groups).",Population pharmacokinetic model for human growth hormone in adult patients in chronic dialysis compared with healthy subjects. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19303337/),[μg] / [h·kg],9.37,236732,DB00052,Somatropin recombinant
,19303337,maximum elimination rate (VM),"The following estimates were obtained: maximum absorption rate (VMA) - 11.3 microg/kg/h (both groups); amount of drug corresponding to half-maximum absorption rate (KMA) - 1.06 and 18.8 microg/kg (ESRD patients and HVs, respectively; P<0.001); maximum elimination rate (VM) - 9.37 and 13.0 microg/kg/h (ESRD patients and HVs, respectively; P<0.001); amount of drug corresponding to half-maximum elimination rate - 18.9 microg/kg (both groups).",Population pharmacokinetic model for human growth hormone in adult patients in chronic dialysis compared with healthy subjects. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19303337/),[μg] / [h·kg],13.0,236733,DB00052,Somatropin recombinant
,19303337,half-maximum elimination rate,"The following estimates were obtained: maximum absorption rate (VMA) - 11.3 microg/kg/h (both groups); amount of drug corresponding to half-maximum absorption rate (KMA) - 1.06 and 18.8 microg/kg (ESRD patients and HVs, respectively; P<0.001); maximum elimination rate (VM) - 9.37 and 13.0 microg/kg/h (ESRD patients and HVs, respectively; P<0.001); amount of drug corresponding to half-maximum elimination rate - 18.9 microg/kg (both groups).",Population pharmacokinetic model for human growth hormone in adult patients in chronic dialysis compared with healthy subjects. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19303337/),[μg] / [kg],18.9,236734,DB00052,Somatropin recombinant
,2574646,half-life,The disappearance curve of serum GH was mono-exponential and the mean half-life was 8.9 min (SD 1.5).,The half-life of exogenous growth hormone after suppression of endogenous growth hormone secretion with somatostatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2574646/),min,8.9,237834,DB00052,Somatropin recombinant
,15846462,bioavailability,"Creation of MCs in the outer layers of the skin enabled efficient delivery of hGH, with a bioavailability of 75% (rats) or 33% (GPs) relative to subcutaneous (s.c.) injection with plasma profiles resembling that of s.c. injection.",Transdermal delivery of human growth hormone through RF-microchannels. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15846462/),%,75,242492,DB00052,Somatropin recombinant
,15846462,bioavailability,"Creation of MCs in the outer layers of the skin enabled efficient delivery of hGH, with a bioavailability of 75% (rats) or 33% (GPs) relative to subcutaneous (s.c.) injection with plasma profiles resembling that of s.c. injection.",Transdermal delivery of human growth hormone through RF-microchannels. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15846462/),%,33,242493,DB00052,Somatropin recombinant
,25192817,association constants (Ka),The association constants (Ka) calculated by Scatchard analysis of size exclusion chromatography (SEC) data were in the order of 10(5)M(-1).,A novel soluble supramolecular system for sustained rh-GH delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25192817/),1/[M],10(5),246963,DB00052,Somatropin recombinant
,25192817,burst release,"However, during the first 8h the protein formulations obtained with mPEG(10kDa)-cholane and mPEG(20kDa)-cholane showed a burst release of 8 and 28%, respectively.",A novel soluble supramolecular system for sustained rh-GH delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25192817/),%,8,246964,DB00052,Somatropin recombinant
,25192817,burst release,"However, during the first 8h the protein formulations obtained with mPEG(10kDa)-cholane and mPEG(20kDa)-cholane showed a burst release of 8 and 28%, respectively.",A novel soluble supramolecular system for sustained rh-GH delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25192817/),%,28,246965,DB00052,Somatropin recombinant
,5822572,MCR,MCR values calculated from constant infusion studies were 203 +/-7.8 liters/day per m(2) and values derived from single injection studies agreed closely with this.,Metabolic clearance rate of radioiodinated human growth hormone in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/5822572/),[d·l] / [m(2],203,250102,DB00052,Somatropin recombinant
,23996121,volumetric productivity,"A volumetric productivity of ~10 μg hTSH/mL was repeatedly obtained, with a 3.3-fold increase over a control culture carried out in the absence of NaBu.",Enhancement of human thyrotropin synthesis by sodium butyrate addition to serum-free CHO cell culture. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23996121/),h·μg,10,250207,DB00052,Somatropin recombinant
,12364460,metabolic clearance rate,"The metabolic clearance rate was dose dependently reduced with increasing GH doses (57.2 +/- 5.1, 45.2 +/- 3.8, and 39.2 +/- 2.4 ml/min(-1) per meter(-2) following injection of 1, 3, and 6 micro g/kg(-1) GH, respectively, P < 0.001), and half-time was increased (14.2 +/- 0.6, 16.2 +/- 0.4, and 18.0 +/- 0.5 min, respectively, P < 0.0001).",Dose dependency of the pharmacokinetics and acute lipolytic actions of growth hormone. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12364460/),[ml] / [(meter)^2·min],57.2,253291,DB00052,Somatropin recombinant
,12364460,metabolic clearance rate,"The metabolic clearance rate was dose dependently reduced with increasing GH doses (57.2 +/- 5.1, 45.2 +/- 3.8, and 39.2 +/- 2.4 ml/min(-1) per meter(-2) following injection of 1, 3, and 6 micro g/kg(-1) GH, respectively, P < 0.001), and half-time was increased (14.2 +/- 0.6, 16.2 +/- 0.4, and 18.0 +/- 0.5 min, respectively, P < 0.0001).",Dose dependency of the pharmacokinetics and acute lipolytic actions of growth hormone. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12364460/),[ml] / [(meter)^2·min],45.2,253292,DB00052,Somatropin recombinant
,12364460,metabolic clearance rate,"The metabolic clearance rate was dose dependently reduced with increasing GH doses (57.2 +/- 5.1, 45.2 +/- 3.8, and 39.2 +/- 2.4 ml/min(-1) per meter(-2) following injection of 1, 3, and 6 micro g/kg(-1) GH, respectively, P < 0.001), and half-time was increased (14.2 +/- 0.6, 16.2 +/- 0.4, and 18.0 +/- 0.5 min, respectively, P < 0.0001).",Dose dependency of the pharmacokinetics and acute lipolytic actions of growth hormone. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12364460/),[ml] / [(meter)^2·min],39.2,253293,DB00052,Somatropin recombinant
,12364460,half-time,"The metabolic clearance rate was dose dependently reduced with increasing GH doses (57.2 +/- 5.1, 45.2 +/- 3.8, and 39.2 +/- 2.4 ml/min(-1) per meter(-2) following injection of 1, 3, and 6 micro g/kg(-1) GH, respectively, P < 0.001), and half-time was increased (14.2 +/- 0.6, 16.2 +/- 0.4, and 18.0 +/- 0.5 min, respectively, P < 0.0001).",Dose dependency of the pharmacokinetics and acute lipolytic actions of growth hormone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12364460/),min,14.2,253294,DB00052,Somatropin recombinant
,12364460,half-time,"The metabolic clearance rate was dose dependently reduced with increasing GH doses (57.2 +/- 5.1, 45.2 +/- 3.8, and 39.2 +/- 2.4 ml/min(-1) per meter(-2) following injection of 1, 3, and 6 micro g/kg(-1) GH, respectively, P < 0.001), and half-time was increased (14.2 +/- 0.6, 16.2 +/- 0.4, and 18.0 +/- 0.5 min, respectively, P < 0.0001).",Dose dependency of the pharmacokinetics and acute lipolytic actions of growth hormone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12364460/),min,16.2,253295,DB00052,Somatropin recombinant
,12364460,half-time,"The metabolic clearance rate was dose dependently reduced with increasing GH doses (57.2 +/- 5.1, 45.2 +/- 3.8, and 39.2 +/- 2.4 ml/min(-1) per meter(-2) following injection of 1, 3, and 6 micro g/kg(-1) GH, respectively, P < 0.001), and half-time was increased (14.2 +/- 0.6, 16.2 +/- 0.4, and 18.0 +/- 0.5 min, respectively, P < 0.0001).",Dose dependency of the pharmacokinetics and acute lipolytic actions of growth hormone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12364460/),min,18.0,253296,DB00052,Somatropin recombinant
,3093356,half-lives,"The half-lives were 6.8 +/- 0.4 min and 43.2 +/- 3 min for distribution and elimination phases, respectively.",Investigation of human growth hormone releasing factor in adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3093356/),min,6.8,254950,DB00052,Somatropin recombinant
,3093356,half-lives,"The half-lives were 6.8 +/- 0.4 min and 43.2 +/- 3 min for distribution and elimination phases, respectively.",Investigation of human growth hormone releasing factor in adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3093356/),min,43.2,254951,DB00052,Somatropin recombinant
,10496658,terminal half-life,"The PK parameters showed dose-proportionality, with a short terminal half-life of 2 hours, a clearance of 0.078 L/h/kg and a volume of distribution at steady-state of 0.22 L/kg.","Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10496658/),h,2,255202,DB00052,Somatropin recombinant
,10496658,clearance,"The PK parameters showed dose-proportionality, with a short terminal half-life of 2 hours, a clearance of 0.078 L/h/kg and a volume of distribution at steady-state of 0.22 L/kg.","Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10496658/),[l] / [h·kg],0.078,255203,DB00052,Somatropin recombinant
,10496658,volume of distribution at steady-state,"The PK parameters showed dose-proportionality, with a short terminal half-life of 2 hours, a clearance of 0.078 L/h/kg and a volume of distribution at steady-state of 0.22 L/kg.","Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10496658/),[l] / [kg],0.22,255204,DB00052,Somatropin recombinant
,10496658,concentration (SC50),Ipamorelin induces the release of GH at all dose levels with the concentration (SC50) required for half-maximal GH stimulation of 214 nmol/L and a maximal GH production rate of 694 mIU/L/h.,"Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10496658/),[nM] / [l],214,255205,DB00052,Somatropin recombinant
,10496658,maximal GH production rate,Ipamorelin induces the release of GH at all dose levels with the concentration (SC50) required for half-maximal GH stimulation of 214 nmol/L and a maximal GH production rate of 694 mIU/L/h.,"Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10496658/),[miu] / [h·l],694,255206,DB00052,Somatropin recombinant
,25115329,plasma half-life,"Human growth hormone (hGH) suffers from a short plasma half-life of ∼15 min, necessitating frequent injections to maintain its physiological effect.",Phenyl amide linker improves the pharmacokinetics and pharmacodynamics of N-terminally mono-PEGylated human growth hormone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25115329/),min,∼15,255782,DB00052,Somatropin recombinant
,30371791,maximum dosage,The maximum dosage of BIM23B065 administered in this study was 1.5 mg.,A Novel Somatostatin-Dopamine Chimera (BIM23B065) Reduced GH Secretion in a First-in-Human Clinical Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30371791/),mg,1,258706,DB00052,Somatropin recombinant
,8636290,production rate,"Five days of fasting induced a 1.8-fold increase in the 24-h endogenous cortisol production rate (fed, 2504 +/- 308; fasted, 4528 +/- 488 nmol/L distribution volume; P < 0.006).",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),[nM] / [l],2504,260312,DB00052,Somatropin recombinant
,8636290,production rate,"Five days of fasting induced a 1.8-fold increase in the 24-h endogenous cortisol production rate (fed, 2504 +/- 308; fasted, 4528 +/- 488 nmol/L distribution volume; P < 0.006).",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),[nM] / [l],4528,260313,DB00052,Somatropin recombinant
,8636290,distribution,"Five days of fasting induced a 1.8-fold increase in the 24-h endogenous cortisol production rate (fed, 2504 +/- 308; fasted, 4528 +/- 488 nmol/L distribution volume; P < 0.006).",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),[nM] / [l],2504,260314,DB00052,Somatropin recombinant
,8636290,distribution,"Five days of fasting induced a 1.8-fold increase in the 24-h endogenous cortisol production rate (fed, 2504 +/- 308; fasted, 4528 +/- 488 nmol/L distribution volume; P < 0.006).",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),[nM] / [l],4528,260315,DB00052,Somatropin recombinant
,8636290,mass of,"This enhanced cortisol production rate was accounted for by a 1.6-fold increase in the mass of cortisol secreted per burst (fed, 115 +/- 12.1; fasted, 183 +/- 17.3 nmol/L; P < 0.02).",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),[nM] / [l],115,260316,DB00052,Somatropin recombinant
,8636290,mass of,"This enhanced cortisol production rate was accounted for by a 1.6-fold increase in the mass of cortisol secreted per burst (fed, 115 +/- 12.1; fasted, 183 +/- 17.3 nmol/L; P < 0.02).",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),[nM] / [l],183,260317,DB00052,Somatropin recombinant
,8636290,number,"Moreover, the number of computer-resolved cortisol secretory bursts per 24 h (fed, 22 +/- 1.4; fasted, 25 +/- 2.0; P = NS) and the interburst interval (fed, 65 +/- 4.0; fasted, 57 +/- 4.4 min) did not change significantly during a 5-day fast.",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),,22,260318,DB00052,Somatropin recombinant
,8636290,number,"Moreover, the number of computer-resolved cortisol secretory bursts per 24 h (fed, 22 +/- 1.4; fasted, 25 +/- 2.0; P = NS) and the interburst interval (fed, 65 +/- 4.0; fasted, 57 +/- 4.4 min) did not change significantly during a 5-day fast.",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),,25,260319,DB00052,Somatropin recombinant
,8636290,interburst interval,"Moreover, the number of computer-resolved cortisol secretory bursts per 24 h (fed, 22 +/- 1.4; fasted, 25 +/- 2.0; P = NS) and the interburst interval (fed, 65 +/- 4.0; fasted, 57 +/- 4.4 min) did not change significantly during a 5-day fast.",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),min,65,260320,DB00052,Somatropin recombinant
,8636290,interburst interval,"Moreover, the number of computer-resolved cortisol secretory bursts per 24 h (fed, 22 +/- 1.4; fasted, 25 +/- 2.0; P = NS) and the interburst interval (fed, 65 +/- 4.0; fasted, 57 +/- 4.4 min) did not change significantly during a 5-day fast.",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),min,57,260321,DB00052,Somatropin recombinant
,8636290,half-life,"The calculated half-life of endogenous cortisol was not significantly altered by fasting (fed, 108 +/- 9.7; fasted, 129 +/- 11 min).",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),min,108,260322,DB00052,Somatropin recombinant
,8636290,half-life,"The calculated half-life of endogenous cortisol was not significantly altered by fasting (fed, 108 +/- 9.7; fasted, 129 +/- 11 min).",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),min,129,260323,DB00052,Somatropin recombinant
,7686916,peak,"The mean pretreatment IGF-I level (36 +/- 2 micrograms/L) was 19% of the Ecuadorian control value (190 +/- 15 micrograms/L), it achieved a peak (253 +/- 11 micrograms/L) between 2-6 h after IGF-I injection, and at 12 h it was 137 +/- 8 micrograms/L.",Hormonal and metabolic effects and pharmacokinetics of recombinant insulin-like growth factor-I in growth hormone receptor deficiency/Laron syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7686916/),[μg] / [l],253,260584,DB00052,Somatropin recombinant
,7686916,half-life,"There were no significant changes in the half-life (8.2 +/- 1.5 to 9.7 +/- 1.9 h) or metabolic clearance (0.35 +/- 0.1 to 0.24 +/- 0.05 mL/kg.min) between days 1 and 7; however, distribution volume increased (183 +/- 10 to 266 +/- 36 mL/kg; P < 0.03).",Hormonal and metabolic effects and pharmacokinetics of recombinant insulin-like growth factor-I in growth hormone receptor deficiency/Laron syndrome. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7686916/),h,8.2,260585,DB00052,Somatropin recombinant
,7686916,half-life,"There were no significant changes in the half-life (8.2 +/- 1.5 to 9.7 +/- 1.9 h) or metabolic clearance (0.35 +/- 0.1 to 0.24 +/- 0.05 mL/kg.min) between days 1 and 7; however, distribution volume increased (183 +/- 10 to 266 +/- 36 mL/kg; P < 0.03).",Hormonal and metabolic effects and pharmacokinetics of recombinant insulin-like growth factor-I in growth hormone receptor deficiency/Laron syndrome. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7686916/),h,9.7,260586,DB00052,Somatropin recombinant
,7686916,metabolic clearance,"There were no significant changes in the half-life (8.2 +/- 1.5 to 9.7 +/- 1.9 h) or metabolic clearance (0.35 +/- 0.1 to 0.24 +/- 0.05 mL/kg.min) between days 1 and 7; however, distribution volume increased (183 +/- 10 to 266 +/- 36 mL/kg; P < 0.03).",Hormonal and metabolic effects and pharmacokinetics of recombinant insulin-like growth factor-I in growth hormone receptor deficiency/Laron syndrome. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7686916/),[ml] / [kg·min],0.35,260587,DB00052,Somatropin recombinant
,7686916,metabolic clearance,"There were no significant changes in the half-life (8.2 +/- 1.5 to 9.7 +/- 1.9 h) or metabolic clearance (0.35 +/- 0.1 to 0.24 +/- 0.05 mL/kg.min) between days 1 and 7; however, distribution volume increased (183 +/- 10 to 266 +/- 36 mL/kg; P < 0.03).",Hormonal and metabolic effects and pharmacokinetics of recombinant insulin-like growth factor-I in growth hormone receptor deficiency/Laron syndrome. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7686916/),[ml] / [kg·min],0.24,260588,DB00052,Somatropin recombinant
,7686916,distribution volume,"There were no significant changes in the half-life (8.2 +/- 1.5 to 9.7 +/- 1.9 h) or metabolic clearance (0.35 +/- 0.1 to 0.24 +/- 0.05 mL/kg.min) between days 1 and 7; however, distribution volume increased (183 +/- 10 to 266 +/- 36 mL/kg; P < 0.03).",Hormonal and metabolic effects and pharmacokinetics of recombinant insulin-like growth factor-I in growth hormone receptor deficiency/Laron syndrome. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7686916/),[ml] / [kg],183,260589,DB00052,Somatropin recombinant
,7686916,distribution volume,"There were no significant changes in the half-life (8.2 +/- 1.5 to 9.7 +/- 1.9 h) or metabolic clearance (0.35 +/- 0.1 to 0.24 +/- 0.05 mL/kg.min) between days 1 and 7; however, distribution volume increased (183 +/- 10 to 266 +/- 36 mL/kg; P < 0.03).",Hormonal and metabolic effects and pharmacokinetics of recombinant insulin-like growth factor-I in growth hormone receptor deficiency/Laron syndrome. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7686916/),[ml] / [kg],266,260590,DB00052,Somatropin recombinant
,28595133,Apparent terminal half-lives,"Apparent terminal half-lives were 5-6h in rats, 10-12h in minipigs, and 17-20h in monkeys.",Nonclinical pharmacokinetic and pharmacodynamic characterisation of somapacitan: A reversible non-covalent albumin-binding growth hormone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28595133/),h,5-6,261143,DB00052,Somatropin recombinant
,28595133,Apparent terminal half-lives,"Apparent terminal half-lives were 5-6h in rats, 10-12h in minipigs, and 17-20h in monkeys.",Nonclinical pharmacokinetic and pharmacodynamic characterisation of somapacitan: A reversible non-covalent albumin-binding growth hormone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28595133/),h,10-12,261144,DB00052,Somatropin recombinant
,28595133,Apparent terminal half-lives,"Apparent terminal half-lives were 5-6h in rats, 10-12h in minipigs, and 17-20h in monkeys.",Nonclinical pharmacokinetic and pharmacodynamic characterisation of somapacitan: A reversible non-covalent albumin-binding growth hormone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28595133/),h,17-20,261145,DB00052,Somatropin recombinant
,10499606,steady-state plasma concentration,The average steady-state plasma concentration of tamoxifen was 2.96+/-1.32 microM (mean +/- SD).,A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499606/),μM,2.96,261401,DB00052,Somatropin recombinant
,10499606,partial response/,"One partial response (80% decline in prostate-specific antigen) was observed (3.3%), whereas disease stabilization was observed in six patients (20%), for a combined partial response/stable disease response rate of 23%.",A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499606/),%,23,261402,DB00052,Somatropin recombinant
,10499606,stable disease response rate,"One partial response (80% decline in prostate-specific antigen) was observed (3.3%), whereas disease stabilization was observed in six patients (20%), for a combined partial response/stable disease response rate of 23%.",A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499606/),%,23,261403,DB00052,Somatropin recombinant
,10499606,time to progression,"Median time to progression was 2.1 months, and median survival time was 10.5 months.",A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499606/),month,2.1,261404,DB00052,Somatropin recombinant
,10499606,survival time,"Median time to progression was 2.1 months, and median survival time was 10.5 months.",A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499606/),month,10.5,261405,DB00052,Somatropin recombinant
,19336514,relative bioavailability,Mean relative bioavailability for inhaled GH was 3.5% (90% confidence interval 2.7-4.4%).,"Inhaled growth hormone (GH) compared with subcutaneous GH in children with GH deficiency: pharmacokinetics, pharmacodynamics, and safety. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19336514/),%,3.5,262696,DB00052,Somatropin recombinant
,19336514,relative biopotency,"Mean relative biopotency, based on IGF-I response, was 5.5% (confidence interval 5.2-5.8%).","Inhaled growth hormone (GH) compared with subcutaneous GH in children with GH deficiency: pharmacokinetics, pharmacodynamics, and safety. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19336514/),%,5,262697,DB00052,Somatropin recombinant
,23169607,T(½),Mean ACE-031 AUC(0-∞) and C(max) increased linearly with dose; mean T(½) was 10-15 days.,A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23169607/),d,10-15,264726,DB00052,Somatropin recombinant
,1464653,renal clearance,The mean (+/- SD) renal clearance of GH was significantly greater in the aged group than in the young group (14.3 +/- 2.5 vs. 4.2 +/- 1.0 microL/min; P < 0.05).,"Renal clearance, metabolic clearance rate, and half-life of human growth hormone in young and aged subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1464653/),[μl] / [min],14.3,264769,DB00052,Somatropin recombinant
,1464653,renal clearance,The mean (+/- SD) renal clearance of GH was significantly greater in the aged group than in the young group (14.3 +/- 2.5 vs. 4.2 +/- 1.0 microL/min; P < 0.05).,"Renal clearance, metabolic clearance rate, and half-life of human growth hormone in young and aged subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1464653/),[μl] / [min],4.2,264770,DB00052,Somatropin recombinant
,1464653,MCR,"The mean MCR was greater in the young group than in the aged group (187.1 +/- 43.7 vs. 120.5 +/- 39.5 mL/min; P < 0.05), but the MCR adjusted for body weight was not different between the two groups (2.9 +/- 0.6 vs. 2.3 +/- 0.8 mL/min.kg).","Renal clearance, metabolic clearance rate, and half-life of human growth hormone in young and aged subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1464653/),[ml] / [min],187.1,264771,DB00052,Somatropin recombinant
,1464653,MCR,"The mean MCR was greater in the young group than in the aged group (187.1 +/- 43.7 vs. 120.5 +/- 39.5 mL/min; P < 0.05), but the MCR adjusted for body weight was not different between the two groups (2.9 +/- 0.6 vs. 2.3 +/- 0.8 mL/min.kg).","Renal clearance, metabolic clearance rate, and half-life of human growth hormone in young and aged subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1464653/),[ml] / [min],120.5,264772,DB00052,Somatropin recombinant
,1464653,MCR,"The mean MCR was greater in the young group than in the aged group (187.1 +/- 43.7 vs. 120.5 +/- 39.5 mL/min; P < 0.05), but the MCR adjusted for body weight was not different between the two groups (2.9 +/- 0.6 vs. 2.3 +/- 0.8 mL/min.kg).","Renal clearance, metabolic clearance rate, and half-life of human growth hormone in young and aged subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1464653/),[ml] / [kg·min],2.9,264773,DB00052,Somatropin recombinant
,1464653,MCR,"The mean MCR was greater in the young group than in the aged group (187.1 +/- 43.7 vs. 120.5 +/- 39.5 mL/min; P < 0.05), but the MCR adjusted for body weight was not different between the two groups (2.9 +/- 0.6 vs. 2.3 +/- 0.8 mL/min.kg).","Renal clearance, metabolic clearance rate, and half-life of human growth hormone in young and aged subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1464653/),[ml] / [kg·min],2.3,264774,DB00052,Somatropin recombinant
,1464653,half-life,No difference was noted in the half-life of GH between the two groups (13.8 +/- 0.9 vs. 14.2 +/- 0.4 min).,"Renal clearance, metabolic clearance rate, and half-life of human growth hormone in young and aged subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1464653/),min,13.8,264775,DB00052,Somatropin recombinant
,1464653,half-life,No difference was noted in the half-life of GH between the two groups (13.8 +/- 0.9 vs. 14.2 +/- 0.4 min).,"Renal clearance, metabolic clearance rate, and half-life of human growth hormone in young and aged subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1464653/),min,14.2,264776,DB00052,Somatropin recombinant
,12151425,Maximum serum FSH-CTP concentrations,"Maximum serum FSH-CTP concentrations (0.42, 0.66, 1.49 and 3.27 ng/ml after administration of 15, 30, 60 and 120 micro g Org 36286 respectively) were reached between 36 and 48 h after injection and t(1/2) varied between 60 and 75 h.",Single dose pharmacokinetics and effects on follicular growth and serum hormones of a long-acting recombinant FSH preparation (FSH-CTP) in healthy pituitary-suppressed females. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12151425/),[ng] / [ml],0.42,265855,DB00052,Somatropin recombinant
,12151425,Maximum serum FSH-CTP concentrations,"Maximum serum FSH-CTP concentrations (0.42, 0.66, 1.49 and 3.27 ng/ml after administration of 15, 30, 60 and 120 micro g Org 36286 respectively) were reached between 36 and 48 h after injection and t(1/2) varied between 60 and 75 h.",Single dose pharmacokinetics and effects on follicular growth and serum hormones of a long-acting recombinant FSH preparation (FSH-CTP) in healthy pituitary-suppressed females. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12151425/),[ng] / [ml],0.66,265856,DB00052,Somatropin recombinant
,12151425,Maximum serum FSH-CTP concentrations,"Maximum serum FSH-CTP concentrations (0.42, 0.66, 1.49 and 3.27 ng/ml after administration of 15, 30, 60 and 120 micro g Org 36286 respectively) were reached between 36 and 48 h after injection and t(1/2) varied between 60 and 75 h.",Single dose pharmacokinetics and effects on follicular growth and serum hormones of a long-acting recombinant FSH preparation (FSH-CTP) in healthy pituitary-suppressed females. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12151425/),[ng] / [ml],1.49,265857,DB00052,Somatropin recombinant
,12151425,Maximum serum FSH-CTP concentrations,"Maximum serum FSH-CTP concentrations (0.42, 0.66, 1.49 and 3.27 ng/ml after administration of 15, 30, 60 and 120 micro g Org 36286 respectively) were reached between 36 and 48 h after injection and t(1/2) varied between 60 and 75 h.",Single dose pharmacokinetics and effects on follicular growth and serum hormones of a long-acting recombinant FSH preparation (FSH-CTP) in healthy pituitary-suppressed females. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12151425/),[ng] / [ml],3.27,265858,DB00052,Somatropin recombinant
,12151425,t(1/2),"Maximum serum FSH-CTP concentrations (0.42, 0.66, 1.49 and 3.27 ng/ml after administration of 15, 30, 60 and 120 micro g Org 36286 respectively) were reached between 36 and 48 h after injection and t(1/2) varied between 60 and 75 h.",Single dose pharmacokinetics and effects on follicular growth and serum hormones of a long-acting recombinant FSH preparation (FSH-CTP) in healthy pituitary-suppressed females. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12151425/),h,60 and 75,265859,DB00052,Somatropin recombinant
,12151425,Maximum mean inhibin-B levels,"Maximum mean inhibin-B levels were 30.4, 322.7 and 1059.3 pg/ml in the 30, 60 and 120 micro g dose group respectively.",Single dose pharmacokinetics and effects on follicular growth and serum hormones of a long-acting recombinant FSH preparation (FSH-CTP) in healthy pituitary-suppressed females. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12151425/),[pg] / [ml],30.4,265860,DB00052,Somatropin recombinant
,12151425,Maximum mean inhibin-B levels,"Maximum mean inhibin-B levels were 30.4, 322.7 and 1059.3 pg/ml in the 30, 60 and 120 micro g dose group respectively.",Single dose pharmacokinetics and effects on follicular growth and serum hormones of a long-acting recombinant FSH preparation (FSH-CTP) in healthy pituitary-suppressed females. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12151425/),[pg] / [ml],322.7,265861,DB00052,Somatropin recombinant
,12151425,Maximum mean inhibin-B levels,"Maximum mean inhibin-B levels were 30.4, 322.7 and 1059.3 pg/ml in the 30, 60 and 120 micro g dose group respectively.",Single dose pharmacokinetics and effects on follicular growth and serum hormones of a long-acting recombinant FSH preparation (FSH-CTP) in healthy pituitary-suppressed females. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12151425/),[pg] / [ml],1059.3,265862,DB00052,Somatropin recombinant
,11994362,MCRs,"During primed constant infusions of GH at rates of 1.5 and 3.0 microg/kg x h, the corresponding MCRs of GH were 148.8 +/- 5.4 and 89.8 +/- 2.4 ml/min x m(-2), respectively, and the MCRs were inversely related to the achieved steady state GH levels (P < 0.0001).","Body composition and circulating levels of insulin, insulin-like growth factor-binding protein-1 and growth hormone (GH)-binding protein affect the pharmacokinetics of GH in adults independently of age. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11994362/),[min·ml] / [(m)^2],148.8,272323,DB00052,Somatropin recombinant
,11994362,MCRs,"During primed constant infusions of GH at rates of 1.5 and 3.0 microg/kg x h, the corresponding MCRs of GH were 148.8 +/- 5.4 and 89.8 +/- 2.4 ml/min x m(-2), respectively, and the MCRs were inversely related to the achieved steady state GH levels (P < 0.0001).","Body composition and circulating levels of insulin, insulin-like growth factor-binding protein-1 and growth hormone (GH)-binding protein affect the pharmacokinetics of GH in adults independently of age. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11994362/),[min·ml] / [(m)^2],89.8,272324,DB00052,Somatropin recombinant
,18719021,inhibitory constant,"Tranzyme Pharma (TZP)-101 is a small-molecule agonist with potent binding affinity (inhibitory constant = 16 nm) and full agonist activity (EC50 = 29 nm, maximum response = 111%) at the human recombinant GRLN-R.","Pharmacological demarcation of the growth hormone, gut motility and feeding effects of ghrelin using a novel ghrelin receptor agonist. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18719021/),nm,16,273322,DB00052,Somatropin recombinant
,18719021,EC50,"Tranzyme Pharma (TZP)-101 is a small-molecule agonist with potent binding affinity (inhibitory constant = 16 nm) and full agonist activity (EC50 = 29 nm, maximum response = 111%) at the human recombinant GRLN-R.","Pharmacological demarcation of the growth hormone, gut motility and feeding effects of ghrelin using a novel ghrelin receptor agonist. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18719021/),nm,29,273323,DB00052,Somatropin recombinant
,18719021,plasma elimination half-life,Pharmacokinetic profiling of TZP-101 in rat determined a plasma elimination half-life of 99 min and low blood-brain barrier permeability (0.09%).,"Pharmacological demarcation of the growth hormone, gut motility and feeding effects of ghrelin using a novel ghrelin receptor agonist. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18719021/),min,99,273324,DB00052,Somatropin recombinant
,18719021,blood-brain barrier permeability,Pharmacokinetic profiling of TZP-101 in rat determined a plasma elimination half-life of 99 min and low blood-brain barrier permeability (0.09%).,"Pharmacological demarcation of the growth hormone, gut motility and feeding effects of ghrelin using a novel ghrelin receptor agonist. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18719021/),%,0.09,273325,DB00052,Somatropin recombinant
,12757833,total area under the plasma concentration-time curve from time zero to 8 hr (AUC(0-->8 hr)),"First, the total area under the plasma concentration-time curve from time zero to 8 hr (AUC(0-->8 hr)) of OH-CZX in rats with U-ARF1 (36,100 microg min/ml) was significantly greater and smaller than those in control rats (1040 microg min/ml) and rats with U-ARF (50,300 microg min/ml), respectively.",Effects of recombinant human growth hormone on the pharmacokinetics of intravenous chlorzoxazone in rats with acute renal failure induced by uranyl nitrate. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12757833/),[min·μg] / [ml],"36,100",274117,DB00052,Somatropin recombinant
,12757833,total area under the plasma concentration-time curve from time zero to 8 hr (AUC(0-->8 hr)),"First, the total area under the plasma concentration-time curve from time zero to 8 hr (AUC(0-->8 hr)) of OH-CZX in rats with U-ARF1 (36,100 microg min/ml) was significantly greater and smaller than those in control rats (1040 microg min/ml) and rats with U-ARF (50,300 microg min/ml), respectively.",Effects of recombinant human growth hormone on the pharmacokinetics of intravenous chlorzoxazone in rats with acute renal failure induced by uranyl nitrate. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12757833/),[min·μg] / [ml],1040,274118,DB00052,Somatropin recombinant
,12757833,total area under the plasma concentration-time curve from time zero to 8 hr (AUC(0-->8 hr)),"First, the total area under the plasma concentration-time curve from time zero to 8 hr (AUC(0-->8 hr)) of OH-CZX in rats with U-ARF1 (36,100 microg min/ml) was significantly greater and smaller than those in control rats (1040 microg min/ml) and rats with U-ARF (50,300 microg min/ml), respectively.",Effects of recombinant human growth hormone on the pharmacokinetics of intravenous chlorzoxazone in rats with acute renal failure induced by uranyl nitrate. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12757833/),[min·μg] / [ml],"50,300",274119,DB00052,Somatropin recombinant
,12757833,AUC(0-->8 h,"Second, the AUC(0-->8 hr, OH-CZX)/AUC(CZX) ratio in rats with U-ARF1 (28.9) was significantly greater and smaller than those in control rats (0.468) and rats with U-ARF (72.6), respectively.",Effects of recombinant human growth hormone on the pharmacokinetics of intravenous chlorzoxazone in rats with acute renal failure induced by uranyl nitrate. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12757833/),,28.9,274120,DB00052,Somatropin recombinant
,12757833,AUC(0-->8 h,"Second, the AUC(0-->8 hr, OH-CZX)/AUC(CZX) ratio in rats with U-ARF1 (28.9) was significantly greater and smaller than those in control rats (0.468) and rats with U-ARF (72.6), respectively.",Effects of recombinant human growth hormone on the pharmacokinetics of intravenous chlorzoxazone in rats with acute renal failure induced by uranyl nitrate. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12757833/),,0.468,274121,DB00052,Somatropin recombinant
,12757833,AUC(0-->8 h,"Second, the AUC(0-->8 hr, OH-CZX)/AUC(CZX) ratio in rats with U-ARF1 (28.9) was significantly greater and smaller than those in control rats (0.468) and rats with U-ARF (72.6), respectively.",Effects of recombinant human growth hormone on the pharmacokinetics of intravenous chlorzoxazone in rats with acute renal failure induced by uranyl nitrate. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12757833/),,72.6,274122,DB00052,Somatropin recombinant
